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GENERAL INTRODUCTION AND AIMS OF THE THESIS 
 
Introduction 
 
Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth leading cause of cancer related death in 
Western countries and it is predicted to become second in the United States by 2030 with an 
increase up to 70% from 2010 [1, 2] (Figure.1) . Likewise, in Italy PDAC has showed, compared 
to other cancers, an incremental trend in both sex (although more pronounced in the male sex) with 
a  5-year survival rate less than 10% [3] (Table.1). The prognosis of this tumour  is dismal because 
of the delayed diagnosis, biological aggressiveness and poor response to medical treatment [4]. 
Currently, oncological treatment permits only to extend the survival, therefore, the only potentially 
curative treatment available nowadays is the radical surgery. Unfortunately, due to the delayed 
diagnosis and the late onset of symptoms, only 15 to 20% of patients are candidate for surgery[5]. 
The median survival for an early diagnosed  PDAC after surgery (  T ≤ 2 cm, N0,M0) is 38 months 
(33-43)  compared to 15 months ( 14-16) in patients with positive lymph nodes,  even though the 
rate of Stage IA  represents only the 17 % of patents amenable of surgery [6].  
Hence, prevention seems to be the only way to decrease pancreatic cancer related death.  As far as 
regard primary prevention, it consists in reduce the modifiable proven risk factors related to PDAC 
such as obesity and cigarette smoking  with the aim to reduce the PDAC incidence [7]. On the 
other hand, secondary prevention that consists on screening the whole population can’t be 
prosecuted in the setting on PDAC , as happen  for other cancers such as breast  and colorectal 
cancer,  for two main  reasons : firstly, the overall lifetime risk  of developing PDAC is relatively 
low (close to 1%) therefore it doesn’t make cost effective such approach , secondly , so far  there 
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are  limited data regarding the accuracy of  the  screening tests available and  the interpretations of 
the test’s findings for clinical decisions (surgical treatment/ follow-up) .   
Actually, despite it has been recognized that some neoplastic precursor lesions, such as intraductal 
papillary mucinous neoplasms (IPMNs) or pancreatic intraepithelial neoplasia (PanINs) 
(Figure.2), can be detected at an early stage using currently available imaging techniques[8],  they 
are extremely common findings in healthy subjects, increasing with age. Moreover, the managing 
of those lesions, when discovered in the general population, is already not well known as well as 
their exact prevalence.  
Since the diagnostic accuracy of a screening test depends also on the prevalence of the disease in 
a certain population (pre-test probability) there is an accordance between experts about the target 
population for which screening for PDAC could be feasible. Since a hereditary component has 
been known for approximately 5-10% of PDAC cases[8], surveillance is therefore currently 
advised for high-risk individuals (HRIs) with a known elevated risk of developing the disease (i.e., 
>5% lifetime risk, or five fold increased relative risk) (Table.2). The International Cancer of the  
 
 
 
Figure1. Projecting cancer deaths in both sex in 
USA. As showed, Pancreas is predicted to be the 
second leading cause of death by 2030 overcame 
after 2020 cancer related deaths due to colorectal 
and breast . 
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Table1. Top five causes of cancer death in Italy and relatively proportion in respect of the total cancer deaths by 
gender and age range. 
*
Central nervous system 
 
Pancreas Screening (CAPS) Consortium [9] in 2013 has defined selection criteria for subjects with 
“familial pancreatic cancer” (FPC) or with hereditary syndromes of which PDAC is one of the 
phenotypic manifestations for whom surveillance has to be considered in the setting of research 
protocols.  
 
High-risk individuals  
The definition of FPC is not fully established yet, but an individual can be considered at high risk 
if two or more blood relatives are affected by PDAC, of whom at least one is a 1st degree relative 
(FDR). The distribution of PC in some families meets the criteria for autosomal dominant 
transmission with reduced penetrance, although a susceptibility gene for FPC has not been 
identified yet. The risk to develop PDAC in such a families goes up to 32 folds if  ≥ 3 first degree 
relatives are affected. 
Concerning the syndromic pancreatic cancer, they are characterized by a defined gene alteration 
and a specific transmission. They account for approximately 20% of hereditary pancreatic cancer, 
  Male   Female  
Rank  Age   Age  
 0-49 50-69 70+ 0-49 50-69 70+ 
1st Lung 
[14%] 
Lung 
[30%] 
Lung 
[26%] 
Breast 
[29%] 
Breast 
[22%] 
Breast 
[15%] 
2nd CNS* 
[10%] 
Colorectal 
[10%] 
Colorectal 
[11%] 
Lung 
[9%] 
Lung 
[14%] 
Colorectal 
[13%] 
3rd Colorectal 
[8%] 
Liver 
[8%] 
Prostate 
[10%] 
Colorectal 
[7%] 
Colorectal 
[10%] 
Lung 
[10%] 
4th Leukemia 
[8%] 
Pancreas 
[7%] 
Liver 
[7%] 
Ovary 
[6%] 
Pancreas 
[7%] 
Pancreas 
[8%] 
5th Liver 
[7%] 
Stomach 
[6%] 
Stomach 
[7%] 
CNS* 
[6%] 
Ovary 
[7%] 
Stomach 
[7%] 
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penetrance varies between different syndromes and individuals/families and the cumulative 
lifetime risk varies between 2 – 3% and 40%.  In addition, some studies have found FPC 
individuals more prone to develop cystic lesions compare to the general population [9].  
Surveillance is indicated for all patients with Peutz–Jeghers syndrome (PJS) regardless of family 
history of PDAC. Furthermore, p16 (familial atypical multiple mole melanoma syndrome, 
FAMMM syndrome), BRCA2, PALB and mismatch repair gene (hereditary nonpolyposis 
colorectal cancer, HNPCC) mutation carriers with one FDR or two other family members affected 
by PDAC should also be considered for surveillance[10] (Table.2).  
In detail, PJS is an autosomal dominant hereditary disease linked to a mutation of the STK 11 gene 
increased with an increased risk of developing gastrointestinal and extra-digestive cancer. The 
most representative phenotype of the syndrome are benign hamartomatous polyps in the 
gastrointestinal tract in association with a hyperpigmentation on the lips and oral mucosa. 
 One of those is PDAC with a 132-fold higher in these patients compared to the general population 
[9]. 
FAMMM syndrome is due to an alteration of CDKN2A gene and it is characterized by multiple 
nevi (usually in the hundreds) typically diagnosed 10–20 years earlier than sporadic melanoma 
and extra-cutaneous tumors. The risk to develop PDAC is up to 25% ranging from 34- to 39-fold 
higher than in the general population. Moreover, from previous study, it seems that in this setting 
is more frequent to diagnose directly PDAC during surveillance instead of its precursor.  
The mutations of the BRCA1 or BRCA2 genes is typical of breast and ovarian cancer syndrome 
(HBOC) in which together with the high lifetime risk of developing breast and ovarian cancers 
there is from 2.3- to 10-fold increased risk of PDAC. The BRCA2 mutation itself was also 
identified in FPC families in about 13%-17% of the cases.   
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Hereditary pancreatitis (HP) is characterized by recurrent attacks of acute pancreatitis in 
childhood, progressing to chronic pancreatitis with time. It is an autosomal dominant condition 
with 80% penetrance. Different types of HP are described but only HP associated with PRSS1 
gene mutation seems liked to an elevated risk to develop PDAC (RR equal to 50-70) mostly in 
presence of early-onset chronic pancreatitis and a family history of PDAC.    
Since the heterogeneity between the different kind of HRIs in terms of hereditary transmission, 
family history of PDAC, knowing gene alteration, target lesion to diagnose (PDAC or precursor) 
it seems reasonable that surveillance should be tailored in terms of screening methods and follow 
up depending on the type of HRIs.  
 
Table.2 Characteristics of the syndrome associated with increased risk of pancreatic cancer and their estimated 
lifetime risk of pancreatic cancer  
 
Syndrome associated with increased risk of pancreatic cancer 
 
Syndrome 
 
Gene 
Estimated Lifetime Risk of 
Pancretic Cancer (%) 
Peutz-Jeghers syndrome STK11 11-36 
Familial Atypical Multiple Mole 
Melanoma syndrome 
P16/CDKN2A 10-17 
Hereditary breast and ovarian cancer 
BRCA1 
BRCA2 
5 
3.6 
Hereditary Pancreatitis PRSS1 40 
Familial  Pancreatic Cancer 
1 FDR 
2 FDR 
≥ 3 FDR 
Majority unknown  
6 
8-12 
40 
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Precursor lesions 
The ultimate goal of surveillance programs is to decrease PDAC-related mortality. In order to 
reach this goal, programs should focus on the detection and treatment of high-grade non-invasive 
precursor lesions of PDAC, such as advanced pancreatic intraepithelial neoplasia (PanINs3) or 
IPMNs with high grade dysplasia apart from early-stage asymptomatic PDAC still amenable for 
surgical treatment[11].  
PanINs are neoplastic microscopic lesions (<0.5 cm), characterized by flat or papillary epithelium 
non-invasive duct cell proliferations separated into a group with low-grade (PanIN grade 1 and 2) 
and high-grade dysplasia (PanIN grade 3). The low grade PanINs are common findings into the 
pancreatic gland of people affected by chronic pancreatitis  or in healthy people aged  > 40 years 
old contrary to high grade PanINs that are associated to PDAC [12, 13]. The accumulation of 
genetic changes during time is responsible of the histological progression from low-grade to high 
grade (Figure.2). Early genetic alterations include activating KRAS mutation (PanIN 1 by flat or 
papillary). Subsequent mutations involved inactivation of P16 ( PanIN2 more complex architecture 
with additional nuclear alterations) and  in later stages mutation concern inactivation of the tumor 
suppressor genes TP53 and SMAD4 and rarely BRCA 2 mutation (PanIN3 or carcinoma in situ). 
It remains debated if the diagnostic methods available can be able to detect those kind of lesions 
that are microscopic by definition.  In HRIs, some data suggest that PanINs are associated to 
chronic pancreatitis-like parenchymal changes that could be visualized by EUS  as ectasia, 
irregularity of the duct and/or parenchyma heterogeneityand lobularity despite they cannot be 
reliably distinguish from non-neoplastic alterations [14]. 
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Figure.2 Transition 
between acinar, 
ductal or 
centroacinar normal 
pancreatic cell into 
IPMN/PanIN and 
from those 
precursors to 
pancreatic ductal 
adenocarcinoma 
(PDA). 
 
 
 
 
 
 
IPMNs are nowadays well described neoplasms involving the main pancreatic duct (main duct 
IPMN or MD-IPMN), the side branches (SB-IPMN) or both (Mixt type IPMN).  Those with wall 
nodules or thickened wall, as called “worrisome features”,  present a higher risk of progression in 
adenocarcinoma[15] (Figure.2). Currently, due to the widespread use of cross-sectional imaging 
the incidentally discovered pancreatic cysts are more and more frequent with IPMN being the 
majority of them.  From the histological point of view, IPMNs display a differ types of neoplastic 
epithelium that can be characterized as gastric, intestinal, pancreatobiliary or oncocytic type[16], 
with  the first type being morphologically and prognostically identical to conventional PC whereas  
the latter two more indolent. Interestingly, there is a complex relationship between IPMNs and 
PDAC due to the fact that PDAC can develop not only as a cancerous transformation of the cystic 
lesions , but often can occur as a synchronous lesion  in a different place of the gland 
topographically separate from the IPMN (mostly gastric type SD-IPMN) [17]. Almost 70% of the 
pancreatic cysts are discovered incidentally and the prevalence varies among different studies from 
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3 to 20% depending on the radiological modalities employed. The prevalence seems to increase 
with the age as showed in autopsy studies where pancreatic cysts  were discovered up to 50% in 
the elderly population[18, 19] . The exactly incidence, prevalence and clinical out-come of the 
asymptomatic incidentally discovered pancreatic cyst is not well known as far as their clinical 
behavior in HRIs.  
From previous studies about surveillance in HRIs  it has emerged that both PanINs and IPMNs are 
more frequent, with higher grade and  most of the time multifocal in this kind of setting than in 
patients with sporadic disease[10]. 
 
Screening modalities  
Who can be considered the best imaging modalities to diagnose early PDAC/ high grade precursors 
in the population of HRIs it is still debated. From previous surveillance programs the imaging 
methods employed in this setting were:  computed tomography scan (CT scan), Endoscopic 
retrograde cholangiopancreatography (ERCP) , magnetic resonance imaging (MRI) and 
endoscopic ultrasonography (EUS). 
As far as regards CT scan, although it became a widely available not invasive imaging methods 
with the opportunity to detect intra and extra pancreatic lesions it  is not considered an adequate 
candidate for screening programs mostly because of the radiation exposure that the population 
should undergo during screening campaigns. 
ERCP  has been proposed by Brentnall et al. [20] in 1999 as a imaging modalities able to screen a 
small prospective cohort of a family composed by 14 HRIs. The use of this method has been 
progressively abandoned for this purpose because of the disadvantages of being an invasive 
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technique with the risk of post ERCP pancreatitis and the low sensitivity for small pancreatic 
lesions compared to other radiological tests. 
Nowadays, two imaging modalities are considered as a candidate for screening HRIs: MRI and 
EUS. Both of them have been employed for surveillance of HRIs as first line modalities but no 
imaging test has gained a univocal evidence based consensus for preferred use.  
EUS has the advantages to perform better in the setting of small lesion with a sensitivity for 
pancreatic lesions less than 2 cm around 93 % with a 100 % of predictive negative value for tumor 
detection[21]. It has also been described how this technique can early detected “worrisome 
features” (e.g. mural nodule, thickened of the cystic wall) in the setting of IPMNs and it also carries 
the advantage to perform guided fine needle aspiration (FNA) that permits to obtain tissue samples 
for a histopathological evaluation of the lesion with low risk of complications (less than 5%). 
Although in the setting of surveillance for PDAC the low negative predictive of FNA ( value equal 
to 64% ) doesn’t allow to a certain exclusion of malignancy when  suspected. 
This modality has been used as imaging tests , alone or in combination with others screening tests,  
in several screening studies. Capurso et al .[10] has showed how the diagnostic yield defined as 
EUS detection of any lesions morphologically suspicious for BD-IPMN or histologically proven 
(pre) malignant lesion (PanIN≥2, IPMN and pancreatic adenocarcinoma)  at baseline evaluation 
and, when performed, during the follow up of EUS is about 22% with a wide range between all 
the studies (from 2.6 to 26% ) (Table 3). Although the number of histologically confirmed target 
lesions for which surgical treatment could be considered a success of the screening program 
(resectable PDAC, MD-IPMN or IPMN with dysplasia, PanIN3) was only 2.2% of all the lesions 
diagnosed. Moreover a considerable amount of HRIs underwent to surgery for a low grade lesions 
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such as PanIN 1-2 or IPMN with low grade of dysplasia or even a nbenign cystic lesion sich as 
serocystic adenoma.  
 
 
 
 
As far as regards MRI, it carries the advantages of being a non-invasive and  less operator 
dependent as compared to EUS. Moreover,  it is a radiologic modalities that offers the possibility 
to detect extrapancreatic lesions without radiation exposure and it show an excellent visualization 
of the ductal system ( pancreatic and biliary tree) and provide a good sensibility in characterizing 
 
Table 3.  Summary of diagnostic yields of  Endoscopic Ultrasound based based protocols for familiar pancreatic cancer screening in       
High risk Individuals  
Study 
(reference) 
Patients and 
Syndrome 
Diagnostic 
Yield 
Solid 
lesions 
(mass or 
nodule) 
Cystic 
lesions 
Chronic 
Pancreatitis 
features 
Pre/malignant 
lesions 
suspected at 
baseline or FU 
Histologically 
confirmed target 
lesions (success )** 
Brentnall et 
al.1999  
13 (FPC) 46.2% - - 10 (77%) 6 (46.2%) ? 
Kimmey et 
al. 2002  
46 (FPC) 26% - - 24 (52.2%) 12 (26 %) ? 
Canto et al 
2004  
38 (FPC, PJS) 10.5 % 
12 
(31.5%) 
- 17 (44.7%) 6 (15.7%) 
2/7 patients who 
underwent resection (1 
PDAC, 1 PanIN3). 
Canto et al 
2006   
78 (FPC, PJS) 10.2% 
8 (10.2%) 
 
9 (11.8%) 
61 (78.2%) 
 
8 (10.2 %) 
3/7 patients who 
underwent resection (1 
IPMN+ca in situ, 1 
IPMN + PanIN3, 1 
PanIN3). 
Poley et al 
2009  
44 (FPC , PJS, 
FAMM, FBOC, 
HP, LFS) 
22.7% 3 (6.8%) 7 (16 %) 3 (6.8%) 
10 (22.7%) 
 
3/3 patients who 
underwent resection (3 
PDAC). 
Langer et al 
2009  
76 
(FPC, FAMM) 
2.6 % 
 
7 (9.2%) 3 (3.9%) 17 (22.3%) 7 (11.8%) 
0/7 patients who 
underwent resection. 
Verna et al 
2010  
31 
(FPC, FBOC) 
22.5% 2 (6.4) 
12 (38.7) 
 
9 (29%) 7 (22.6%) 
1/5 who underwent 
surgery (1  PDAC). 
Canto et al. 
2012  
216 (FPC, 
FBOC, PJS) 
37 % 3 (1.4%) 
79 (36%) 
 
54 (25%) 79 (37%) 
3/5 who underwent 
surgery (2 MD-IPMN, 
1BDIPMN+panIN3) 
Total 542 22.2 % 
35 
(6.5 %) 
110 
(20.3%) 
195 
(36%) 
135 
(25%) 
12/542 
(2.2%) of total 
 
EUS, endoscopic ultrasonography; FNA, fine-needle aspiration; FPC, familial pancreatic cancer; IPMN, intraductal papillary mucinous neoplasm, 
PDAC, pancreatic ductal adenocarcinoma; PJS, Peutz–Jeghers syndrome; PanIN, pancreatic intraepithelial neoplasia, FAMMM: Familial atypical 
multiple mole melanoma; FBOC: Familial breast ovarian cancer; HP: hereditary pancreatitis; LFS: Li fraumeni syndrome 
** Treatment is considered a success if any of the following lesions is found at surgery: resectable PDAC, MD-IPMN or IPMN with dysplasia, PanIN3. 
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cystic lesions such as IPMNs that are the most common precursor lesions diagnosed in HRI [22]. 
In the same review above mentioned[10] , the authors analyzed the  
results of seven papers that employed MRI like a screening modalities for detecting pancreatic 
lesions in HRIs. The diagnostic yield was 26.8 % (ranging from 3.3 to 50.4%) (Table 4) .  Notably, 
the MRI methods varies between  all the studies with an extremely heterogeneity in terms of using 
or not contrast agent and/or secretin and the type of MRI scanner used 
Few studies compared the diagnostic yield of these two modalities in a pancreatic surveillance 
program [23, 24]. Some authors have recently suggested that an MRI-based surveillance program, 
 
Table 4. Summary of diagnostic yield of MRI based protocols for familiar pancreatic cancer screening in high risk individuals 
Study 
(reference) 
Patients 
and 
Syndrome 
Diagnostic 
Yield 
Solid 
lesions 
(mass or 
nodule) 
Cystic 
lesions 
Chronic 
pancreatitis 
features 
Pre/malignant 
lesions 
suspected at 
baseline or FU 
Histologically 
confirmed target 
lesions (success )** 
Langer et al. 
2009   
76 
(FAMMM, 
MPCS, 
FBOC) 
23.3% 6 (7.8%) 2 (2.6%) 1 (1.3%) 12 (15%) 
1/7 who underwent surgery 
(1 PDAC) 
Vasen et al. 
2012  
77 
(FAMMM) 
20.7% 7 (9%) 
Not 
specified 
9 (11.6%) 7 (9%) 
4/5 who underwent surgery 
(4 R0 PDAC) 
Ludwig et al. 
2011  
109 (FPC) 16.5% 1 (0.9%) 
Not 
specified 
2 (1.8%) 18 (17.4%) 
4/6 who underwent surgery 
(2 MD-IPMN, 1 PDAC, 1 
PanIn3) 
Canto et al. 
2012  
216 (PJG, 
FPC, 
FBOC) 
33.7% 1  (0.4%) 71 (32.8%) - 45 (20.8%) 
3/5 who underwent surgery 
(1 MD-IPMN+ HGD,  1MD 
IPMN, 1 BD IPMN+ 
PNET+HGD) 
Al-Sukhni et 
al. 2012  
226 (PJG, 
FPC, 
FBOC, 
FAMMM, 
HP) 
50.4% 2 (0.8%) 80 (35.3%) 25 (11%) 5 (2%) 
1/4 who underwent surgery 
(1 PDAC) 
Verna et al. 
2010 
 
33 (FPC, 
FAMMM, 
FBOC, 
HNPCC) 
3.3% 3 (9%) 7 (21.2%) 1 (3%) 5 (15%) 
Not specified how may 
pathological reports had 
been previously described 
in MRI 
Total 737 34% 20 (2.7%) 160 (21.7%) 38 (5.1%) 92 (12.4%) 13/737 (1.7%) of total 
 
FPC, familial pancreatic cancer; IPMN, intraductal papillary mucinous neoplasm, PDAC, pancreatic ductal adenocarcinoma; PJS, Peutz–Jeghers 
syndrome; PanIN, pancreatic intraepithelial neoplasia, FAMMM: Familial atypical multiple mole melanoma; FBOC: Familial breast ovarian 
cancer; HP: hereditary pancreatitis. 
** Treatment is considered a success if any of the following lesions is found at surgery: resectable PDAC, MD-IPMN or IPMN with dysplasia, 
PanIN3. 
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with additional EUS at baseline and every 3rd year or when changes in MRI occur, appears to be 
efficient in the surveillance of FPC families[25] . 
 
 
Aim of the studies  
As compared to others screening policies, surveillance for HRIs to develop PDAC still carries 
various areas of improvement and some issues to be clarified. For this reason, it is indicated only 
in reference centers as a research protocols. 
However so far several screening programs for HRIs has been published all over the world, the 
results are still difficult to interpret because of different policies employed in terms of HRIs 
enrolled, screening test chosen, and follow-up intervals so as data on the efficacy of such 
surveillance programs are still limited and heterogeneous. 
Both magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS) have 
been employed as first line modalities for HRIs surveillance, but no imaging test has gained a 
univocal evidence-based consensus.  
Furthermore, the results of screening might be different in terms of relevant detected 
lesions depending on the t HRIs subgroups enrolled. As an example, patients with FAMMM were 
reported to develop more solid lesions while FPC individuals more cystic ones[26, 27].  
No one of the screening studies in literature was conducted in Italy at so that a national protocol 
for PDAC surveillance was needed, as already reported in a position paper in 2010 written by the 
Italian Association for the Study of the Pancreas (AISP) [28]. 
Finally, it is still unknown if some pancreatic parenchymal changes as called chronic pancreatitis-
like features  related to the presence of microscopic PDAC precursor ( Pan-INs) and the presence 
17 
of IPMNs might show a different risk of progression and  characteristics in HRIs compared to the 
general population.  
To improve the knowledge on this field we therefore conducted the subsequent studies: 
1) A systematic review and meta-analysis of the surveillance studies published  aimed to 
asses in individuals at high risk to develop  PDAC: a) the prevalence of solid and cystic 
lesions and of lesions considered a successful target of the surveillance programs; b) the 
prevalence of solid and cystic lesions diagnosed by EUS and/or MRI; c) the prevalence of 
lesions considered a successful target of the surveillance programs in the different HRIs 
subgroups. 
2) A multicenter surveillance program included asymptomatic HRIs with familial (FPC) or 
genetic frailty (BRCA1/2, p16/CDKN2A, STK11/LKB1 and PRSS1 mutations) 
predisposition to PC published as results of the first screening round of the Italian 
multicenter program supported by the Italian Association for the study of the Pancreas 
(AISP). 
 
3) A Case-control study on pancreatic changes in High-Risk Individuals compare to 
control to evaluate the pancreatic parenchyma changes of HRIs and asses if some them 
(such as cystic lesions or chronic pancreatitis features) occur more often in the setting of a 
high risk population compared to healthy controls.  
 
4) A Systematic review and meta-analysis on the prevalence of incidentally detected 
pancreatic cystic lesions in asymptomatic individuals, conducted as an ancillary study 
to better clarify the prevalence Pancreatic cystic lesions (PCLs) in asymptomatic 
individuals particularly mucinous lesions (PDAC precursors). 
18 
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ABSTRACT  
Background: Data on surveillance for pancreatic ductal adenocarcinoma (PDAC) in high-risk 
individuals (HRIs) with “familiar pancreatic cancer” (FPC) and specific syndromes are limited 
and heterogeneous.  
Objective: We conducted a systematic review and meta-analysis of PDAC surveillance studies. 
Methods: Prevalence of solid/cystic pancreatic lesions and of lesions considered a successful 
target of surveillance (proven resectable PDAC and high-grade precursors) was pooled across 
studies. The rate of lesions diagnosed by EUS/MRI and across different HRIs groups were 
calculated.  
Results: Sixteen studies incorporating 1588 HRIs included. The pooled prevalence of pancreatic 
solid and cystic lesions was 5.8% and 20.2%, respectively. The pooled prevalence of patients with 
lesions considered a successful target of surveillance was 3.3%, being similar with EUS or MRI 
and varied across subgroups, being 3% in FPC, 4% in hereditary pancreatitis, 5% in familiar 
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melanoma, 6.3% in hereditary breast/ovarian cancer and 12.2% in Peutz Jeghers. The pooled 
estimate rate of lesions considered a successful target of surveillance during follow-up was 5/1000 
person-years.  
Conclusion: Surveillance programs identifiy successful target lesions in 3.3% of HRIs with 
similar yield of EUS and MRI and an annual risk of 0.5%. A higher rate of target lesions was 
reported in HRIs with specific DNA mutations.  
 
Key Summary 
 
1. Summarize the established knowledge on this subject: 
- Surveillance of pancreatic cancer is advised in subjects with “familiar pancreatic 
cancer” (FPC) and specific genetic syndromes.   
- No evidence-based consensus is available on the imaging test preferred between 
magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS).  
- Whether surveillance protocols should be different in the different high-risk individuals 
subgroups is unknown. 
2. What are the significant and/or new findings of this study?  
- The rate of resected lesions considered a successful target of surveillance during 
pancreatic cancer surveillance programs in HRIs is 3.3% or 0.5% per year. 
- No differences between EUS and MRI in diagnosing “successful” target of the 
screening.  
- The rate of successful target lesions in FPC is lower compared to specific genetic 
syndromes, thus surveillance programs might need to be accordingly individualized. 
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INTRODUCTION 
 
Pancreatic Ductal Adenocarcinoma (PDAC) is an increasing cause of cancer-related death, 
partially because of delayed diagnosis[1, 2]. Although precursor lesions, such as intraductal 
papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanINs) can be 
detected at an early stage [3] , a screening program is not advised for the general population as the 
overall lifetime PDAC risk is relatively low. 
However, since a hereditary component accounts for 5-10% of cases [3] surveillance is advised 
for high-risk individuals (HRIs). The International Cancer of the Pancreas Screening (CAPS) 
Consortium [4] defined subjects with “familial pancreatic cancer” (FPC) or with hereditary 
syndromes of which PDAC is one phenotypic manifestation as candidates for surveillance. FPC 
definition is not fully established, but an individual can be considered at high risk if ≥ two blood 
relatives are affected by PDAC, of whom at least one is a 1st degree relative (FDR).  Regarding 
genetic syndromes with a known mutation, surveillance is indicated for all Peutz–Jeghers 
syndrome (PJS) patients regardless of family history. Furthermore, p16 (familial atypical multiple 
mole melanoma syndrome, FAMMM), BRCA2, PALB and mismatch repair gene (hereditary 
nonpolyposis colorectal cancer, HNPCC) mutation carriers with one FDR or two other family 
members with PDAC should undergo surveillance [5]. 
The ultimate goal of surveillance is to detect and surgically treat noninvasive precursor lesions, 
such as advanced PanINs or IPMNs with high-grade dysplasia, or early-stage PDAC, that are 
considered successful targets of surveillance according to the CAPS Consortium.4 Data on the 
efficacy of such surveillance programs in HRIs in terms of identification of the above-mentioned 
lesions are limited and heterogeneous, thus HRI surveillance is generally performed in the setting 
of research protocols. Both magnetic resonance imaging (MRI) and endoscopic ultrasonography 
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(EUS) are employed as firstline modalities for HRI surveillance, but no imaging test has gained 
evidence-based consensus[6,7].  Furthermore, the results of screening might differ in terms of 
detected lesions in each HRI subgroup. As an example, patients with FAMMM were reported to 
develop more solid lesions while FPC individuals more cystic ones[8,9]. 
This systematic review and meta-analysis is therefore aimed to assess in HRIs (a) the prevalence 
of solid and cystic lesions and of lesions considered a successful target of surveillance, (b) the 
prevalence of lesions diagnosed by EUS and/or MRI, and (c) the prevalence of lesions considered 
a successful target of the surveillance in different HRI subgroups. 
MATERIALS AND METHODS 
 
Search strategy 
A search of PubMed and Scopus databases (see Appendix 1) was run until June 2017 to identify 
studies investigating the prevalence of pancreatic lesions in HRIs in surveillance programs. 
Duplicates were removed. The methodology was developed from the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) statement[10]. 
 The titles of all identified articles were assessed for their relevance, and abstracts and/or 
full texts of potentially relevant papers screened and evaluated. A manual search of all relevant 
articles and references was conducted to identify further relevant studies. 
 
Inclusion and exclusion criteria 
Inclusion criteria were: English language, inclusion of patients belonging to FPC families and/or 
with other specific high-risk syndromes or germline mutations carriers, surveillance carried out 
with MRI and/or EUS, the prevalence and type of diagnosed pancreatic lesions (solid and/or cystic) 
was reported. In the case of duplicate publications, the most recent or the most informative was 
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included. Two independent reviewers (MS and GZ) carried out study identification, selection and 
discussed disagreements with a third reviewer (GC). Excluded studies and the reasons for 
exclusion were recorded. 
Data extraction and quality assessment 
Two reviewers (MS and GZ) independently extracted data from each study into a Microsoft Excel 
spreadsheet (XP Professional Edition; Microsoft Corp., Redmond, Washington, USA). 
Disagreements were resolved by consulting a third reviewer (GC). Study year, design and location, 
number of screened subjects and type of high-risk subgroups and of imaging, duration of follow-
up, number and type of diagnosed lesions and of patients with an indication for surgery and with 
an identified lesion considered to be a success of the surveillance or diagnosed with 
advanced/metastatic PDAC were recorded. A summary table of the relevant studies listing the 
population characteristics and outcomes was developed. The quality of the studies was evaluated 
independently by two reviewers (MS and GC) using the Newcastle–Ottawa Scale[11] with a 
dedicated quality appraisal tool including 7 items. Studies with a score ≥7 were considered of high 
quality. 
Data analysis 
We examined 1) the pooled prevalence rate of all solid or cystic lesions 2) the pooled prevalence 
of lesions being considered a successful target of the surveillance protocols as defined by gold-
standard pathology after surgery. Lesions considered as successful target of surveillance were: 
PanIN3 (or high grade PanIN if not specified), IPMNs with high grade dysplasia or main 
duct/mixed type IPMN, any resectable PDAC with R0 pathology. This definition is adapted from 
the CAPS one, as some of the papers did not provide enough information for detailed grouping; 3) 
the pooled prevalence rate of advanced/metastatic PDAC, not amenable of R0 resection. 4) the 
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pooled prevalence of the above-mentioned lesions detected either by EUS or by MRI. 5) the pooled 
prevalence of successful target lesions in each specific HRIs group.  
Data were combined to generate a pooled prevalence rate. To better reflect the incidence of 
detected lesions over time, we also calculated the incidence rates of lesions being a successful 
target of surveillance by dividing the total number of events by the total number of person-years 
(pyrs) of follow-up. If these latter data were not provided in a study, it was estimated by 
multiplying the number of patients who underwent surveillance by the reported mean follow-up 
time. The corresponding 95% confidence intervals (CIs) were calculated using exact methods and 
assuming a Poisson distribution. When the number of events was 0, a continuity correction of 0.5 
was used for the purpose of calculation, as previously reported[12]. 
A meta-analysis was performed using the software package Comprehensive Meta-Analysis 
(Biostat, Englewood, New Jersey, USA) by using a random-effects model[13]. In addition to 
within-study variance, the random effects model considers heterogeneity among studies and gives 
more conservative estimates. The quantity of heterogeneity was assessed by means of the I2 
value[32]. The I2 describes the percentage of total variation across studies that is caused by 
heterogeneity and not by chance. Publication bias was assessed using the Begg and Mazumdar 
test. A p-value<0.05 was accepted as statistically significant. We also developed the following a 
priori hypotheses that would explain heterogeneity and planned sensitivity analyses for 1) Area of 
origin (i.e. USA/Canada or Europe); 2) quality of the study (quality score>7 or ≤7).  
  
26 
RESULTS 
Search results and study selection and characteristics 
The process of study selection is summarized in Figure 1. Sixteen studies met the eligibility 
criteria and were included for qualitative analysis and quantitative synthesis. One of them[15], is 
a multicenter study whose findings were already reported in three previous single-center studies[9, 
16,17]. As the population of this latter study was larger and the results regarding the different HRIs 
subgroups more detailed, we used this manuscript for the analysis of pooled prevalence of overall 
lesions. However, as this more recent paper does not report the exact number of cystic/solid lesions 
diagnosed by either EUS or MRI, we used data from the older studies for the analyses on the role 
of MRI and EUS. 
The descriptive characteristics of the 16 included studies are shown in Table 1. Two papers 
reported only the first surveillance round[18,19] while two other studies did not report the exact 
follow-up period[20,21]. The mean follow-up in studies reporting>one surveillance round[2, 6-7, 
15,22-26] was 32.4 months. The total number of enrolled HRIs was 1588. Considering the 1572 
individuals for whom this information was available, the largest group of screened individuals was 
FPC (1043, 66.3% of total) followed by FAMMM (243, 15.4%) and HBOC individuals or carriers 
of BRCA1/2 mutations (140, 8.9%). Some of studies also enrolled subjects that did not meet the 
criteria to be designated as “HRI” according to the CAPS consortium[2, 7,18-20]. There were 4 
subjects with Li-Fraumeni syndrome [9,22], 5 with only one affected family member [25], 9 with 
a family member with early onset PDAC [24], and 6 with>1 relative with a cancer being not 
pancreatic[2]; all together those subjects accounted for 1.6% of the investigated individuals. Two 
studies enrolled patients with a very low risk to develop pancreatic cancer based on family history 
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[19,21] and those subjects therefore were not included in the analysis. Only four[4, 7, 20,25] of 
the sixteen  studies were scored as of ‘high quality’. 
 
Figure.1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of assessment of 
studies identified in the preset systematic review. 
 
Prevalence of solid pancreatic lesions in HRIs 
A total of 79 pancreatic solid lesions were detected during the surveillance programs, with a pooled 
prevalence of 5.8% (95%CI 3%–9%; I2=77.5%) (Figure 2). No publication bias was found (Begg 
and Mazudmar Kendall’s tau=-0.21; p=0.27). When considering only the 7 studies conducted in 
USA or Canada, the pooled estimate prevalence was 3.8% (95%CI 2-8; I2=68.8%), compared to 
6.8% with similar heterogeneity (95%CI 4-12; I2=61.2%) in the 6 studies from Europe. The pooled 
prevalence of solid lesions in studies of high quality [4,7,20,25] was 2.8% (95%CI 1%–6 %) 
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compared to 7.7% (95%CI 5%–12%) in the eleven studies of lower quality[2,9,16–19,21–24,26], 
with lower heterogeneity (I2= 38.2% vs I2=72.3%) in high quality studies.   
Prevalence of Cystic Pancreatic lesions 
A total of 340 pancreatic cystic lesions were detected during the surveillance programs with a 
pooled prevalence of 20.2% (95%CI 14%–28%; I2 =88.9%) (Figure 2). Information on prevalence 
of pancreatic cystic lesions was not provided in one study[44]. No publication bias was found 
(Begg and Mazudmar Kendall’s tau=-0.34 p=0.09). The pooled prevalence of cystic lesions was 
23.4% (95%CI 16%–34%; I2 =84.1%) in the 7 studies conducted in USA and Canada, and 18.4% 
(95%CI 8%–37%; I2 =92.1%) in the studies conducted in Europe. In studies with a high quality 
score[9, 24, 38, 43], the pooled prevalence of cystic lesions was 33.6% (95%CI 21%–49%; I2= 
90.3%), being higher than the 15.4% (95%CI 10%–24%) of studies with a low quality score [2, 
27, 34-37, 39-42, 44] yet with similar heterogeneity(I2 =83.7%). 
 
Prevalence of successful target lesions of the surveillance 
Of 1588 screened HRIs, 95 were considered to have an indication for surgery (pooled prevalence 
6.8%; 95% CI 4%–11%; I 2¼ 81%). However, the pooled prevalence of individuals for whom 
surveillance identified a lesion considered a successful target of surveillance was 3.3% (95% CI 
2%–5%; I 2¼ 40.5%) (Figure 3). In high-quality studies, this pooled prevalence was 2.9% (95% 
CI 1%–8%; I 2 ¼ 69.2%), being 3.4% (95% CI 2%–5%; I 2¼ 23.4%) in studies of lower quality. 
In the sensitivity analysis by country of origin, the pooled prevalence was 2.7% (95% CI 1%–5%; 
I 2¼ 43.3%) for studies conducted in the USA or Canada and 4.1% (95% CI 2%–8%; I 2 ¼ 52.2%) 
for studies conducted in Europe. No publication bias was found (Begg and Mazudmar Kendall’s 
tau ¼ –0.16; p ¼ 0.45). Furthermore, when we repeated this analysis excluding individuals who 
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were not at high risk according to the guidelines [2,7,18–20] the pooled prevalence was 3.4% (95% 
CI 2%–5%; I 2¼ 44.7%). As the ideal target of the surveillance programs should be the diagnosis 
of ‘‘premalignant’’ lesions, the pooled prevalence rate of advanced IPMNs and PanIN3 lesions 
was also calculated, and resulted in 1.6% (95% CI 1%–2%; I 2¼ 0%) (see Supplementary Figure 
1). In detail, 26 (1.6%) patients were diagnosed with a resectable PDAC, 11 (0.7%) with branch 
duct (BD)- IPMNs with high-grade dysplasia or an MD-IPMN, and four (0.3%) with advanced 
PanINs. Six individuals were diagnosed with pancreatic neuroendocrine neoplasms (pNENs) 
[2,6,15,24].  Four of them were resected and all but one2 had a diameter <15 mm. Type and 
number of histologically confirmed lesions, including those successfully operated on, are 
summarized in Supplementary Table 1. The pooled estimate rate of lesions considered a successful 
target of surveillance was calculated for 11 studies in which follow-up length was reported, and 
resulted in 0.005/pyrs (95%CI 0.001%–0.005%; I 2 ¼ 56%), equal to 5/1000 pyrs (Figure 4). 
 
Prevalence of advanced /metastatic pancreatic adenocarcinoma  
During the surveillance programs, nine advanced/metastatic adenocarcinoma were diagnosed. Six 
metastatic PDAC were diagnosed and histologically confirmed by percutaneous or EUS-guided 
fine needle aspiration [2,9,19,23] the other three underwent surgical resection but histology 
showed a positive resection margin [9,15] The pooled prevalence of HRIs for which surveillance 
identified advanced PDAC was 1.0% (95% CI 1%–2%), without heterogeneity (I 2¼ 0%). 
 
 
30 
Table 1. Study demographics, population size and characteristics.  
 
 
* Includes high risk individuals from Langer 2009, Vasen 2011 and Mocci 2015 
  # The exact number of each HRIs is not provide 
FPC: Familial pancreatic cancer; FAMMM: familial atypical multiple mole melanoma syndrome; HBOC: Hereditary breast-ovarian cancer syndrome; PJS: Peutz–Jeghers 
syndrome ; HP: hereditary pancreatitis LFS: Li-fraumeni syndrome; EOPCF: early onset pancreatic cancer family,  MCFDR: multi cancers first degree relatives; OFMA: one 
family member affected, EUS : Endoscopic Ultrasound ; MRI: Magnetic Resonance Imaging; MRCP: Magnetic resonance cholangiopancreatography ; 
CE:  Contrast Enhancement;  CT: Computed Tomography; NR: not reporte 
 
First Author of 
the study 
 
 
Year 
 
Country 
 
 
Study 
design 
 
 
Number 
screened 
 
Mean age 
(range) 
 
Types of High-risk group screened 
 
Mean Months 
of Follow-up 
(intervals) 
 
Type of imaging 
 
Kimmey [22] 
 
 
2002 
 
USA 
 
Single center 
 
46 
 
NR 
 
46 FPC 
 
60  
 
EUS 
Canto [23] 2006 USA Single center 78 52 (32-77) 72 FPC,6 PJS 12 (within one 
year) 
EUS  
Poley [18] 
 
2009 The Netherlands  Multicenter 44 Nr (32-75) 21 FPC,3 BRCA1, 2 BRCA2, 2 PJS, 13FAMMM, 
2 HP, 1 LFS 
Baseline  EUS 
Langer [16] 2009 Germany Multicenter 76 NR FPC, FAMMM# NR (annualy) EUS and MRI/MRCP 
with CE 
Verna  [19] 2010 USA Single center 41 52 (29-77) 30 FPC, 6 BRCA1/2, 5 OFMA Baseline  EUS and MRI (MRCP) 
Ludwig [20] 2011 USA Single center 109 54 (43-65) 93 FPC ,7 BRCA, 9 EOPCF   NR MRCP 
Vasen [15] 2011 The Netherlands  Single center 79 56 (39-72) 79 FAMMM 48 (annualy) MRI/MRCP with CE 
Canto (CAPS3) 
[4] 
2012 USA Multicenter 216 56 (28-79) 195 FPC,19 BRCA2 ,2 PJS 28.8 (1 to 3 
years ) 
EUS and CT and 
MRI/MRCP with CE 
and secretin 
Al-Sukhni [ 2] 
 
2012 Canada Single center 226 54 (22-89) 146 FPC, 51 BRCA2,5BRCA1, 10 FAMMM, 6 
PJG, 2HP, 6 MCFDR  
50.4 (annualy) 
 
MRI/MRCP without 
CE 
Sud [24] 2014 USA Single center 16 NR FPC, BRCA1, BRCA2, PJS, FAMMM, HNPCC# 12(annualy) EUS 
Harinck  [7] 
 
2015 The Netherlands  Multicenter 139 51 (20-73) 68 FPC, 3 BRCA1, 20 BRCA2, 38 FAMMM, ,7 
PJS,3 LFS 
12 ( annualy) EUS and MRI/MRCP 
with CE 
Del Chiaro 
[ 25] 
2015 Sweden Single center 40 50 (23-76) 32 FPC, 3 BRCA2, 1 BRCA1, 4 FAMMM 12.9 (annualy) MRI/MRCP with 
secretin 
Mocci [17] 
 
2015 Spain Multicenter 41 NR 24 FPC, 12 HBOC, 
5 EOPCF 
24 (3 to 12 
months ) 
EUS and CT 
Joergensen [26] 2016 Danmark Multicenter 71 51 (27-72) 40 FPC, 31 HP 60 (annualy) EUS 
Vasen* [15] 2016 The Netherlands, 
Gemany, Spain 
Multicenter 411 NR 214 FPC,178 FAMMM, 19 BRCA1/2 PALB2 43.2 (annualy)  EUS and/or MRI 
Chang [25] 2017 Taiwan Single center 151 NR 1 BRCA2, 64 HP, 86 FPC NR (annauly) MRI/MRCP with CE 
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Figure 2. Forest plot showing the pooled prevalence of pancreatic solid lesions (panel A, on the left) diagnosed in 
high-risk individuals in all the 14 included studies and of the pooled prevalence of cystic lesions (panel B, on the right) 
diagnosed in high-risk individuals in the 13 studies reporting this information. Random-effects model demonstrating 
a pooled prevalence of 5.8 % (95% CI 3%–8%) with moderate heterogeneity (I2=77.5%) for solid lesions and a pooled 
prevalence of 20.2 % (95% CI 14%–29%) with considerable heterogeneity (I2=88.9 %) for the cystic ones. 
 
 
Prevalence of pancreatic lesions diagnosed either by EUS or by MRI  
Ten studies employed EUS [6,7,16–19,22–24,26] and nine MRI [2,6,7,9,16,19–21,25] The pooled 
prevalence of solid lesions was higher in studies employing EUS (5.2%, 95% CI 3%–9%; I 2¼ 
60.6%) compared with those using MRI (4.1%, 95% CI 2%–9%; I 2¼ 83%) (Figure 5). The pooled 
prevalence of cystic lesions was instead 22.4% (95% CI 15%–32%; I 2¼ 89.3%) with MRI and 
16.6% (95% CI 10%–27%; 85.7%) with EUS in the eight studies providing this information, which 
was lacking in two studies.17,26 The pooled prevalence of pancreatic lesions considered a 
successful target of surveillance was 2.9% with EUS (95% CI 2%–5%; I 2¼ 27.4%) and 2.5% 
with MRI (95% CI 1%–5%; I 2 ¼ 51.7%) (see Figure 5). 
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Figure 3. Forest plot showing the overall pooled 
prevalence of successful target lesions of the 
surveillance that is equal to 3.3% (95% CI 2%–
5%), with moderate heterogeneity (I2=40.5%). 
 
 
 
 
 
Prevalence of lesions considered a successful target of surveillance in different HRIs subgroups 
The pooled prevalence of lesions considered a successful target of surveillance was 3% (95% CI 
2%–5%; I 2¼ 22.2%) in FPC individuals. In people with a specific genetic syndrome it was 4% in 
HP (95% CI 1%–14%), 5% for FAMMM (95% CI 3%–9%), 6.3% in HBOC or BRCA1/2, PALB2 
mutation carriers (95% CI 3%–14%), and 12.2% in PJS (95% CI 4%– 32%), without heterogeneity 
(I 2¼ 0%) in all these subgroups except for people with HP (I 2¼ 12.2%) (Figure 6). We also 
analyzed the pooled prevalence rate of histologically confirmed solid lesions diagnosed at the 
baseline examination in each subgroup. These data were available for all studies but one.21 The 
pooled rate of solid lesions at baseline resulted respectively in: 1.6% (95% CI 1%–3%; I 2¼ 0%) 
in FPC, 5.8% (95% CI 2%–14%; I 2¼ 0.8%) in HBOC or BRCA1/2 mutation carriers, 4.6% (95% 
CI 2%–12%; I 2¼ 35%) in FAMM, 12% (95% CI 4%–32%; I 2 ¼ 0%) in PJS, and 7.2% (95% CI 
1%–30%; I 2¼ 0.8%) in HP. The number of pancreatic cancer cases and the relative proportion of 
unresectable/metastatic cases were respectively 12 (25% metastatic) in FPC, 15 (20% metastatic) 
in FAMMM, four (25% metastatic) in HBOC, and one (0% metastatic) in HP. No PDAC cases 
were diagnosed in PJS patients. 
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Table 2. Histologically proven pancreatic lesions diagnosed during the screening programs. 
 
*one of them was multifocal  
PDAC: Pancreatic Ductal Adenocarcinoma; IPMN: intraductal papillary mucinous neoplasms; PanIN: pancreatic 
intraepithelial neoplasia SCA: Serous Cystadenoma;  pNENs: pancreatic neuroendocrine neoplasms 
 
 
 
 
 
Figure 4. Summary of the pooled 
prevalence of pancreatic lesions (solid, 
cystic and successful target lesions of the 
surveillance) diagnosed either by 
Endoscopic Ultrasound (EUS) or Magnetic 
Resonance (MRI)
Study 
 
Successfull target lesions    Other lesions                                                              
Resecabl
e PDAC  
IPMN  PanIN3 Advanced/
Metastatic 
PDAC 
IPMN PanIN
1/2 
SCA pNEN 
Kimmey - - - - - 15 - - 
Canto(2006) - 3 - 1 3 1 - - 
Poley 3 - - - - - - - 
Verna  1 - - 1 4 - - - 
Ludwig 1 2 1 - - 1 1 - 
Canto(CAPS3) - 3 - - 2 - - 3* 
Al-Sukhni 1 - - 2 1 1 - 1 
Sud 2 - - - 1 - - 1 
Harinck 1 - - - - 2 - - 
Del Chiaro 3 1 - - 1 - - - 
Joergensen  2 - - - - - - - 
Vasen (2016) 9 1 3 5 7 3 4 1 
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DISCUSSION 
 
As data on the prevalence of lesions diagnosed during surveillance programs in individuals at high 
risk of PDAC are scanty and heterogeneous, we conducted a meta-analysis to estimate the pooled 
prevalence of solid and/or cystic lesions, and more important, whether detected lesions could be 
considered a successful target of surveillance. We also calculated the pooled estimated rate of 
detected lesions during the course of subsequent surveillance rounds, the prevalence of lesions 
diagnosed by either EUS or MRI, and the differential prevalence of lesions among the various HRI 
subgroups. Data from 1588 enrolled HRIs were included. The pooled prevalence of solid and 
cystic lesions in these individuals was 5.8% and 20.2%, respectively (Figure 2). The pooled 
prevalence of lesions considered a successful target of surveillance according to the CAPS 
definition was 3.3% (Figure 3), while the actual pooled prevalence of ‘‘preneoplastic’’ target 
lesions (advanced IPMNs and PanIN3 lesions) was 1.6% (see Supplementary Figure 1). The 
pooled estimated rate of lesions considered a successful target of surveillance during follow-up 
amounted to five cases per 1000 pyrs, equal to an annual risk of 0.5% (Figure 4). EUS seemed 
able to diagnose more solid lesions and MRI more cystic ones (Figure 5). Moreover, the rate of 
lesions considered a successful target of surveillance was much lower in FPC compared to HRI 
with specific syndromes (Figure 6). This is not surprising as in FPC the causal mutation is 
unknown despite a clear autosomal dominant inheritance pattern. Therefore, half of FPC 
individuals undergo surveillance without carrying the causal mutation. Of the 1588 screened HRIs, 
6.8% underwent surgery, with histologically confirmed lesions considered a successful target of 
surveillance in 3.3%. To date, there is little consensus about which lesions detected by surveillance 
represent an indication for surgery [4]considering the morbidity of pancreatic surgery[27] It is 
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unknown whether for example in the case of BDIPMNs the same criteria for resection apply in 
HRIs compared to sporadic cases[28]. A recent study showed that cystic lesions diagnosed in HRIs 
with a known mutation are more prone to progress compared to those discovered in FPC 
individuals, although this latter group had a significantly higher prevalence of cystic lesions.29 
There is also evidence of a high rate of lymph node involvement and poor prognosis in HRIs with 
PDAC even with very small lesions [9,18] This might justify a more aggressive attitude toward 
resecting precursor lesions in this setting. A proportion of patients diagnosed with PDAC (n ¼ 9, 
pooled prevalence 1%) were identified at an advanced/metastatic stage. Two of them were 
prevalent cases diagnosed at baseline. The other patients who underwent surgical resection with 
positive resection margins, or who were diagnosed with an unresectable interval cancer during 
subsequent follow-up, however, should be considered a failure of surveillance. The proportion of 
unresectable PDAC was similar in people with FPC, FAMMM, and HBOC. This raises concerns 
about the validity of currently performed surveillance programs. In four cases the resected lesions 
were pNENs, only one [2] with diameter >1.5 cm. The European Neuroendocrine Tumours Society 
guidelines[30] would not recommend surgery for incidentally detected pNENs. 
Few studies compared the diagnostic yield of EUS and MRI/magnetic resonance 
cholangiopancreatography. A high concordance between the two methods was described by Canto 
et al.[6] while only a 55% agreement was shown by Harinck et al.[7] for the detection of clinically 
relevant lesions. In the present study, the pooled prevalence of solid lesions detected by EUS was 
higher compared to MRI (5.2% vs 4.1%), while MRI had a higher yield for cystic lesions (22.4% 
vs 16.6%). The pooled prevalence of lesions considered a successful target of surveillance was 
similar for EUS and MRI. A limitation of this analysis is the high heterogeneity between studies 
in terms of MRI protocols, and the use of radial EUS in some studies, while linear EUS is able to 
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detect more pancreatic lesions in HRIs [31] The two methods might be considered complementary 
rather than interchangeable in surveillance programs[7]and their use should be tailored considering 
local expertise. The yield of surveillance programs in different HRI subgroups is another 
interesting subject. The pooled prevalence of lesions considered a successful target of surveillance 
in the present meta-analysis was 3% in FPC individuals, representing the majority of people 
screened, 4% in HP, 5% in FAMMM, 6.3% in HBOC, BRCA1/2, or PALB2 mutations carriers, 
and 12.2% in PJS. Notably, while the results obtained in FPC showed a certain heterogeneity, this 
was not the case in patients with genetic syndromes. It would be attractive to tailor surveillance in 
terms of age at which to start, modality, and follow-up intervals based on the frequency and growth 
characteristics of the lesions diagnosed in each HRI subgroup. Vasen et al.[15] recently reported 
that IPMNs with high-grade dysplasia and multifocal PanINs3 were more frequent in FPC 
compared to FAMMM patients, while the rate of diagnosed PDAC was higher in this latter group. 
Further studies into the differential risk and growth characteristics of the various subgroups of 
HRIs are needed. This is the first study to systematically appraise the available literature evidence 
from surveillance studies in HRIs for developing PDAC. Although we developed a priori 
hypotheses for sensitivity analyses considering likely sources of heterogeneity, the observed 
heterogeneity between studies reflecting differences in surveillance tests, intervals, type of 
reported lesions, and kind of HRIs enrolled is a potential limitation. The lack of individual patient 
data limited the possibility of performing any analysis other than that of aggregate data, and the 
influence of factors such as the age of the individuals enrolled in the surveillance programs, and 
the relevance of risk factors such as smoking, could not be appropriately considered. In conclusion, 
the pooled prevalence rate of resected lesions that can be considered a successful target of 
surveillance during PDAC surveillance programs in HRIs is 3.3% with an annual risk of 0.5%. 
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The pooled prevalence rate of successful ‘‘premalignant’’ target lesions is, however, lower and 
equal to only 1.6%. A higher prevalence rate was observed in HRI carriers with a specific DNA 
mutation compared to HRIs with FPC in whom the mutation is unknown. 
 
 
  
 
Figure 5. Forest plot showing the 
pooled estimate rate of successful 
target lesions of the surveillance in the 
11 studies that reported the follow-up 
length. The pooled estimate rate 
resulted of 5/1000 person years with 
moderate heterogeneity (I2=56%). 
 
 
 
 
 
 
 
 
 
 
Figure 6. Pooled prevalence of lesions considered a 
successful target of surveillance in the different high risk 
individuals subgroups. The pooled prevalence of lesions 
considerable a successful target of surveillance diagnosed 
in familial pancreatic cancer (FPC) was 3 % (95% CI 2%–
5%) with moderate heterogeneity (I2=22.2%). The pooled 
prevalence in familial atypical multi mole melanoma 
syndrome (FAMMM) was 5% (95% CI 3%–9%), in 
hereditary pancreatitis (HP) was 4 % (CI 1%–14%),  in 
hereditary breast-ovarian cancer syndrome (HBOC) or 
BRCA1/BRCA2 or PALB2  mutation carriers was 6.3% 
(95% CI 3%–14%), and in Peutz–Jeghers syndrome (PJS) 
it was 12.2% (95% CI 4%–32%). Notably, in all these 
genetic syndromes but HP, there was no heterogeneity (I2  
equal to 0%).  
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Appendix 1: Search strategy  
(Neoplasm, Pancreatic OR Pancreatic Neoplasm OR Neoplasms, Pancreas OR Pancreas 
Neoplasm OR Neoplasms, Pancreatic OR Cancer of Pancreas OR Pancreas Cancers OR 
Pancreas Cancer OR Cancer, Pancreas OR Cancers, Pancreas OR Pancreatic Cancer OR Cancer, 
Pancreatic OR Cancers, Pancreatic OR Pancreatic Cancers OR Cancer of the Pancreas)  
AND (Cancer Early Detection OR Cancer Screening OR Screening, Cancer OR 
Cancer Screening Tests OR Cancer Screening Test OR Screening Test, Cancer OR 
Screening Tests, Cancer OR Test, Cancer Screening OR Tests, Cancer Screening OR 
Early Diagnosis of Cancer OR Cancer Early Diagnosis)  
AND (High Risk OR High-Risk individuals OR High-Risk patients OR High-Risk cohort OR 
High-Risk population OR  FPC OR familial pancreatic cancer OR inherited pancreatic cancer 
OR HBOC OR hereditary breast and ovarian cancer syndrome OR BRCA OR FAMMM OR 
familial atypical multiple mole melanoma OR PJS OR Peutz–Jeghers syndrome OR HNPCC OR 
hereditary nonpolyposis colorectal cancer OR PALB OR mismatch repair gene mutation OR 
Genetic Susceptibility OR Genetic Susceptibilities OR Susceptibilities, Genetic OR 
Susceptibility, Genetic OR Genetic Predisposition OR Genetic Predispositions OR 
Predispositions, Genetic OR Predisposition, Genetic) 
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Study highlights: 
 
› WHAT IS CURRENT KNOWLEDGE 
 Pancreatic cancer surveillance programs may detect malignant and pre-malignant lesions 
in high-risk individuals. 
 Two groups of HRIs can be identified, one with a familial predisposition and one with a 
known genetic frailty.  
› WHAT ARE THE NEW FINDINGS? 
 After the first-round of screening of the Italian registry the rate of malignancies was 
2.6%. 
 Some risk factors for the detection of pre-malignant or malignant lesions were found. 
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Abstract 
Introduction: Surveillance programs on high-risk individuals (HRIs) can detect premalignant 
lesions or early pancreatic cancer (PC). We report the results of the first screening round of the 
Italian multicenter program supported by the Italian Association for the study of the Pancreas 
(AISP). 
Methods: The multicenter surveillance program included asymptomatic HRIs with familial (FPC) 
or genetic frailty (GS: BRCA1/2, p16/CDKN2A, STK11/LKB1 and PRSS1) predisposition to PC. 
The surveillance program included at least an annual magnetic resonance 
cholangiopancreatography (MRCP). Endoscopic ultrasound (EUS) was proposed to patients who 
refused or could not be submitted to MRCP.  
Results: One-hundreds eighty-seven HRIs underwent a first-round screening examination with 
MRCP (174;93.1%) or EUS (13;6.9%) from September 2015 to March 2018.The mean age was 
51 years (range 21-80).One-hundreds sixty-five (88.2%) FPC and 22 (11.8%) GF HRIs were 
included. MRCP detected 27 (21.9%) presumed branch-duct intraductal papillary mucinous 
neoplasms (IPMN), 1 invasive carcinoma/IPMN and one low-grade mixed-type IPMN, 
respectively. EUS detected 4 PC (2.1%): 1 was resected, 1 was found locally advanced 
intraoperatively and 2 were metastatic. Age>50 (OR 3.3, 95%CI 1.4-8), smoking habit (OR 2.8, 
95%CI 1.1-7.5), and having >2 relatives with PC (OR 2.7, 95%CI 1.1-6.4) were independently 
associated with detection of pre-malignant and malignant lesions. The diagnostic yield for 
MRCP/EUS was 20.3% for cystic lesions. The overall rate of surgery was 2.6% with nil mortality. 
Discussion: The rate of malignancies found in this cohort was high (2.6%). According to the 
International Cancer of the Pancreas Screening Consortium the screening goal achievement was 
high (1%).  
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INTRODUCTION 
 Pancreatic ductal adenocarcinoma (PC) is one of the deadliest solid tumors. It is predicted 
to become the second cause of tumor-related death by 2030[1]. Surgical resection is the only 
potential cure and it is possible in less than 20% of patients at the time of diagnosis[50]. PC is 
usually asymptomatic until the disease has spread outside the gland, causing jaundice or abdominal 
and back pain. However, similarly to other solid tumors, even PC has precursor lesions, namely 
pancreatic intraepithelial neoplasia (PanIN), and intraductal papillary mucinous neoplasms 
(IPMN)[14, 51].  
Considering the wide window of opportunity to detect PC at its earlier stages[52] and the low 
incidence of this tumor (6.3-7.3 per 100,000 people in Europe)[53], it might seem reasonable and 
advantageous to focus diagnostic efforts to identify precursor lesions or early PC on a selected 
population of high-risk individuals (HRIs). Population screening is not recommended.  
In 2013, the International Cancer of the Pancreas Screening (CAPS) Consortium established that 
PC screening should be recommended only for HRIs with a lifetime risk of PC greater than 5% or 
a fivefold increased relative risk, as this would eventually lead to a better prognosis [9]. 
 Guidelines for screening define two groups of HRIs: a) individuals with a defined genetic 
syndrome (e.g. Hereditary breast and ovarian cancer syndrome, familial atypical multiple mole-
melanoma (FAMMM) syndrome, Peutz-Jeghers Syndrome, PRSS-1 related hereditary 
pancreatitis, Lynch syndrome) or genetic mutations (PALB2 gene mutations); b) individuals 
without a diagnosed syndrome but with familiar pancreatic cancer (FPC)[54]. According to the 
CAPS Consortium, the goal of a PC surveillance program should be the identification of early 
(pT1N0M0R0) PC, or advanced precursor lesions such as PanIN3 or high-grade IPMN[9]. 
However, an internationally standardized protocol for PC surveillance is not available yet, as the 
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current evidence is based on single- or multi-centric experiences with heterogeneous policies in 
terms of inclusion criteria, diagnostic methods and frequency of screening being adopted[55, 56]. 
Three recent meta-analyses reported that the probability of reaching the screening goal is 
satisfactory[55-57], thus reinforcing the rationale in the pursuit of the early diagnosis of PC.  
 In 2010, the Italian Association for the Study of the Pancreas (AISP) developed a position 
paper for the surveillance at high-risk of PC, including both HRI with familial and genetic 
predisposition[8]. In 2015, an official registry of asymptomatic HRI was created following these 
guidelines. This manuscript reports the results of the first-round of screening.  
METHODS 
 Definition of Individuals at high risk and surveillance protocol 
 In 2015, six Italian high-volume centers started the enrollment of HRIs according to the 
Italian Guidelines (Table 1)[8]. Criteria for entry into the registry as an HRI include being defined 
as FPC if having: ≥ 3 relatives affected by PC until the third degree of kinship (TDR) or 2 relatives 
affected if at least one being a first degree relative (FDR); having a known genetic mutation of 
BRCA 1, BRCA2 or p16/CDKN2a genes with at least a FDR or a second degree relative (SDR) 
affected by PC; a previous diagnosis of hereditary pancreatitis or Peutz-Jeghers Syndrome (PJS). 
Whenever possible, the diagnosis of pancreatic cancer in affected relatives had to be verified 
through medical records evaluation. Demographic, clinical and anamnestic data were 
prospectively collected by each center involved. HRIs aged > 18 could enter the surveillance 
registry after having signed a proper informed consent. 
 Each enrolled subject received an outpatient visit and was offered a baseline MRI with 1.5 
T to 3.0 T Cholangio-Wirsung-MRI (MRCP). MRI with MRCP was chosen as a baseline 
diagnostic method because of no radiation risks, low complication rates and high sensitivity[58-
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60]. In case of a normal MRCP the subjects were planned to receive annual MRI for 5 years. 
Identified lesions were classified as solid or cystic with or without connection to pancreatic ducts. 
Patients who refused or could not be investigated by means of MRCP were offered endoscopic 
ultrasound (EUS) as first screening tool. EUS was also proposed to patients with alterations at 
baseline MRI, according to the local practice at each center. Any indication for surgery was center-
based after a multidisciplinary board meeting. Each center received the local ethics committee 
approval and enrolled subjects signed a proper informed consent. The registry is currently 
promoted through word of mouth, social networks, YouTube channels, the websites of the 
individual Institutions, as well as the website of the AISP (http://www.aisponline.it). The potential 
HRIs contact the involved centers spontaneously or they are referred by the general practitioner or 
other medical doctors. A genetic testing is not part of the protocol, but can be advised at each 
Centre based on clinical judgment.  
 Recorded Variables  
 The surveillance registry data include age, gender, category of risk (FPC or defined GS), 
total number of relatives with PC and degree of kinship, age of the youngest relative with PC, 
smoking and alcohol history, personal medical and oncological history, presence of diabetes and 
time of its diagnosis. 
 Statistical analysis 
 The chi-squared test was performed to test for differences of categorical parameters 
between subgroups, and t-test for continuous variables. A multivariate logistic regression analysis 
was performed to identify any risk factor associated with MRCP/EUS detection of pre-malignant 
or malignant lesion. 
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RESULTS 
Population characteristics 
Between September 2015 and March 2018, 245 eligible subjects were offered to enter the registry 
and accepted, and through March 2018, 187 subjects (76.3%) completed the first round of 
screening and represent the study population described in the present manuscript. According to the 
risk categories, FPC and "genetic syndrome" (GS) cases were 165 (88.2%) and 22 (11.8%), 
respectively. Table 1 shows the composition of the risk categories as well as their demographics. 
The population of HRIs included 100 women and 87 men. Mean age was 52±12. The mean number 
of affected relatives was 2 (range 1-5). Fifty-two (27.8%) HRIs had ≥2 FDR affected and the mean 
age of the youngest affected relative was 61 (range 28-79). Twenty-five HRIs (13.3%) reported a 
personal history of previous neoplasms, mostly gynecological cancers. MRCP and EUS were used 
as initial screening methods in 174 (93.1%) and 13 (6.9%) HRIs. Nine HRIs (4.8%) received EUS 
as supplementary investigation after MRCP. Of note, the reliability of reported family history of 
pancreatic cancer was verified in 120 out of 187 HRIs (64.1%) through evaluation of charts or 
other original documents of affected family members. 
MRCP findings and risk categories 
Figure 1 depicts the flow chart of screening results. Overall, 44 (25.3%) HRIs had an abnormal 
finding at MRCP, with pancreatic cystic lesions being the most frequently diagnosed abnormality 
(n=42, 24.1%). At MRCP the presumed radiological diagnosis of these cysts was mostly branch-
duct IPMN (BD-IPMN) (n=27, 61.3% of the cysts detected and 21.9% of the cohort of HRI 
submitted to MRCP), 14 (51.9%) were multifocal. The mean diameter was 9 mm (range 3-25). 
Two (1.3%) HRI received a diagnosis of a suspected solid pancreatic mass, which was not further 
confirmed at EUS. One subject received a diagnosis of mixed-type (M)-IPMN, that was found to 
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be a BD-IPMN at EUS. One subject with PJS received a diagnosis of malignant main-duct (MD)-
IPMN, which was confirmed by EUS with fine-needle aspiration (FNA), and one FPC subject was 
diagnosed with a M-IPMN, further confirmed by EUS. Surgery revealed an invasive 
carcinoma/IPMN and a low-grade M-IPMN, respectively in these two cases. No complications 
related to MRCP were reported. The diagnosis rate of MRCP for pre-malignant (IPMNs) or 
malignant lesions was 17.2% and 0.6%, respectively. BD-IPMNs and undefined cysts are currently 
enrolled in Institution-specific follow-up programs for pancreatic cystic neoplasms. The diagnosis 
rate of MRCP for cystic lesion was 24.1%. 
EUS findings 
The flow-chart of Figure 1 reports EUS findings. Thirteen (6.9%) HRIs received EUS as first-line 
investigation. EUS detected 4 PC (30.8%) (all confirmed by FNA), 1 (7.7%) undefined cyst, 2 
(15.4%) EUS features of chronic pancreatitis and one solid pseudopapillary tumor (7.7%). The 
examination was normal in 5 cases (38.5%). Two tumors were deemed amenable to surgery, the 
remaining two being metastatic cases that were treated with chemotherapy. In 9 further cases EUS 
was performed as supplementary diagnostic tool after MRCP, due to suspicious findings. In such 
cases, EUS confirmed 6 MRCP findings and deemed insignificant 2 suspected solid lesions and 1 
suspected M-IPMN found at MRCP, that revealed to be fibrotic areas and a BD-IPMN, 
respectively. No complications related to EUS were reported. The 2 undefined cysts are currently 
enrolled in Institution-specific follow-up programs for cystic pancreatic neoplasms. 
Risk categories and MRCP/EUS findings 
Table 2 reports the MRCP/EUS findings of the cohort, comparing the results obtained in the 
groups of FPC and GS cases. When comparing the FPC and GS HRIs, there was no difference 
either in the rate of abnormalities and malignancies detected (27.9% vs 27.3% and 2.5% vs 4.5%, 
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Fisher's exact p=1 and p=0.469, respectively). No malignant lesions were diagnosed in the 
BRCA1/2 HRIs subgroup.  
Surgery and pathology 
After multidisciplinary consultation, surgery was offered to 5 subjects (2.6%). Two total 
pancreatectomies and 2 distal pancreatectomies with splenectomy were performed. One further 
PC case deemed resectable was found locally advanced intraoperatively and a bypass surgery was 
performed. Pathology revealed an invasive carcinoma/IPMN, 1 PC (T1N0M0R0), a 
pseudopapillary tumor and a low-grade panglandular M-IPMN. No postoperative complications 
were reported. Considering the CAPS guidelines[9], the diagnostic yield of the present study for 
success of surveillance with diagnosis of target lesions was 1%. The 90-day postoperative 
mortality was nil. 
Risk factors associated with diagnosis of pre-malignant or malignant lesion  
A binary logistic regression analysis was performed with the diagnosis of pre-malignant or 
malignant lesion as dependent variable (yes/no), to ascertain the effects of age (≤> 50 years), 
gender, alcohol and smoking habit, number of relatives affected (≤/> 2), number of FDR affected 
(≤/> 1), previous history of any malignancy (yes/no), medical certification of relatives suffering 
from PC (yes/no), familial or genetic predisposition. At the multivariate analysis, age > 50 years 
(OR 3.3, 95%CI 1.4-8), smoking habit (OR 2.8, 95%CI 1.1-7.5) and having >2 relatives with PC 
(OR 2.7, 95%CI 1.1-6.4) were independent factors associated with the diagnosis of pre-malignant 
and malignant lesions at MRCP/EUS (Table 3). Table 4 depicts the detailed individual features of 
HRIs who received a diagnosis of malignancy. 
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Follow-up 
At the time this manuscript was written 2 out of 5 patients that received a malignant diagnosis 
were alive (mean follow-up 6.2 months, range 2-12). The two patients submitted to surgery were 
alive and free of recurrence after a median follow-up of 6.5 months. Of the remaining three patients 
who were diagnosed with an advanced disease, two died after a median follow-up of 7 months 
from the diagnosis; one patient died due to cardiovascular disease.  
 
DISCUSSION 
 
This is the first report of the Italian multicenter study on HRIs submitted to surveillance. After the 
first round of screening (n=53, 28.3%) of subjects were diagnosed with a MRCP/EUS abnormality. 
Five malignant lesions were detected (2.6%); an unexpectedly high number of PC were identified 
by EUS (n=4, 2.1% overall), whereas MRCP identified only 1 invasive carcinoma/IPMN (0.6%). 
Of note, the category of HRIs that reported the greatest number of MRCP/EUS abnormalities was 
the one made of FPC subjects, however, the small sample size of the non-FPC subcohort does not 
allow us to make further speculations regarding this difference.  
The diagnostic yield for MRCP/EUS was 23.5% for cystic lesions. The great majority of the 
detected cysts were BD-IPMN (n=28, 60.8% of the cysts detected, 14.9% of the whole cohort). 
This finding is not surprising, as these lesions are frequent incidental findings in the general 
population, given the wide use of cross-sectional imaging, and it is debatable whether they should 
be considered a positive result of the screening process or not. This prevalence is in line with data 
already reported in a metanalysis by Signoretti et al. in 2018, where the pooled prevalence of cystic 
lesions in HRI enrolled in surveillance program was around 20%[55]. 
The rate of malignancies detected (2.6%) in our cohort is one of the highest reported so far [55-
57, 61]. Notably, all but one malignancy was detected by EUS. As only 4.8% of probands was 
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submitted to both MRCP and EUS, it is not possible to speculate about any possible difference in 
the detection rate of solid or cystic abnormalities with the two techniques. Current literature 
suggest that the two techniques are complementary with MRCP being able to detect more easily 
any cystic lesion, whereas EUS is likely more sensitive in the detection of solid ones[55, 62]. Two 
out of the five (40%) cancers diagnosed in the screening asymptomatic subjects were at a 
metastatic stage, and one was locally advanced. This rate is higher than in previous reports[55, 
56], however this finding is consistent with a calculated pooled prevalence of 1%[55], and it cannot 
be considered a failure of a surveillance policy as the present results regard fist-screening round 
only. On the other hand, in the two PC cases who received radical surgery, pathology revealed pT1 
disease, thus potentially suggesting that surveillance led to early diagnosis with improved survival. 
Globally, there were no unnecessary surgical procedures being performed for benign lesions in 
this series, as the other resections were due to a M-IPMN and a solid pseudopapillary tumor, for 
whom surgery is the treatment of choice. 
Personalization of the surveillance strategy is a key issue in screening protocols for pancreatic 
cancer. We therefore investigated factors that were associated with an increased risk of diagnosis 
of pancreatic abnormalities. HRIs aged > 50 years, ever smokers, and subjects with >2 relatives 
with PC had a significantly increased risk of having a diagnosed pre-malignant or malignant lesion. 
Previous studies partially explored the association between such factors and the detection of a 
worrisome abnormality [23, 43, 63]. However, those studies were retrospective and more prone to 
bias or lack of information, and these three factors were not reported as independently associated 
with risk of significant abnormalities at a multivariate analysis before. Despite the design of this 
registry regarding each center discretion on the use of MRCP or EUS as a screening tool based 
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also on patients’ preference, it likely that in such a subgroup of HRIs the combined use of both 
MRCP and EUS, or their alternate use, possibly at shorter intervals, might be appropriate.  
Some limitations, however, should be considered. First, although MRI with MRCP was the first-
line examination in most cases, some subjects were investigated by EUS first, due to personal 
preferences.  However, the results obtained by the two diagnostic tools are pooled in the present 
analysis to reflect the actual rate of significant findings in the whole cohort. Secondly, a quote of 
the diagnosed small pancreatic lesions considered BD-IPMN at MRCP might be other cystic 
lesions, despite experienced radiologists have been involved. The present protocol, indeed, did not 
include the need to perform EUS in all cases of cystic lesions, but this was done in some instances, 
similarly to what is considered common practice in sporadic cystic lesions. Finally, in our logistic 
regression analysis we considered as outcome variable the diagnosis of any malignant or pre-
malignant pancreatic lesion, including BD-IPMN and not malignant lesions only. This was done 
due to the relatively low rate of malignant lesions which would not permit a meaningful analysis. 
Third, compared to current literature[55, 56], our registry differed on the age to initiate the 
surveillance and this might have been responsible for differences in the detection rate of pre-
malignant or malignant lesions. However, the mean age of our cohort is in line with the one other 
studies[55, 56], giving more strength to the finding that HRI > 50 years are at higher risk to be 
diagnosed with a worrisome lesion.  
Some of the limitations reported might have been addressed by building a proper surveillance 
program, based on MRCP and EUS imaging, genetic testing and shared among the Institutions 
involved. The form of the registry, with a high level of center discretion in the diagnostic pathway 
to follow, had been chosen since no dedicated funds were available and each center draws from 
personal resources and facilities. 
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In conclusion, the first-round screening results in Italy report a high rate of pancreatic malignancies 
(n=5, 2.6%), mostly being advanced at baseline (60%). We identified factors associated with an 
increased risk of diagnosis of malignant or pre-malignant pancreatic lesions in HRIs (age > 50, 
smoking habit and > 2 relatives diagnosed with PC). Whether these data will also reflect an 
increased risk of developing de novo lesions or of progression of initial finding needs to be 
investigated during the following screening rounds that are planned for a duration of at least five 
years, with a planned end of enrollment in 2020. 
Tables 
Table 1. Detail and demographics of HRIs enrolled. Data are expressed as number (%) or as mean 
(±SD). 
Characteristics of asymptomatic HRI 
who were enrolled in the registry 
n 
FPC 
HBOC (BRCA1) 
HBOC (BRCA2) 
FAMMM (p16/CDKN2A) 
Peutz-Jegher syndrome (STK11/LKB1) 
Hereditary pancreatitis (PRSS1) 
165 (88.2) 
5 (2.7) 
5 (2.7) 
3 (2.7) 
5 (1.6) 
4 (2.1) 
Variable All 
patients  
(n=187) 
FPC  
(n=165) 
GS 
(n=22) 
p-
value 
Age, mean (SD) 
Female, gender 
Ever smokers/current smokers* 
Any regular alcohol intake 
AYR with PC, median (IQR) 
Personal history of malignancies, n (%) 
HRI with 1 FDR affected 
HRI with ≥ 2 FDR affected 
HRI with family history of malignancies 
  Number of relatives affected, median 
51±12 
100 (53.4) 
28 (15) 
16 (8.5) 
61±10 
25 (13.3) 
120 (64.2) 
53 (28.3) 
118 (63.1) 
1 
51±12 
67 (54.5) 
24 (14.5) 
12 (7.2) 
60±11 
19 (11.5) 
110 (66.7) 
53 (32.1) 
101 (61.1) 
1 
47±11 
33 (51.5) 
4 (18.1) 
4 (18.1) 
66±8 
6 (24) 
11 (50) 
- 
17 (77.3) 
1 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
<0.05 
n.s 
 
HRI: high-risk individual; FPC: familial pancreatic cancer; HBOC: Hereditary breast–ovarian 
cancer syndrome; FAMMM: Familial Atypical Multiple Mole Melanoma; GS: genetic syndrome; 
AYR: age of the youngest relative; FDR: first-degree relative.  
*: Ever smoker is a person who has smoked 100 cigarettes or more in his/her lifetime. 
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Table 2. MRCP/EUS findings per categories (p=n.s.). Data are expressed as number. 
                                                                            Category of risk 
Screening results FPC (n=165)  GS (n=22) 
Abnormalities 
      -  PC 
      -  BD-IPMN 
      -  Undefined cystic lesions  
      -  Suspected solid lesions 
      -  Features of CP 
      -  M-IPMN 
      -  Degenerated IPMN 
46 (27.9) 
4 (2.4) 
26 (15.7) 
7 (4.2) 
2 (1.2) 
5 (30.3) 
1 (0.6) 
- 
6 (27.2) 
1 (4.5) 
1 (4.5) 
1 (4.5) 
- 
2 (18.1) 
- 
1 (4.5) 
FPC: familial pancreatic cancer; GS: genetic syndrome; PC: Pancreatic ductal  
adenocarcinoma BD-IPMN: branch-duct intraductal papillary mucinous neoplasm;  
CP: chronic pancreatitis; M-IPMN: mixed-type intraductal papillary mucinous neoplasm. 
 
 
Table 3.. Binary logistic regression analysis for risk factors associated with the diagnosis of a 
pre-malignant or malignant lesion at MRCP/EUS.  
Variable Univariate Analysis  
(OR; 95% CI) 
p Value Multivariate Analysis 
 (OR; 95% CI) 
p Value 
Male Sex (1; 0.4-1.1) 0.946   
Age > 50 years (4.1; 1.7-9.6) 0.001* OR 3.3, 1.4-8 0.008* 
Ever Smoking (4.6; 1.9-11.1) 0.001* OR 2.8, 1.1-7.5 0.032* 
Alcohol Drinker (1; 0.2-3.8) 0.951   
Number of relatives affected 
    > 2     
(3.6; 1.6-8.1) 0.001* 
 
OR 2.7, 1.1-6.4 0.026* 
Number of FDR affected 
    > 1 
(1; 0.4-2.3) 0.967   
Previous history of any 
malignancy 
(1; 0.8-1.2) 0.287   
Diagnosis of a defined GS (0.4; 0.1-1.8) 0.253   
Verified certification of 
affected family members 
(1; 0.4-2.3) 0.954   
FDR: first-degree relative; GS: genetic syndrome. 
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Table 4. Features of High Risk Individuals who received a diagnosis of malignancy. 
Patient Category 
of risk 
Location Size 
(mm) 
Pathology-
Stage[64] 
Treatment F-up F-up 
(mo) 
1 PJS Body 20 iCa/IPMN 
(pT1N0M0R0) 
Stage 1A 
DPS Alive, 
FoR 
11 
2 FPC Body 25 Stage IV  Chemotherapy Deceased* 2 
3 FPC 
 
Head 40 cT4N1M0, 
Stage III 
By-pass surgery  Deceased 2 
4 FPC Head 30 pT1N0M0R0, 
Stage 1A 
TP Alive, 
FoR 
4 
5 FPC Head-
Body 
70 Stage IV Chemotherapy Deceased 12 
PJS; Peutz-Jeghers syndrome; iCa: invasive carcinoma; DPS: distal pancreatectomy with 
splenectomy; FoR: free of recurrence; FPC: familial pancreatic cancer; PC: pancreatic ductal 
adenocarcinoma; LAPC: locally advanced pancreatic cancer; TP: total pancreatectomy; PD: 
pancreaticoduodenectomy. *due to cardiovascular problems. 
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ABSTRACT  
Background and Aims: Different pancreatic abnormalities (e.g. chronic pancreatitis like features, 
cystic lesions, solid lesions) have been reported in in high-risk individuals (HRIs) with “familiar 
pancreatic cancer” (FPC) and specific syndromes undergoing surveillance protocols for pancreatic 
ductal adenocarcinoma (PDAC). Previous studies compared pancreatic parenchymal alterations 
detected by endoscopic ultrasonography (EUS) in HRIs to those seen in controls reporting that 
abnormal changes occur more frequently in HRIs than in controls. However, while magnetic 
resonance imaging (MRI) with Magnetic Resonance Cholangiopancreatography (MRCP) is the 
most frequently employed method for HRI surveillance, no studies compared the rate of abnormal 
pancreatic finding in HRIs investigated by MRI/MRCP to those seen in controls. We therefore 
conducted a case-control study enrolling HRIs who underwent surveillance with MRI/MRCP and 
controls without pancreatic disorders to compare the rate and type of pancreatic abnormalities. 
Methods: A single-centre case control study was conducted. Cases were HRIs meeting the CAPS 
criteria who underwent surveillance for the risk of pancreatic cancer and controls were consecutive 
patients undergoing MRI/MRCP for benign biliary disease without history of pancreatic disorders. 
62 
The rate of pancreatic findings was compared with Fisher extact test and logistic regression 
analysis was performed to examine factors associated with pancreatic findings. 
Results: 28 HRIs and 26 controls were included in the study. HRIs were subjects belonging to 
FPC families (70%), Peutz-Jeghers syndrome (14%), familial atypical multiple mole melanoma 
syndrome (7%) , BRCA1/2 mutation carriers (7%) . Cases and controls did not differ in terms of 
sex distribution and age (male 50% vs 53.6, p=0.5; mean age 55.6 vs 59.6 years p = 0.1). The 
overall rate of any pancreatic abnormality was similar between cases and controls (64.3% vs 
53.8%; p=0.58) and parenchymal atrophy was the most common abnormal finding (32% vs 38%, 
p= 0.8). Branch-duct IPMNs were diagnosed in 25% of cases and 23% of controls (p= 1)(mean 
diameter 6.4 vs 5 mm respectively).  Notably, however, at the first year of follow-up two further 
HRIs were diagnosed with IPMNs, bringing this rate to 32%.  
Conclusion: The rate of pancreatic changes observed in HRIs at the first round of surveillance 
with MRI/MRCP does not differ from that of controls. Most abnormalities do not have clinical 
significance, the most common being parenchymal atrophy and small BD-IPMNs without 
worrisome features.  These results differ from those previously reported regarding EUS, possibly 
suggesting that EUS might diagnose more frequently subtle pancreatic changes as compared to 
MRI in HRIs.  
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INTRODUCTION 
 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in 
western countries. Due to the biological aggressiveness, the poor response to medical treatment 
and delayed diagnosis[1], PDAC is predicted to become second killers in the United States by 
2030 also because of the decreasing of cancer-related deaths for colorectal and breast cancer [2]. 
For colorectal and breast cancer indeed specific screening programs are nowadays available while 
such approach seems to be not cost effective for PDAC considering the relatively low lifetime risk 
of developing a sporadic PDAC (close to 1%). The International Cancer of the Pancreas Screening 
(CAPS) Consortium [3] in 2013 has defined selection criteria for surveillance of subjects with 
“familial pancreatic cancer” (FPC) or with hereditary syndromes of which the risk of developing  
PDAC is more than 5-fold greater  compared to the general population called high-risk individuals 
(HRIs). Because of the limited data regarding the accuracy of  the  screening tests used and  the 
interpretations of the test’s findings for clinical decisions (surgical treatment/ follow-up) [4]  
screening for PDAC in HRIs should take place preferably in high-volume center as a research 
protocols with a multidisciplinary team [3].  Data on the prevalence of pancreatic abnormalities 
diagnosed during screening and the lesions considered a successful target that are small resectable 
PDAC, intraductal papillary mucinous neoplasms (IPMNs) with high-grade dysplasia and 
advanced pancreatic intraepithelial neoplasia (PanIN3) are heterogeneous. The screening methods  
include endoscopic ultrasonography (EUS) and/or magnetic resonance imaging (MRI) with the 
first one  able to diagnose more solid mass and MRI more cystic lesions [5]. Cystic lesions are 
diagnosed in around 20 % during screening HRIs and they are more often discovered in FPC 
families compared to genetic syndromes  [6] . If the risk of developing PDAC from a cancerized 
cyst ( IPMN) as well as if  the association between IPMNs and synchronous  PDAC (already 
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described in the general population) is more elevated in HRIs is still debated [7]. PanINs lesions 
are also frequent findings in pancreatic parenchyma of HRIs who underwent to surgery and more 
common detected in HRIs with  PDAC compared to  sporadic pancreatic cancer [8, 9]. They are 
microscopic lesions (<0.5 cm) with different grade of dysplasia. In HRIs, some data suggest that 
PanINs and IPMN are associated to chronic pancreatitis-like parenchymal changes that could be 
visualized  as ectasia/irregularity of the pancreatic ducts and/or parenchyma heterogeneity despite 
they cannot be reliably distinguish from non-neoplastic alterations [10]. Signs of Chronic 
pancreatitis (CP) were observed in more than 50% of HRIs screened with endoscopic 
ultrasonography (EUS), although only in 7% those features where consistent with CP according 
to Rosemont criteria [11 e 12]. 
Few studies compared pancreatic parenchymal alterations in HRIs to controls by using EUS 
reporting that abnormal changes occur more often in HRIs than controls. [6, 13]. Canto et al.  in 
2006 [6] have found more CP changes (60%  vs 15% and  ) in HRIS comparing with controls  as 
well as Mizrahi at al. in the setting of BRCA2 carriers (13 % vs 1 % ) [13]. In a recent study 
,Thiruvengadam et al.[14] found CP features in 18% of HRIs compared to 2 % in controls (p< 
0.01) with a significance maintained also after adjusted  for confounder factors  (such as smoking 
and drinking habits). Same results were observed for cystic lesions with HRIs more prone to have 
any kind of cysts compared to control (p< 0.01). No one of the above mentioned study categorized 
the type  of cystic  lesion detected so that the exact number of  precancerous cystic lesions ( IPMN) 
described in HRIs compared to controls is not explicit  probably to the lower sensitivity of EUS 
compare to MRCP  to describe a connection between the cyst and the ductal system [5] . Although 
MRI/MRCP is unable to detect signs of CP in the very early phase,  it has showed  instead very 
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sensitive for identifying the relation with the cyst and main pancreatic duct as well as whether the 
PCN  is a single or multiple [15] .  
We therefore conducted a case-control study between HRIs who underwent to surveillance with 
MRI with Magnetic resonance cholangiopancreatography (MRCP) and controls to evaluate and 
compare the rate of overall parenchymal changes and the presence and type of cystic lesions in 
both groups. 
 
METHODS 
Study design and population 
This was a retrospective case–control study. Cases of HRIs were selected among those 
prospectively enrolled in a dedicated database. The inclusion criteria for the case group were 
subjects  FPC if having: ≥ 3 relatives affected by PC until the third degree of kinship (TDR) or 2 
relatives affected if at least one being a first degree relative (FDR); having a known genetic 
mutation of BRCA 1, BRCA2 or p16/CDKN2a genes or Hereditary nonpolyposis colorectal cancer 
(HNPCC) with at least a FDR or a second degree relative (SDR) affected by PC; a previous 
diagnosis of hereditary pancreatitis or Peutz-Jeghers Syndrome (PJS) . HRIs underwent to 
contrast-enhanced magnetic resonance imaging (MRI) and magnetic resonance 
cholangiopancreatography (MRCP) at our Radiology Department. The control group consisted of 
inpatients admitted to the hospital, who underwent to MRI and MRCP for benign biliary 
indications such us cholecystitis or evaluation of CBD (e.g. stones, stricture) and pancreas-
unrelated indications. Exclusion criteria for the control group were a previous diagnosis or familial 
history of pancreatic disorders or of gastrointestinal neoplasms. Data on alcohol, tobacco use, or 
BMI were not available for controls, who were not matched for such variables. 
All patients gave written informed consent.  
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Nuclear magnetic resonance (MR).  
MR examination was carried out with 1.5 Tesla equipment with a foursingle phased array coil 
positioned on the patient’s upper abdomen. The MR protocol involved the use of T1-weighted 
gradient echo (GRE) sequences with in-phase and out-of-phase echotime, T1-weighted 
fatsuppressed GRE sequences, and T2- weighted halfFourier single-shot turbo spin-echo 
(HASTETSE). The dynamic study was performed during administration of 0.1 mmol/kg body 
weight of gadolinium chelates with a four-phase technique: precontrast, pancreatic phase (30–40 
s), portal venous phase (80 s) and delayed phase (180 s). The dynamic study used a T1-weighted 
3D GRE volumetric interpolated breath-hold examination (VIBE) sequence with chemically 
selective fat saturation in the axial plane.  Magnetic resonance cholangiopancreatography (MRCP). 
MRCP was performed using a 2D single-slab rapid acquisition in coronal planes and a 3D HASTE 
sequence with respiratory triggering in a coronal oblique plane depending on the course of the 
main pancreatic duct as visualized on a 2D sequence acquired in the axial plane. The 3D HASTE 
source images were analysed and subsequently processed with thin Maximumintensity projection 
(MIP) algorithm and MPR. The MRI images were reviewed independently by two radiologists 
(I.M. and E.I.). A template was designed to record the parenchymal changes, ductal alteration and 
cyst morphology details according to standard radiological criteria.[16-17]. About the 
parenchymal changes of chronic pancreatitis, they include loss of normal high signal intensity of 
the pancreas on T1-weighted fat-suppressed image, decreased and heterogeneous enhancement of 
the pancreas in the arterial phase with progressive enhancement in delayed and atrophy. In 
addition, abnormalities of the pancreatic duct were recorded. A regards the presence of cystic 
lesions and cyst morphology details, each reader recorded the number, size and location of each 
cyst, ‘worrisome features’ (such as cyst of 3 cm, thickened enhanced cyst walls, non-enhanced 
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mural nodules, main pancreatic duct size of 5–9 mm, abrupt change in the main pancreatic duct 
with distal pancreatic atrophy and lymphadenopathy). 
 
Statistics  
Statistics Differences between HRIs and controls in terms of prevalence of Parenchymal Features 
of CP, Ductal alteration or pancreatic cyst were analyzed. The Fisher test was used for comparison 
of proportions for categorical variables and Student’s t-test for continuous variables. Multiple 
logistic regression analysis was employed to investigate factors associated with the diagnosis of 
PCLs. Tests of statistical significance and confidence intervals were two-sided; a p value < 0.5 
was considered statistically significant. Dedicated software (MedCalc, Mariakerke, Belgium) was 
used throughout the study. 
 
RESULTS  
Thirty-two HRIs fulfilled the defined inclusion criteria for enrolment in surveillance registry  
according to the study protocol. Between the HRIs the most common subgroups were subjects 
belonging to Familial Pancreatic Cancer (62.5%) with two family member affected by pancreatic 
cancer; four patients had a diagnosis of Peutz-Jeghers syndrome (12.5%), two HRIs had Familial 
Atypical Multiple Mole Melanoma syndrome  while two were BRCA1/2 carriers (genes mutations in the 
Hereditary breast and ovarian cancer syndrome)  (see Table 1).Three subjects were affected by 
hereditary chronic pancreatitis thus were excluded from the current study because of the presence 
of chronic pancreatitis features linked to the disease. One subject, with a diagnosis of Hereditary 
nonpolyposis colorectal cancer and one first degree relative affected by PDAC, decided to undergo 
EUS instead of MRI as a screening test. At the end 28 HRIs were enrolled and compared with 26 
matched controls. Cases and controls did not differ in terms of sex distribution and age (in both 
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groups 14 were male, p = 0.5; mean age 55,6 and 59.6 years p = 0.1) (see Table 2). No one of the 
enrolled subjects had a radiological diagnosis of chronic pancreatitis. The overall prevalence of 
any pancreatic alterations was similar between the two groups (p= 0.58). 
In particular, as regards parenchymal features of CP, parenchymal atrophy was the most common 
alteration point out from the MRI. It was observed equally between cases and controls (32.1% vs 
38.5% , p= 0.8). 
No decrease or loss of lobularity were observed. One HRIs presented a delayed enhancement of 
the pancreatic parenchyma while one control a decreased on contrast T1 signal intensity. The most 
common ductal alteration was the irregularity of the Wirsung duct due to the presence of a Kinking 
of the duct (5 cases and 3 controls; 17% vs 11.5%) or a diagnosis of pancreas divisum (2 cases and 
1 control). No ductal dilation was detected (neither main pancreatic duct nor side branches). 
All the cystic lesions discovered during the radiological tests had a presumptive diagnosis of side 
branches IPMNs. The prevalence SD-IPMNs was also not different between cases and controls 
(25% vs 23 %; P= 1). The maximum diameter of the cyst was 15 mm in HRIs and 11 mm in control 
group (mean diameter 6.4 vs 5 mm respectively). No one of the cystic lesions had worrisome 
features at MRI.  
In order to investigate the factors associated with the pancreatic alteration observed (parenchymal 
atrophy and SD-IPMNs) , we performed a logistic regression analysis, demographic  and  clinical 
were considered as explanatory variables (see Table 3).  
In the analysis, as expected, only the age at the time of the imaging procedure (OR = 1.25 per 
increasing year, 95% CI 1.02–1.03, p = .002) was associated with the presence of parenchymal 
atrophy (Fig 1). On the other hand, the diagnosis of IPMN was not associated with any of the 
considered variables (see Table 4). 
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Between the 28 HRIs enrolled, 13 subjects underwent to a follow-up examination after 12 months 
from the basal MRI as reported into the screening protocols.   
Four of them had a diagnosis of presumptive SB-IPMN at the first surveillance round and no 
modifications of the cysts were observed at the subsequent MRI. In 12 months two HRIs with a 
negative first test developed new pancreatic cystic lesions multifocal compatible with SB-IPMNs 
between 3 to 2 mm without any additional pancreatic alteration. A comparable radiological finding 
was notice for the remaining HRIs with a first negative test. 
 
DISCUSSION 
To our knowledge, this is the first study who compared pancreatic parenchymal alterations in HRIs 
to controls by using MRI. In the present study, few signs of chronic pancreatitis were observed in 
case and controls without any statistical differences, with parenchymal atrophy being the most 
common alteration (9 cases and 10 controls). The prevalence of cystic lesion was high (25% vs 23 
% between cases and controls; P= 1) all with a clear connection with the pancreatic duct so the 
most common presumptive diagnosis was small SD-IPMNs. 
Previous surveillance programs investigated the use of MRI for the screening HRIs. A small 
percentage of chronic pancreatitis-like changes have been reported for the detection of chronic 
pancreatitis-like changes ranging from 1.3 to 11.6 % while pancreatic cystic lesions are diagnosed 
in a higher percentages of patients (2.6%-35.3%) [4]. Previous published data suggest that PanINs 
when multifocal are associated to chronic pancreatitis-like parenchymal change at EUS (such as 
ectasia, irregularity of the duct and/or parenchyma heterogeneity and lobularity)[16]. 
On the other hand, by using EUS as a screening method a higher percentage of pancreatic 
abnormalities were found around 36 % (from 6.8% to 78.2%). As far as regards cystic lesions, as 
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reported in a recent meta-analysis [5] EUS showed a lower sensitivity compared to MRI with a 
pooled prevalence of cystic lesions being 16.6% when EUS was employed and 22.4% when MRI 
was the screening test.  
Few studies compared pancreatic parenchymal alterations in HRIs to controls by using endoscopic 
ultrasonography (EUS) reporting that abnormal changes occur more often in HRIs than controls. 
[6, 11]. Canto et al.  in 2006 [6] have found more CP changes (60%  vs 15% and  ) in HRIs 
comparing with controls  as well as Mizrahi at al.[11] in the setting of BRCA2 carriers (13 % vs 1 
% ). Thiruvengadam et al.[14] in a recent study found CP features in 18% of HRIs compared to 2 
% in controls (p< 0.01) with a significance maintained also after adjusted  for confounder factors  
(such as smoking and drinking habits). Same results were observed for cystic lesions with HRIs 
more prone to have any kind of cysts compared to control (p< 0.01) (11.8% vs 9% [6] 21% vs 6% 
[13] and 76% vs 1% [14]).  
No one of the above mentioned study categorized the type of cystic lesion detected so that the 
exact number of precancerous cystic lesions ( IPMN) described in HRIs compared to controls is 
not known. It is probably due, as reported many studies [5,18-19] to the lower sensitivity of EUS 
compare to MRI- MRCP  in describing the connection between the cyst and the ductal system [5] 
. MRI/MRCP is instead very sensitive for identifying the relation with the cyst and main pancreatic 
duct as well as whether it is a single or multifocal [15] .  
In our cohort of HRIs, no major signs of CP were diagnosed. Some ductal irregularity where 
observed such as kinging of the main duct and the presence of pancreas divisum although those 
findings did not differ between case and controls. As far as regard the parenchymal alteration, 
atrophy was the most common and related, as expected, to the age of the patient as showed by 
logistic regression analysis.  
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A consistent number of small (from 2 to 15 mm) cystic lesions were observed in case and controls 
group equal to 25% vs 23%. Those results are in line with those already published between HRIs 
and also in asymptomatic subjects by using MRI-MRCP [5,20]. 
All the cystic lesions showed a connection with the PD so that the presumptive diagnosis was BD-
IPMN without worrisome features. No one of the demographic characteristics where correlate to 
the diagnosis of such a lesion at the logistic regression. In HRIs those lesions where stable after 
12 months of follow-up while two subjects, with a previous negative examination, showed a new 
diagnosis of multifocal very small SD-IPMNs.  
Those results are limited to the small number of HRIs and controls enrolled and the lack of 
individual demographic and clinical data such as smoking habits, BMI, alcohol consumption in 
both groups. Moreover, data of a longer follow-up are need to evaluate the clinical significance of 
pancreatic alteration detected in HRIs and their correlation with the development of malignancy. 
In conclusion, even with the above limitation, our results reported that HRIs were less likely to 
exhibit CP changes when studied with MRI while the rate of cystic lesions was higher in our cohort 
compared to previous published paper employed EUS as a surveillance method. No one of the 
pancreatic changes discovered in a HRIs group were significantly more frequent than in controls.  
It remains still unclear if IPMNs diagnosed in HRIs are more prone to develop malignant features. 
Future studies with a long follow-up are needed to clarify this important issue.  
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Table 1. Type of high-risk individuals (HRIs) that fulfilled the defined inclusion criteria for 
enrolment 
Type of HRIs  Number (32) % of total  
Familial  Pancreatic Cancer 
 
1 FDR+ 1SDR 
1 FDR+ 2SDR 
2 FDR 
                         ≥ 3 FDR 
20 
 
7 (35%) 
5 (25%) 
6 (30%) 
0 
 
 
62.5% 
Peutz-Jeghers syndrome 4 12.5% 
Familial Atypical Multiple Mole 
Melanoma syndrome 
2 6.2% 
Hereditary breast and ovarian cancer 
(BRCA1/2 carriers) 
2 6.2% 
Hereditary Pancreatitis 3 9.4% 
Hereditary nonpolyposis colorectal 
cancer (HNPCC) 
1 3.1 % 
 
Table 2. Demographic and clinical characteristics of HRIs and controls. 
Demographic  Controls (26) HRIs (28) P value  
Age (mean) 59.6 (30-79) 55.6 (36-79) 0.1 
Sex (F:M) 12:14 14:14 0.5 
History of Diabetes  3 (11.5%) 4/28 (14.2%) 0.6 
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Fig.1 logistic regression curve for age which resulted the only one single independent variable related with the 
probability of diagnosing atrophy of the pancreatic parenchyma.  
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Table 3. Prevalence of pancreatic alteration in  high-risk individuals (cases) and controls  . 
Outcome Variable Controls 
(n=26) 
HRIs 
(n=28) 
P 
Any Pancreatic Alteration  14 (53.8%) 18 (64.2%) 0.58 
Parenchymal Features of CP: 
Decrease or loss of lobularity 
Decreased on contrast T1 signal intensity 
Delayed enhancement 
Atrophy 
 
 
0 
1  
0 
10 (38.4%) 
 
0 
0 
1 
9 (32.1%) 
 
 
0.5 
0.5 
0.8 
Ductal Alterations: 
 Ductal irregularity 
Ductal narrowing or stricture 
Ductal dilatation 
Calculi/filling defect 
≥3 Dilated side branches 
 
4 (15.4%) 
0 
0 
0 
0 
 
7 (25%) 
0 
0 
0 
0 
 
0.5 
Pancreatic cyst: 
IPMN-BD 
Multifocal IPMN 
Max diameter (mm) 
Worrisome features 
 
6 (23%) 
5 (2-11) 
11 
0 
 
7 (25%) 
6.4 (2-15) 
15 
0 
 
0.5 
1 
0.3 
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Table 4. Factors associated with the diagnosis of pancreatic atrophy at the logistic regression 
analysis 
 OR 95% CI P Value  
Case (HRIs) 1.67 1.3-8 0.52 
Age  
(per increasing year) 
1.02 1.2-1.3 0.002 
Sex (Male) 1.7 0.3-8 0.5 
Diabetes 0.6 0.07-4.4 0.6 
 
 
Table 5. Factors associated with the diagnosis of intraductal papillary mucinous neoplasms in the 
logistic regression analysis. 
 OR 95% CI P Value  
Case (HRIs) 1.3 0.3-4.9 0.7 
Age  
(per increasing year) 
1 0.9-1 0.3 
Sex (Male) 2.4 0.6-9.7 0.2 
Diabetes 1.6 0.3-10.6 0.6 
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ABSTRACT: 
Background & Aims: Pancreatic cystic lesions (PCLs) are frequent incidental findings. As most 
PCLs require costly diagnostic evaluation and active surveillance, it is important to clarify their 
prevalence in asymptomatic individuals. We therefore aimed at performing a systematic review 
and meta-analysis to determine it. 
Methods: a systematic search was conducted and studies meeting inclusion criteria were included. 
The prevalence of PCLs was pooled across studies. A random effect model was used with 
assessment of heterogeneity. 
Results: 17 studies, with 48,860 patients, were included. Only 3 were prospective; 5 studies were 
conducted in the US, 7 in Europe, 4 in Asia and 1 in Brazil. The pooled prevalence of PCLs was 
8% (95% CI 4-14) with considerable heterogeneity (I2=99.5%). This prevalence was higher in 
studies of higher quality, examining older subjects, smaller cohorts, and employing MRCP (24.8% 
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vs 2.7% with CT-scan). The pooled rate of PCLs was four times higher in studies conducted in the 
US than in Asia (12.6% vs 3.1%). 7 studies reported the prevalence of mucinous lesions, with a 
pooled rate of 4.3% (95% CI 2-10; I2=99.2%), but of 0.7% only for worrisome features or high 
risk stigmata. 
Conclusion: The rate of incidentally detected PCLs is of 8%. Mucinous lesions are the most 
common incidentally detected PCLs, although they rarely present with potential indication for 
surgery. The observed different rates in the US and other geographic Areas suggest that different 
protocols might be necessary to help balancing costs and effectiveness of follow-up investigations 
in asymptomatic subjects 
 
INTRODUCTION: 
Pancreatic cystic lesions (PCLs) are frequent incidental findings diagnosed during abdominal 
ultrasonography or cross-sectional imaging. The increasingly widespread use and the improved 
detection accuracy of imaging tests have led to an epidemic of PCLs with prevalence rates reported 
as high as 40%, in a clinical scenario that might be considered that of a “technology-related 
disease” [1]. PCLs comprise different entities, each of them with peculiar biological behavior 
ranging from benign to premalignant or frankly malignant neoplasms [2]. Mucinous pancreatic 
cystic lesions are associated with a potential risk to develop malignancy and deserve either an 
active treatment or surveillance [3], while serous cysts are benign lesions [4]. 
Intraductal Papillary Mucinous Neoplasms (IPMNs) represent the most common PCL. According 
with current guidelines [5,6,7,8] they should be treated surgically in the presence of major 
symptoms, morphological changes often defined as high risk stigmata (HRS), or when malignancy 
is demonstrated by cytology. In the presence of an IPMN of the branch ducts (BD-IPMN) with 
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size exceeding 30 mm or thickened and enhanced cystic wall or non-enhancing mural nodule or 
moderate main duct dilatation (5-9 mm) or in presence of abrupt change in pancreatic duct caliber 
with distal gland atrophy (characteristics usually named worrisome features -WF-), surgery might 
be considered and endoscopic ultrasound (EUS) with or without aspiration/biopsy is indicated to 
better analyze the morphology/cytology of the PCL, in order to stratify the risk of malignancy. 
However, the vast majority of IPMNs are BD-IPMNs without any of the above mentioned signs 
and in patients who would be fit for surgery, these lesions require follow-up by means of Magnetic 
Resonance Imaging (MRI) with contrast medium and cholangio-pancreatography (MRCP) or with 
EUS with specific time intervals. 
In a recent meta-analysis [9] the risk of malignant transformation of these lesions has been 
calculated to be equal to 7/1,000 per year, and despite the need to maintain surveillance in the 
long-term is debated [10], recent data suggest that it cannot be stopped after 5 years [11,12,13]. 
The surveillance of PCLs, and particularly of IPMNs, has become a challenge for health\insurance 
systems considering their substantial costs and resource burden. Moreover, the sustainability of a 
surveillance policy depends on the actual prevalence of PCLs in the general population. It is, 
therefore, important to clarify as accurately as possible the prevalence of PCLs, and particularly 
of mucinous cystic lesions, in subjects without a history of pancreatic disease. 
However, these data are sparse, heterogeneous, with a wide range of prevalence rates, but no 
systematic and comprehensive analyses examined this issue. The present systematic review and 
meta-analysis aimed at evaluating the prevalence of incidentally diagnosed PCLs, particularly 
mucinous lesions. 
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MATERIALS AND METHODS: 
 
Search strategy 
 
A computerized literature search of the MEDLINE database did not identify any publication 
related to systematic review on the prevalence of incidentally diagnosed pancreatic cystic lesions 
in healthy subjects or in asymptomatic population. A MEDLINE search was therefore run until 
January 2018. Specific search terms were: (pancreatic cyst OR pancreatic cysts OR pancreatic 
cystic lesions OR intraductal papillary mucinous neoplasia OR pseudocyst OR pancreatic 
mucinous cyst) AND (radiological technique OR magnetic resonance OR multi-detector OR 
radiological imaging OR EUS OR ecoendoscopic ultrasound OR tomography OR MRI OR 
cholangiopancreatography OR abdominal imaging OR US OR MDCT OR CT) AND (occasional 
OR incidental OR incidence OR prevalence OR accidentally OR asymptomatic). The methodology 
was developed from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement [14]. The titles of all identified articles were screened to ascertain their 
relevance. Abstracts and/or full texts of selected potentially relevant papers were evaluated. 
Possible further articles were identified by hand-searching reference 
lists in order to identify potentially relevant studies, missed at our search. In the case of duplicate 
publications, the most recent or the most informative one in terms of number of cases or available 
data, was included. 
Inclusion / exclusion criteria 
Studies were considered if they met the following criteria: 1) written in English; 2) inclusion of 
patients without history of pancreatic disorders or symptoms suggestive for them; 3) all patients 
underwent second or third level imaging (CTscan, MRI+MRCP or EUS) not to investigate 
primarily the pancreatic gland; 4) data about prevalence and characteristics of cystic lesions were 
reported. Studies were excluded if they were available as abstract only because the abstracts did 
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not allow full data extraction. We also excluded: 1) case reports or small case series of <20 cases; 
2) papers investigating the prevalence of pancreatic cystic lesions in specific subset of patient, 
such as liver/ pancreas transplanted patients or cluster of patients with specific type of neoplastic 
disease. Two independent reviewers (G.Z. and M.S.) carried out study identification and selection 
and resolved their disagreements by discussion or by consulting a third reviewer (G.C.). Excluded 
studies and the reasons for exclusion were recorded.  
 
Data extraction and quality assessment. 
Two reviewers (G.Z. and M.S.) independently extracted the data from each study and resolved 
their disagreements by discussion or by consulting a third reviewer (G.C.). 
From the studies that met the eligibility criteria, the following data were collected: 1) study: 
publication year, study design, study location; 2) patients: total number of asymptomatic patients 
evaluated, age, sex, risk factors for pancreatic disease; 3) imaging: type of imaging procedure, 
imaging review, indication for imaging; 4) cases: total number of patients incidentally diagnosed 
with PCLs, prevalence according with age; 3) cyst features: single cyst, mean/median cyst size, 
maximum cist size, connection to the main duct, location, calcification, MD dilatation, worrisome 
features and/or high risk stigmata; 4) Cyst diagnosis: IPMN, pseudocysts, MCN, SCN; 5) extra-
pancreatic cysts. 
We then developed a summary table of the relevant studies listing the population characteristics 
and outcomes. 
The quality of the studies was evaluated independently by two reviewers (GZ and MS) using the 
Newcastle-Ottawa Scale with a dedicated quality appraisal tool including 7 items. Studies with a 
score ≥7 were considered of high quality [15]. 
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Statistical Analysis: 
A meta-analysis of all eligible studies identified was planned using the software package 
Comprehensive Meta-Analysis (Biostat, Englewood, NJ, USA) using a random-effects model. In 
addition to within-study variance, the random-effects model considers heterogeneity among 
studies. The corresponding 95% confidence intervals (CI) were calculated using exact methods 
and assuming a Poisson distribution. We present the random-effect model because we believe that 
the relevant variation in the risk is most likely a consequence of inter-study differences. The 
quantity of heterogeneity was assessed by means of the I2 value [16]. The I2 quantity describes 
the percentage of total variation across studies that is caused by heterogeneity and not by chance. 
We considered an I2 value of 25% or lower as trivial heterogeneity, and an I2 value of 75% or 
higher as considerable heterogeneity. Publication bias was assessed using the Begg and Mazumdar 
test. A p-value <0.05 was accepted as statistically significant. Before performing the analysis, we 
developed the following a priori hypotheses to examine whether these had any effect on the 
prevalence of PCLs in asymptomatic 
individuals and to explore reasons for any heterogeneity observed: (a) type of imaging employed 
to investigate the pancreas (MRCP vs MDTC or MRI); (b) sample size (< 1000 or > 1000 
individuals); (c) mean age (>55 or <55 years) of the analysed population; (d) area of origin (i.e. 
United States, European or Asian countries); (e) quality of the studies (quality score<7 or >7/10). 
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RESULTS: 
Search result and study selection 
The study selection process is summarized in Figure 1. A total of 1,070 references were identified 
by the MEDLINE search. After a primary screening of the titles, 1,009 studies were excluded 
because they did not fit the area of interest. 
The remaining 61 records were screened in more detail and 24 were considered potentially 
appropriate for the analysis. However, only 17 of them fulfilled all inclusion criteria, and were 
considered both for qualitative analysis and quantitative synthesis. 
Study characteristics and quality assessment 
The 17 included studies were published between 2008 and 2018 [1,18-33 ]. Five were conducted 
in the USA, 7 in Europe (4 in Italy and one respectively in The Netherlands, Germany and Turkey), 
4 in Asian countries (two studies both in Korea and in Japan) and one in South America (Brazil). 
All papers were in English language. 
Two studies [29,32] investigated the prevalence of incidental PCLs in a specific subgroup of 
patients compared with controls and we included in our analysis only data concerning the latter. 
Overall, 48,860 asymptomatic patients without history or clinical suspect of pancreatic disorders 
were included. 
The descriptive characteristics of the seventeen included studies are summarized in Table 1. 
All studies were mono-institutional and the study design was cross-sectional for all of them, being 
retrospective in 14 and prospective in 3 [18,27,28],respectively. The number of enrolled patients 
ranged from 110 [29] to 21,745 [30], and the percentage of males ranged from 26% [24] to 65% 
[21]. 
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The mean age of the enrolled subjects ranged from 47 [24] to 68 years [32], while these data were 
not available in two studies [25,26]. The performed diagnostic procedures varied considerably 
among the studies. However, all but one study [32] in which the 192 enrolled patients underwent 
different investigations (either CT scan or MRI+MRCP), employed a single diagnostic tool. 
Abdominal MRI with or without intravenous contrast was the most commonly employed 
diagnostic procedure (11 studies). MRCP was also performed in 6 of them [1,22,23,31,32,33] with 
a huge variability: in two studies [1,32] it was employed in a minority of patients (respectively 
19% and 15%) and in another one [22] all patients underwent MRCP and only a little part of them 
(20%) was investigated also with MRI with intravenous contrast. 
Few studies reported patients’ exposition to well known risk factors for developing pancreatic 
disorders (such as cigarettes smoking, alcohol consumption, increased BMI and diabetes mellitus) 
[1,27,31,33] and first degree family history for pancreatic diseases [1,21,31]. 
While a “pancreatic indication” for the diagnostic procedure was an exclusion criterion for study 
inclusion, the recent study employing EUS [27] included 6% of cases with a previous acute 
pancreatitis episode. As it was clarified that the episode occurred at least 3 months before the study 
enrolment, with pain resolution 8 weeks before the EUS and no evidence of acute fluid collection 
or pseudocyst at the previous abdominal imaging, this study was not excluded. 
As far as regards the quality of the included studies, the Newcastle-Ottawa score ranges from 4/10 
to 9/10. Only six studies were scored as “high quality” (>7/10) [1,21,24,27,31,33] . 
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Pooled Prevalence Rate of Pancreatic Cystic Lesions 
The prevalence of incidentally diagnosed pancreatic cystic lesions ranges from 0.2% to 45.9%, 
with a pooled prevalence of 8% (95% CI 4-14), as detailed in Figure 2. No publication bias was 
found (Begg and Mazudmar Kendall’s tau=-0.07, p=0.64). There was however a considerable 
heterogeneity between the studies (I2=99.5%). 
In order to explore possible reasons for this substantial heterogeneity, we repeated the analysis 
based on our a priori hypothesis considering different covariates (see Figure 3). Studies with mean 
age of the enrolled subjects >55 years old [1,18,19,22,23,27,31,32,33] had a pooled prevalence of 
11.3%, while those with mean age <55 years [20,21,24,28,29,30] of only 5.7%. In both cases, 
however, the heterogeneity was very high (I2>99% for both). 
When we analyzed the results taking into consideration the performed diagnostic procedure, the 
pooled prevalence of PCLs resulted 2.7% (95% CI 2-4) in the studies employing MDCT+ 
c.e.[18,19,25,26,30,32], without a reduction of heterogeneity (I2=93.7%). In the four studies using 
MRCP [22,23,31,33] the prevalence of PCLs was instead as high as 24.8% (95% CI 10-48), with 
similar heterogeneity (I2=99.5%).  
 
 
 
Figure 1. Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses 
(PRISMA) diagram of assessment of studies 
identified in the systematic review 
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When the sample size of the studies (<1,000 or >1,000) nwas considered, a higher pooled 
prevalence was seen in studies with <1,000 enrolled subjects [1,20,22,25,27,28,29,32] (13.9%, 
95% CI 7-25; I2=97.4%) compared to those enrolling >1,000 people [18,19,21,23,24,26,30,31,33] 
(4.7%, 95% CI 2-11; I2=99.7%). 
When considering the country of origin, the pooled prevalence of PCLs resulted 3.1% (95% CI 1-
10; I2=99.7%) in studies conducted in Asia [18,23,30,31], 12.6% (95% CI 5-27; I2=99%) for those 
carried out in the Americas (either US or South America) [1,19,20,24,27,29], and 8.6% (95% CI 
2-27; I2=99.6%) for those conducted in Europe [21,22,25,26,28,32,33]. 
 
 
Figure 2. Pooled prevalence of all pancreatic cystic lesions (PCLs) in the 17 examined studies. The pooled 
prevalence resulted of 8% (95% CI 4%-14%), with considerable heterogeneity (I2= 99.5%). 
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Figure 3. Prevalence of PCLs according to variables considered a priori for sensitivity analysis: A) age 
(studies with mean/median population age >55 years compared with those with mean/median age <55 years); B) 
different diagnostic procedures [studies using CT scan + medium contrast vs Magnetic Resonance Cholangio- 
Pancreatography (MRCP) with or without MRI]; C) sample size (<1,000 vs >1,000 cases); D) geographic area in 
which the studies were conducted (Asia, Americas and Europe); E) quality of the study (high vs low quality). 
 
 
As far as regards the quality of the studies, the six studies of “high quality” [1,21,24,27,31,33] 
score had a higher pooled prevalence of PCLs of 14.6% (95% CI 6-30), with I2= 99.5%, when 
compared to the 11 studies with a “lower quality”. 
 
Pooled Prevalence Rate of Mucinous Cystic Lesions and of lesions harbouring clinically relevant 
features. 
Seven of the 17 studies reported data on the specific type of PCLs. In these studies, the pooled 
prevalence of all PCLs was 7% (95% CI 2-19), with substantial heterogeneity (I2=99.6%) and the 
pooled prevalence of lesions diagnosed as of likely “mucinous nature” was 4.3% (95% CI 2-10; 
I2 = 99.2%) (see Figure 4). Most of these PCLs were considered IPMNs. 
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Of the included 17 studies, 5 did not provide details about the morphology of the PCLs 
[18,29,30,31,33]. Of the remaining studies, 4 did not report cases with morphological aspects 
suggestive of “worrisome features” or “high risk stigmata” [1,19,21,22], whereas in eight studies 
[20,23,24,25,26,27,28,32] these characteristics were mentioned. The rate of lesions with 
worrisome features (WF) or high risk stigmata (HRS) such as solid nodules, thickening of the wall 
and main duct calibre > 5 mm ranged from 0.1% to 3.6%. The pool prevalence of either WF and/or 
HRS at diagnosis resulted of 0.7% (95% CI 0-1) with considerable heterogeneity (I2 =85.3%) (see 
Supplementary Figure 1).  
 
DISCUSSION: 
To our knowledge, this is the first meta-analysis investigating the prevalence of incidentally 
diagnosed PCLs in individuals asymptomatic for pancreatic disorders. In the present study, data 
from seventeen publications were analysed, resulting in a pooled prevalence rate of 8%, with a 
wide range (0.2% to 45.9%) and considerable heterogeneity. 
Only seven of the included studies provide sufficient data to define the nature of the PCLs. In these 
studies, the pooled prevalence of PCLs was of 7% and that of mucinous lesions was 4.3%, 
representing 60% of all incidentally diagnosed PCLs. However, at the time of incidental diagnosis, 
a minority of these lesions (0.7%) harboured features that might pose the suspicious of malignancy 
and an indication for surgery, such as main pancreatic duct dilation, thickened wall and mural 
nodules. The strengths of the present study include an exhaustive literature search, rigorous 
statistical methods, and pooling of data to allow synthesis of all the available evidence examining 
the possible yield\burden of testing for pancreatic cysts in asymptomatic individuals. Nevertheless, 
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the most relevant weaknesses of the study, as concerns many systematic review and meta-analysis, 
arise from the limits of the available evidence. 
Most of the studies eligible for the current analysis were retrospective and for five of them the past 
medical history was not available; however, they include patients that were asymptomatic at the 
time of examination, without known health co-morbidities. 
Moreover, since the included studies evaluated the radiological results collected during a long time 
span (up to 10 year), imaging were obtained with different machines and protocols. The authors 
of the studies with a longer time of recruitment considered, however, the effect of the different 
distribution of radiological modalities on the PCLs’ rate. 
Moris et al.[1] tried to objectify this correlation performing an adjusted multivariate-analysis, that 
showed a very strong relationship between PCLs detection and both the MRI hardware and the 
software versions. Therefore, they confirmed the direct relationship between the number of PCLs 
detected and the newer MRI version used. On the other hand, Kim J.A. and colleagues [29] 
matched cases and controls (respectively patients affected by autosomal dominant polycystic 
kidney disease -ADPKD- and patients who underwent abdominal MRI imaging without history or 
suspect of both ADPKD and pancreatic disorders) not only for demographic characteristics but 
also for the timing of abdominal procedures (within 1 year of each other), in order to reduce the 
“technology influence” on the results. 
The highest [33] and one of the lowest [28] rates of PCLs were surprisingly reported by two studies 
using the same radiological procedure, such as whole body MRI. Paramagnetic contrast was not 
administrated in both, but, probably, the complementary use of MRCP in one of them [33] could 
explain the increasing rate of pancreatic findings, although the difference remains huge. 
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As mentioned before, a considerable degree of heterogeneity was present in all the conducted 
analyses. A number of a priori hypotheses were made to explain heterogeneity, such as age, 
country of origin, number of enrolled subjects, different type of abdominal cross-sectional imaging 
and quality of the study. However, while some of these factors influence the rate of PCLs, they 
could not explain heterogeneity. 
The pooled estimate rate of occasional PCLs was higher in older subjects, in studies enrolling a 
lower number of patients, in those with a higher quality score and in patients undergoing MRCP. 
As far as concerns the country of origin, the pooled rate of PCLs was four times higher in studies 
conducted in the US than in those conducted in Asia 
(12.6% vs 3.1%), with roughly intermediate results in Europe (see Figure 3). 
Despite the limitations listed above, there are a good similarity between the result from our meta-
analysis and the only prospective study performed with EUS available on this topic [27] 
(respectively pooled rate of 8% and 9.4%), strengthening the reliability of the present data. 
In conclusion, the findings of this meta-analysis highlight the considerable high prevalence of 
PCLs in asymptomatic and/or apparently healthy individuals. On the light of these data there is an 
impingent need to redefine the surveillance strategy proposed by international consensus 
guidelines, according with a new scale of clinical risk. 
Indeed, taking into account both the higher prevalence of PCLs in older and asymptomatic subjects 
and the presence of comorbidities and the low rate of potential malignant features, radiological 
follow-up in this group of patients is expected not to be cost-effective [34]. Furthermore, the 
observed different rates observed in the US and in other geographic Areas might suggest that 
different protocols might be necessary in different Countries.
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    Table 1. General features of the 17 studies included in the quantitative analysis 
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6. SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
 
 
This thesis deal with surveillance for HRIs to develop PDAC with the aim to improve the 
knowledge on this field that still carries various areas of improvement and some issues to clarify. 
Firstly, both EUS and MRI were considered the most accurate test for pancreatic imaging within 
the screening setting [1-3] but no imaging test has gained evidence-based consensus [4]. In order 
to reach the screening goal (reduction of pancreatic cancer related mortality) the best imaging test 
should diagnose the lesions considered a successful target of surveillance that are high-grade 
precursors or small PDAC amenable of curative surgical treatment. The exact prevalence of solid 
and/or cystic lesions, and more important, whether detected lesions could be considered a 
successful target of surveillance are still debated. 
Therefore, we conducted and published on UEG journal a systematic review and meta-analysis 
[5] of the surveillance studies available at that time (see at the end of the thesis).  Our results, 
reporting data from 1588 HRIs, showed a high prevalence of cystic lesions (20.2%) but only 1.6% 
was considered a pre neoplastic relevant lesion (advanced IPMNs and PanIN3 lesions) as well as 
of the 5.8% solid lesion discovered only 1.6% patients were diagnosed with a resectable PDAC. 
Moreover, from our results EUS seemed able to diagnose more solid lesions and MRI more cystic 
ones. Higher prevalence rate was observed in HRIs carriers with a specific DNA mutation 
compared to HRIs with FPC in whom the mutation is unknown. From This study we can conclude 
that both EUS and MRI should be considered for screening HRIs since both solid and cystic lesions 
are considered a target of the screening. However, we still need to clarify of the total premalignant 
lesion diagnosed in HRIs, which will progress to advanced neoplasia or early cancer and the 
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influence of individual factors such as the age of the subjects enrolled in the surveillance programs, 
and the relevance of risk factors such as smoking, can play a role for the progression. 
 
No one of the screening studies considered for the above systematic review and meta-analysis was 
conducted in Italy. Therefore, we carried out multicenter surveillance program included 
asymptomatic HRIs with familial (FPC) or genetic frailty (BRCA1/2, p16/CDKN2A, 
STK11/LKB1 and PRSS1 mutations) predisposition to PDAC.  
The paper was published on the American Journal of Gastroenterology (see at the end of the 
thesis), and reported the results of the first screening round of the Italian multicenter program 
supported by the Italian Association for the study of the Pancreas (AISP). After the first round of 
screening of the Italian registry the rate of malignancies was 2.6%. The diagnostic yield for 
MRCP/EUS was 23.5% for cystic lesions. The great majority of the detected cysts were BD-IPMN 
(n=28, 60.8% of the cysts detected, 14.9% of the whole cohort). The present study aimed also to 
answer one of the most important question that is if subjects related factors (familial or clinical) 
are associated with an increased risk of diagnosis of pancreatic abnormalities. We found that age 
> 50, smoking habit and > 2 relatives diagnosed with PC increased risk of malignant or pre-
malignant pancreatic lesions. Whether these data will also reflect an increased risk of developing 
de novo lesions or of progression of initial finding needs to be investigated.  
Moreover,till now, it is still unknown if some pancreatic parenchymal changes as called chronic 
pancreatitis-like features related to the presence of microscopic PDAC precursor ( Pan-INs) and 
the presence of IPMNs might show a different risk of progression and  characteristics in HRIs 
compared to the general population.  
Few studies compared pancreatic parenchymal alterations in HRIs to controls by using endoscopic 
ultrasonography (EUS) reporting that abnormal changes occur more often in HRIs than controls 
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[2, 6-7] without categorized the type of cystic lesion detected so that the exact number of 
precancerous cystic lesions (IPMN) described in HRIs compared to controls is not known. 
Therefore, we decided to conduct a case-control study on pancreatic changes in High-Risk 
Individuals compare to control to evaluate the pancreatic parenchyma changes of HRIs and asses 
if some them (such as cystic lesions or chronic pancreatitis features) occur more often in the setting 
of a high risk population compared to healthy controls. Our study is the first who compare 
pancreatic changes diagnosed by MRI-MRCP to controls. We were able to enroll and analyzed the 
MRI findings of the first round of screening of 28 HRIs compared to 26 controls.  
The majority pancreatic changes observed in HRIs were parenchymal atrophy and cystic lesions 
(small SB-IPMNs) without worrisome features. The presence of those pancreatic features did not 
differ between cases and controls; in particular, it was high even in HRIs (25%) than controls 
(23%). This study presents some limitations such as the small number of HRIs enrolled, majority 
of them belonging to FPC group. Those group of HRIs indeed, are more prone to present cystic 
lesions 10 mm or greater with a lower probability of progression compared to HRIs with a known 
mutation [8].  A large cohort of subjects and longer follow-up are needed to clarify if the clinical 
value of small SB-IPMN and /or signs of chronic pancreatitis can predict the development of 
advanced neoplasia or early cancer in HRIs compared to controls. In particular, we still not know 
if lesions that arise in HRIs have the same biological behavior as lesions seen in sporadic cases.  
Nowadays, we still need to clarify the exact prevalence of mucinous lesions even in the general 
population of asymptomatic subjects as well as the actual risk of progress of those kind of lesions. 
Therefore, we finally conducted a systematic review and meta-analysis on the prevalence of 
incidentally detected pancreatic cystic lesions in asymptomatic individuals, paper published 
on Pancreatology (see at the end of the thesis) . The prevalence of incidental diagnosed mucinous 
99 
lesions was 4.3% with 0.7% of worrisome features that might pose the suspicious of malignancy 
by using different type of abdominal cross-sectional imaging. The four studies using MRCP the 
prevalence of PCLs was as high as 24.8% (95% CI 10-48), compared to what we found in the case 
and control groups of the previous mentioned study. The findings of this meta-analysis highlight 
the considerable high prevalence of PCLs in asymptomatic and/or apparently healthy individuals 
with low rate of potential malignant features.  
On the light of these data, we still not answer to the ultimate question whether screening HRIs is 
effective or not. However, we have improved the knowledge of this topic for better designed the 
future surveillance policy. 
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Results of surveillance in individuals at high-risk
of pancreatic cancer: A systematic review and
meta-analysis
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Abstract
Background: Data on surveillance for pancreatic ductal adenocarcinoma (PDAC) in high-risk individuals (HRIs) with
‘‘familial pancreatic cancer’’ (FPC) and specific syndromes are limited and heterogeneous.
Objective: We conducted a systematic review and meta-analysis of PDAC surveillance studies in HRIs.
Methods: Prevalence of solid/cystic pancreatic lesions and of lesions considered a successful target of surveillance (proven
resectable PDAC and high-grade precursors) was pooled across studies. The rate of lesions diagnosed by endoscopic
ultrasonography (EUS)/magnetic resonance imaging (MRI) and across different HRI groups was calculated.
Results: Sixteen studies incorporating 1588 HRIs were included. The pooled prevalence of pancreatic solid and cystic lesions
was 5.8% and 20.2%, respectively. The pooled prevalence of patients with lesions considered a successful target of sur-
veillance was 3.3%, being similar to EUS or MRI and varying across subgroups, being 3% in FPC, 4% in hereditary
pancreatitis, 5% in familial melanoma, 6.3% in hereditary breast/ovarian cancer, and 12.2% in Peutz-Jeghers syndrome.
The pooled estimated rate of lesions considered a successful target of surveillance during follow-up was 5/1000 person-
years.
Conclusion: Surveillance programs identify successful target lesions in 3.3% of HRIs with a similar yield of EUS and MRI and
an annual risk of 0.5%. A higher rate of target lesions was reported in HRIs with specific DNA mutations.
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Key summary
1. Summarize the established knowledge on this subject.
. Surveillance of pancreatic cancer is advised in individuals with ‘‘familial pancreatic cancer’’ (FPC) and
specific genetic syndromes.
. No evidence-based consensus is available on the imaging test preferred between magnetic resonance
imaging (MRI) and endoscopic ultrasonography (EUS).
. Whether surveillance protocols should be different in different high-risk individual (HRI) subgroups is
unknown.
2. What are the significant and/or new findings of this study?
. The rate of resected lesions considered a successful target of surveillance during pancreatic cancer sur-
veillance programs in HRIs is 3.3% or 0.5% per year.
1Digestive and Liver Disease Unit, S. Andrea Hospital, Rome, Italy
2Department of Gastroenterology and Hepatology, Erasmus Medical Center,
University Medical Center, Rotterdam, The Netherlands
Corresponding author:
Gabriele Capurso, Digestive and Liver Disease Unit, S. Andrea Hospital,
University Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy.
Email: gabriele.capurso@gmail.com
United European Gastroenterology Journal
2018, Vol. 6(4) 489–499
! Author(s) 2018
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2050640617752182
journals.sagepub.com/home/ueg
. There are no differences between EUS and MRI in diagnosing a ‘‘successful’’ target of screening.
. The rate of successful target lesions in FPC is lower compared to specific genetic syndromes, thus sur-
veillance programs might need to be individualized accordingly.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an
increasing cause of cancer-related death, partially
because of delayed diagnosis.1,2 While precursor
lesions, such as intraductal papillary mucinous neo-
plasms (IPMNs), can be detected at early stages,
whether this is possible for pancreatic intraepithelial
neoplasia (PanINs)3 is a matter of debate. At any
rate, general population screening is not advised as
the overall lifetime PDAC risk is relatively low.
However, since a hereditary component accounts for
5% to 10% of cases,3 surveillance is advised for high-
risk individuals (HRIs). The International Cancer of
the Pancreas Screening (CAPS) Consortium4 defined
individuals with ‘‘familial pancreatic cancer’’ (FPC)
or with hereditary syndromes of which PDAC is
one phenotypic manifestation as HRIs. The FPC
definition is not fully established, but an individ-
ual can be considered at high risk if two blood rela-
tives are affected by PDAC, of whom at least one is
a first-degree relative (FDR). Regarding defined
genetic syndromes, surveillance is indicated for all
Peutz-Jeghers syndrome (PJS) patients regardless of
family history. Furthermore, p16 (familial atypical mul-
tiple-mole melanoma syndrome, FAMMM), breast
cancer type 2 susceptibility gene (BRCA2), partner
and localizer of BRCA2 (PALB), and mismatch
repair gene (hereditary nonpolyposis colorectal
cancer, HNPCC) mutation carriers with one FDR or
two other family members with PDAC should undergo
surveillance.5
The ultimate goal of surveillance is to detect and
surgically treat noninvasive precursor lesions, such as
advanced PanINs or IPMNs with high-grade dysplasia,
or early-stage PDAC, that are considered successful
targets of surveillance according to the CAPS
Consortium.4 Data on the efficacy of such surveillance
programs in HRIs in terms of identification of the
above-mentioned lesions are limited and heteroge-
neous, thus HRI surveillance is generally performed
in the setting of research protocols.
Both magnetic resonance imaging (MRI) and endo-
scopic ultrasonography (EUS) are employed as first-
line modalities for HRI surveillance, but no imaging
test has gained evidence-based consensus.6,7
Furthermore, the results of screening might differ in
terms of detected lesions in each HRI subgroup. As
an example, patients with FAMMM were reported to
develop more solid lesions while FPC individuals more
cystic ones.8,9
This systematic review and meta-analysis is therefore
aimed to assess in HRIs (a) the prevalence of solid and
cystic lesions and of lesions considered a successful
target of surveillance, (b) the prevalence of lesions diag-
nosed by EUS and/or MRI, and (c) the prevalence of
lesions considered a successful target of the surveillance
in different HRI subgroups.
Materials and methods
Search strategy
A PubMed and Scopus databases search (see
Appendix 1) was run until June 2017. Duplicates were
removed. The methodology was developed from the
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement.10
The titles of all identified articles were assessed for
their relevance, and abstracts and/or full texts of poten-
tially relevant papers screened and evaluated. A manual
search of all relevant articles and references was con-
ducted to identify further relevant studies.
Inclusion and exclusion criteria
Inclusion criteria were English language, patients
belonging to FPC families and/or with other specific
high-risk syndromes or germline mutation carriers,
and surveillance carried out with MRI and/or EUS,
with the prevalence and type of diagnosed pancreatic
lesions (solid and/or cystic) being reported. In the case
of duplicate publications, the most recent or most
informative was included. Two independent reviewers
(MS and GZ) carried out study identification and selec-
tion and discussed disagreements with a third reviewer
(GC). Excluded studies and reasons for exclusion were
recorded.
Data extraction and quality assessment
Two reviewers (MS and GZ) independently extracted
data from each study into aMicrosoft Excel spreadsheet
(XP Professional Edition; Microsoft Corp, Redmond,
WA, USA). Disagreements were resolved by consulting
a third reviewer (GC). Study year, design and location,
number of screened individuals, and type of high-risk
subgroups, and of imaging, follow-up duration,
number, and type of diagnosed lesions, and of patients
with an indication for surgery and with an identified
lesion considered to be a success of the surveillance or
diagnosed with advanced/metastatic PDAC were
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recorded. A summary table of the relevant studies listing
the population characteristics and outcomes was devel-
oped. The quality of the studies was evaluated independ-
ently by two reviewers (MS and GC) using the
Newcastle-Ottawa Scale11 with a dedicated quality
appraisal tool including seven items. Studies with a
score 7 were considered of high quality.
Data analysis
We examined (a) the pooled prevalence rate of all solid
or cystic lesions, and (b) the pooled prevalence of
lesions being considered a successful target of surveil-
lance as defined by gold-standard pathology after
surgery. Lesions considered as successful targets of sur-
veillance were: PanIN3 (or high-grade PanIN if not
specified), IPMNs with high-grade dysplasia or main
duct (MD)/mixed-type IPMN, and any resectable
PDAC with R0 pathology. This definition is adapted
from the CAPS one, as some of the papers did not
provide enough information for detailed grouping; the
pooled prevalence rate of advanced IPMNs and
PanIN3 lesions was also calculated, considering them
as ‘‘premalignant’’ target lesions; (c) the pooled preva-
lence rate of advanced/metastatic PDAC, not amenable
to R0 resection; (d) the pooled prevalence of the above-
mentioned lesions detected either by EUS or by MRI;
and (e) the pooled prevalence of successful target
lesions in each specific HRI group.
Data were combined to generate a pooled prevalence
rate. To better reflect the incidence of detected lesions
over time, we also calculated the incidence rates of
lesions being a successful target of surveillance by divid-
ing the total number of events by the total number of
person-years (pyrs) of follow-up. If these latter data
were not provided in a study, it was estimated by multi-
plying the number of patients who underwent surveil-
lance by the reported mean follow-up time. The
corresponding 95% confidence intervals (CIs) were cal-
culated using exact methods and assuming a Poisson
distribution. When the number of events was 0, a con-
tinuity correction of 0.5 was used for the purpose of
calculation, as previously reported.12
A meta-analysis was performed using the software
package Comprehensive Meta-Analysis (Biostat,
Englewood, NJ, USA) by using a random-effects
model.13 In addition to within-study variance, the
random-effects model considers heterogeneity among
studies and gives more conservative estimates. The
quantity of heterogeneity was assessed by means of
the I2 value.14 The I2 describes the percentage of total
variation across studies that is caused by heterogeneity
and not by chance. Publication bias was assessed using
the Begg and Mazumdar test. A p value< 0.05 was
accepted as statistically signiEcant. We developed the
following a priori hypotheses that would explain het-
erogeneity and planned sensitivity analyses for (a) area
of origin (i.e., United States (US)/Canada or Europe)
and (b) quality of the study (quality score >7 or 7).
Results
Search results and study selection and
characteristics
The study selection process is summarized in Figure 1.
Sixteen studies met the eligibility criteria and were
included for qualitative analysis and quantitative
synthesis. One of them15 is a multicenter study whose
findings were already reported in three previous single-
center studies.9,16,17 As the population of this latter
study was larger and results regarding the different
HRIs subgroups more detailed, we used this manu-
script for the analysis of pooled prevalence of overall
lesions. However, as this more recent paper does not
report the exact number of cystic/solid lesions diag-
nosed by either EUS or MRI, we used data from
the older studies for the analyses on the role of MRI
and EUS.
Table 1 summarizes the characteristics of the 16
included studies. Two papers reported only the first
surveillance round18,19 while two other studies did not
report the exact follow-up period.20,21 The mean
follow-up in studies reporting> one surveillance
round2,6,7,15,22–26 was 32.4 months, and the total
number of enrolled HRIs 1588. Considering the 1572
individuals for whom this information was available,
the largest group of screened individuals was FPC
(1043, 66.3% of total) followed by FAMMM (243,
15.4%) and hereditary breast and ovarian cancer
(HBOC) syndrome individuals or BRCA1/2 mutation
carriers (140, 8.9%). Some studies also enrolled indi-
viduals who did not meet the criteria to be designated
as ‘‘HRI’’ according to the CAPS consortium.2,7,18–20
There were four patients with Li-Fraumeni syn-
drome,9,22 five with only one affected family
member,25 nine with a family member with early-
onset PDAC,24 and six with >1 relative with non-
pancreatic cancers;2 all together these people accounted
for 1.6% of the investigated individuals. Two studies
enrolled patients with a very low risk of developing
pancreatic cancer based on family history19,21 and
those individuals therefore were not included in the
analysis. Only four4,7,20,25 of the 16 studies were
scored as of ‘‘high quality.’’
Prevalence of solid pancreatic lesions in HRIs
A total of 79 pancreatic solid lesions were detected,
with a pooled prevalence of 5.8% (95% CI 3%–9%;
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I2¼ 77.5%) (Figure 2). No publication bias was found
(Begg and Mazudmar Kendall’s tau¼ –0.21; p¼ 0.27).
When considering only the studies conducted in the
USA or Canada, the pooled estimate prevalence was
3.8% (95% CI 2%–8%; I2¼ 68.8%), compared to
6.8% with similar heterogeneity (95% CI 4%–12%;
I2¼ 61.2%) in the studies from Europe. The pooled
prevalence of solid lesions in studies of high qual-
ity4,7,20,25 was 2.8% (95% CI 1%–6%) compared to
7.7% (95% CI 5%–12%) in the 11 studies of lower
quality,2,9,16–19,21–24,26 with lower heterogeneity
(I2¼ 38.2% vs I2¼ 72.3%) in high-quality studies.
Prevalence of cystic pancreatic lesions
A total of 340 pancreatic cystic lesions were detected,
with a pooled prevalence of 20.2% (95% CI 14%–28%;
I2¼ 88.9%) (Figure 2). Information on prevalence of
pancreatic cystic lesions was not provided in one
study.26 No publication bias was found (Begg
and Mazudmar Kendall’s tau¼ –0.34; p¼ 0.09). The
pooled prevalence of cystic lesions was 23.4% (95%
CI 16%–34%; I2¼ 84.1%) in the studies conducted in
the USA and Canada, and 18.4% (95% CI 8%–37%;
I2¼ 92.1%) in the studies conducted in Europe. In stu-
dies with a high-quality score, the pooled prevalence of
cystic lesions was 33.6% (95% CI 21%–49%;
I2¼ 90.3%), being higher than the 15.4% (95% CI
10%–24%) of studies with a low-quality score, yet
with similar heterogeneity (I2¼ 83.7%).
Prevalence of successful target lesions
of surveillance
Of 1588 screened HRIs, 95 were considered to have an
indication for surgery (pooled prevalence 6.8%; 95%
CI 4%–11%; I2¼ 81%). However, the pooled preva-
lence of individuals for whom surveillance identified a
lesion considered a successful target of surveillance was
3.3% (95% CI 2%–5%; I2¼ 40.5%) (Figure 3). In
high-quality studies, this pooled prevalence was 2.9%
(95% CI 1%–8%; I2¼ 69.2%), being 3.4% (95% CI
2%–5%; I2¼ 23.4%) in studies of lower quality. In
the sensitivity analysis by country of origin, the
pooled prevalence was 2.7% (95% CI 1%–5%;
I2¼ 43.3%) for studies conducted in the USA or
Canada and 4.1% (95% CI 2%–8%; I2¼ 52.2%) for
studies conducted in Europe. No publication bias was
found (Begg and Mazudmar Kendall’s tau¼ –0.16;
p¼ 0.45). Furthermore, when we repeated this analysis
excluding individuals who were not at high risk accord-
ing to the guidelines,2,7,18–20 the pooled prevalence was
3.4% (95% CI 2%–5%; I2¼ 44.7%). As the ideal target
of the surveillance programs should be the diagnosis of
‘‘premalignant’’ lesions, the pooled prevalence rate of
advanced IPMNs and PanIN3 lesions was also
903 identified through database
searching
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of assessment of studies identified in
the preset systematic review.
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calculated, and resulted in 1.6% (95% CI 1%–2%;
I2¼ 0%) (see Supplementary Figure 1).
In detail, 26 (1.6%) patients were diagnosed with a
resectable PDAC, 11 (0.7%) with branch duct (BD)-
IPMNs with high-grade dysplasia or an MD-IPMN,
and four (0.3%) with advanced PanINs. Six individuals
were diagnosed with pancreatic neuroendocrine neo-
plasms (pNENs).2,6,15,24 Four of them were resected
and all but one2 had a diameter <15mm. Type and
number of histologically confirmed lesions, including
those successfully operated on, are summarized in
Supplementary Table 1. The pooled estimate rate of
lesions considered a successful target of surveillance
was calculated for 11 studies in which follow-up
length was reported, and resulted in 0.005/pyrs (95%
CI 0.001%–0.005%; I2¼ 56%), equal to 5/1000 pyrs
(Figure 4).
Prevalence of advanced/metastatic pancreatic
adenocarcinoma
During the surveillance programs, nine advanced/meta-
static adenocarcinoma were diagnosed. Six metastatic
PDAC were diagnosed and histologically confirmed by
percutaneous or EUS-guided fine needle aspir-
ation;2,9,19,23 the other three underwent surgical resec-
tion but histology showed a positive resection
margin.9,15 The pooled prevalence of HRIs for which
surveillance identified advanced PDAC was 1.0% (95%
CI 1%–2%), without heterogeneity (I2¼ 0%).
Prevalence of pancreatic lesions diagnosed
either by EUS or by MRI
Ten studies employed EUS6,7,16–19,22–24,26 and nine
MRI.2,6,7,9,16,19–21,25 The pooled prevalence of solid
lesions was higher in studies employing EUS (5.2%,
95% CI 3%–9%; I2¼ 60.6%) compared with those
using MRI (4.1%, 95% CI 2%–9%; I2¼ 83%)
(Figure 5). The pooled prevalence of cystic lesions
was instead 22.4% (95% CI 15%–32%; I2¼ 89.3%)
with MRI and 16.6% (95% CI 10%–27%; 85.7%)
with EUS in the eight studies providing this informa-
tion, which was lacking in two studies.17,26 The pooled
prevalence of pancreatic lesions considered a successful
target of surveillance was 2.9% with EUS (95% CI
2%–5%; I2¼ 27.4%) and 2.5% with MRI (95% CI
1%–5%; I2¼ 51.7%) (see Figure 5).
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Figure 2. Forest plot showing the pooled prevalence of pancreatic solid lesions (panel (a), on the left) diagnosed in high-risk individuals
in all the 14 included studies and of the pooled prevalence of cystic lesions (panel (b), on the right) diagnosed in high-risk individuals in
the 13 studies reporting this information. Random-effects model demonstrating a pooled prevalence of 5.8% (95% confidence interval (CI)
3%–8%) with moderate heterogeneity (I2¼ 77.5%) for solid lesions and a pooled prevalence of 20.2% (95% CI 14%–29%) with
considerable heterogeneity (I2¼ 88.9%) for cystic ones.
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Figure 3. Forest plot showing the overall pooled prevalence of
successful target lesions of the surveillance that is equal to 3.3%
(95% confidence interval (CI) 2%–5%), with moderate heterogen-
eity (I2¼ 40.5%).
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Prevalence of lesions considered a successful
target of surveillance in different HRI subgroups
The pooled prevalence of lesions considered a success-
ful target of surveillance was 3% (95% CI 2%–5%;
I2¼ 22.2%) in FPC individuals. In people with a
specific genetic syndrome it was 4% in HP (95% CI
1%–14%), 5% for FAMMM (95% CI 3%–9%),
6.3% in HBOC or BRCA1/2, PALB2 mutation carriers
(95% CI 3%–14%), and 12.2% in PJS (95% CI 4%–
32%), without heterogeneity (I2¼ 0%) in all these
subgroups except for people with HP (I2¼ 12.2%)
(Figure 6). We also analyzed the pooled prevalence
rate of histologically confirmed solid lesions diagnosed
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Figure 5. Summary of the pooled prevalence of pancreatic lesions (solid, cystic and successful target lesions of the surveillance)
diagnosed either by endoscopic ultrasonography (EUS) or magnetic resonance imaging (MRI). CI: confidence interval.
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Figure 4. Forest plot showing the pooled estimate rate of successful target lesions of the surveillance in the 11 studies that reported the
follow-up length. The pooled estimate rate resulted of 5/1000 person years with moderate heterogeneity (I2¼ 56%).
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at the baseline examination in each subgroup. These
data were available for all studies but one.21 The
pooled rate of solid lesions at baseline resulted respect-
ively in: 1.6% (95% CI 1%–3%; I2¼ 0%) in FPC,
5.8% (95% CI 2%–14%; I2¼ 0.8%) in HBOC or
BRCA1/2 mutation carriers, 4.6% (95% CI 2%–12%;
I2¼ 35%) in FAMM, 12% (95% CI 4%–32%; I2¼
0%) in PJS, and 7.2% (95% CI 1%–30%; I2¼ 0.8%)
in HP. The number of pancreatic cancer cases and the
relative proportion of unresectable/metastatic cases
were respectively 12 (25% metastatic) in FPC,
15 (20% metastatic) in FAMMM, four (25% meta-
static) in HBOC, and one (0% metastatic) in HP. No
PDAC cases were diagnosed in PJS patients.
Discussion
As data on the prevalence of lesions diagnosed during
surveillance programs in individuals at high risk of
PDAC are scanty and heterogeneous, we conducted a
meta-analysis to estimate the pooled prevalence of solid
and/or cystic lesions, and more important, whether
detected lesions could be considered a successful
target of surveillance. We also calculated the pooled
estimated rate of detected lesions during the course of
subsequent surveillance rounds, the prevalence of
lesions diagnosed by either EUS or MRI, and the
differential prevalence of lesions among the various
HRI subgroups.
Data from 1588 enrolled HRIs were included. The
pooled prevalence of solid and cystic lesions in these
individuals was 5.8% and 20.2%, respectively
(Figure 2). The pooled prevalence of lesions considered
a successful target of surveillance according to the
CAPS definition was 3.3% (Figure 3), while the
actual pooled prevalence of ‘‘preneoplastic’’ target
lesions (advanced IPMNs and PanIN3 lesions) was
1.6% (see Supplementary Figure 1). The pooled esti-
mated rate of lesions considered a successful target of
surveillance during follow-up amounted to five cases
per 1000 pyrs, equal to an annual risk of 0.5%
(Figure 4).
EUS seemed able to diagnose more solid lesions and
MRI more cystic ones (Figure 5). Moreover, the rate of
lesions considered a successful target of surveillance
was much lower in FPC compared to HRI with specific
syndromes (Figure 6). This is not surprising as in FPC
the causal mutation is unknown despite a clear auto-
somal dominant inheritance pattern. Therefore, half of
FPC individuals undergo surveillance without carrying
the causal mutation.
Of the 1588 screened HRIs, 6.8% underwent sur-
gery, with histologically confirmed lesions considered
a successful target of surveillance in 3.3%. To date,
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Figure 6. Pooled prevalence of lesions considered a successful target of surveillance in the different high-risk individual subgroups.
The pooled prevalence of lesions considered a successful target of surveillance diagnosed in familial pancreatic cancer (FPC) was 3%
(95% confidence interval (CI) 2%–5%) with moderate heterogeneity (I2¼ 22.2%). The pooled prevalence in familial atypical multi-mole
melanoma syndrome (FAMMM) was 5% (95% CI 3%–9%), in hereditary pancreatitis (HP) was 4% (CI 1%–14%), in hereditary breast-
ovarian cancer syndrome (HBOC) or BRCA1/BRCA2 or PALB2 mutation carriers was 6.3% (95% CI 3%–14%), and in Peutz-Jeghers
syndrome (PJS) it was 12.2% (95% CI 4%–32%). Notably, in all these genetic syndromes but HP, there was no heterogeneity (I2¼ 0%).
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there is little consensus about which lesions detected by
surveillance represent an indication for surgery,4 con-
sidering the morbidity of pancreatic surgery.27 It is
unknown whether for example in the case of BD-
IPMNs the same criteria for resection apply in HRIs
compared to sporadic cases.28 A recent study showed
that cystic lesions diagnosed in HRIs with a known
mutation are more prone to progress compared to
those discovered in FPC individuals, although this
latter group had a significantly higher prevalence of
cystic lesions.29 There is also evidence of a high rate
of lymph node involvement and poor prognosis in
HRIs with PDAC even with very small lesions.9,18
This might justify a more aggressive attitude toward
resecting precursor lesions in this setting.
A proportion of patients diagnosed with PDAC
(n¼ 9, pooled prevalence 1%) were identified at an
advanced/metastatic stage. Two of them were prevalent
cases diagnosed at baseline. The other patients who
underwent surgical resection with positive resection
margins, or who were diagnosed with an unresectable
interval cancer during subsequent follow-up, however,
should be considered a failure of surveillance. The pro-
portion of unresectable PDAC was similar in people
with FPC, FAMMM, and HBOC. This raises concerns
about the validity of currently performed surveillance
programs.
In four cases the resected lesions were pNENs, only
one2 with diameter >1.5 cm. The European
Neuroendocrine Tumours Society guidelines30 would
not recommend surgery for incidentally detected
pNENs <2 cm.
Few studies compared the diagnostic yield
of EUS and MRI/magnetic resonance cholangiopan-
creatography. A high concordance between the two
methods was described by Canto et al.,6 while only a
55% agreement was shown by Harinck et al.7 for the
detection of clinically relevant lesions. In the present
study, the pooled prevalence of solid lesions detected
by EUS was higher compared to MRI (5.2% vs 4.1%),
while MRI had a higher yield for cystic lesions (22.4%
vs 16.6%). The pooled prevalence of lesions considered
a successful target of surveillance was similar for EUS
and MRI. A limitation of this analysis is the high het-
erogeneity between studies in terms of MRI protocols,
and the use of radial EUS in some studies, while linear
EUS is able to detect more pancreatic lesions in
HRIs.31 The two methods might be considered comple-
mentary rather than interchangeable in surveillance
programs,7 and their use should be tailored considering
local expertise.
The yield of surveillance programs in different HRI
subgroups is another interesting subject. The pooled
prevalence of lesions considered a successful target of
surveillance in the present meta-analysis was 3% in
FPC individuals, representing the majority of people
screened, 4% in HP, 5% in FAMMM, 6.3% in
HBOC, BRCA1/2, or PALB2 mutations carriers, and
12.2% in PJS. Notably, while the results obtained in
FPC showed a certain heterogeneity, this was not the
case in patients with genetic syndromes. It would be
attractive to tailor surveillance in terms of age at
which to start, modality, and follow-up intervals
based on the frequency and growth characteristics of
the lesions diagnosed in each HRI subgroup.
Vasen et al.15 recently reported that IPMNs with
high-grade dysplasia and multifocal PanINs3 were
more frequent in FPC compared to FAMMM patients,
while the rate of diagnosed PDAC was higher in this
latter group. Further studies into the differential risk
and growth characteristics of the various subgroups
of HRIs are needed.
This is the first study to systematically appraise the
available literature evidence from surveillance studies in
HRIs for developing PDAC. Although we developed a
priori hypotheses for sensitivity analyses considering
likely sources of heterogeneity, the observed heterogen-
eity between studies reflecting differences in surveillance
tests, intervals, type of reported lesions, and kind of
HRIs enrolled is a potential limitation. The lack of
individual patient data limited the possibility of per-
forming any analysis other than that of aggregate
data, and the influence of factors such as the age of
the individuals enrolled in the surveillance programs,
and the relevance of risk factors such as smoking,
could not be appropriately considered.
In conclusion, the pooled prevalence rate of resected
lesions that can be considered a successful target of
surveillance during PDAC surveillance programs in
HRIs is 3.3% with an annual risk of 0.5%. The
pooled prevalence rate of successful ‘‘premalignant’’
target lesions is, however, lower and equal to only
1.6%. A higher prevalence rate was observed in HRI
carriers with a specific DNA mutation compared to
HRIs with FPC in whom the mutation is unknown.
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Appendix 1
Search strategy
The following search strategy was employed:
(Neoplasm, Pancreatic OR Pancreatic Neoplasm
OR Neoplasms, Pancreas OR Pancreas Neoplasm OR
Neoplasms, Pancreatic OR Cancer of Pancreas OR
Pancreas Cancers OR Pancreas Cancer OR Cancer,
Pancreas OR Cancers, Pancreas OR Pancreatic
Cancer OR Cancer, Pancreatic OR Cancers,
Pancreatic OR Pancreatic Cancers OR Cancer of the
Pancreas) AND (Cancer Early Detection OR Cancer
Screening OR Screening, Cancer OR Cancer
Screening Tests OR Cancer Screening Test OR
Screening Test, Cancer OR Screening Tests, Cancer
OR Test, Cancer Screening OR Tests, Cancer
Screening OR Early Diagnosis of Cancer OR Cancer
Early Diagnosis) AND (High Risk OR High-Risk indi-
viduals OR High-Risk patients OR High-Risk cohort
OR High-Risk population OR FPC OR familial pan-
creatic cancer OR inherited pancreatic cancer OR
HBOC OR hereditary breast and ovarian cancer syn-
drome OR BRCA OR FAMMM OR familial atypical
multiple mole melanoma OR PJS OR Peutz-Jeghers
syndrome OR HNPCC OR hereditary nonpolyposis
colorectal cancer OR PALB OR mismatch repair
gene mutation OR Genetic Susceptibility OR Genetic
Susceptibilities OR Susceptibilities, Genetic OR
Susceptibility, Genetic OR Genetic Predisposition OR
Genetic Predispositions OR Predispositions, Genetic
OR Predisposition, Genetic).
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IntroductIon
Pancreatic ductal adenocarcinoma (PC) is one of the deadli-
est solid tumors. It is predicted to become the second cause of 
tumor-related death by 2030 [1]. Surgical resection is the only 
potential cure and it is possible in less than 20% of patients 
at the time of diagnosis [2]. PC is usually asymptomatic until 
the disease has spread outside the gland, causing jaundice or 
abdominal and back pain. However, similarly to other solid 
tumors, even PC has precursor lesions, namely pancreatic 
intraepithelial neoplasia (PanIN), and intraductal papillary 
mucinous neoplasms (IPMN) [3, 4].
Considering the wide window of opportunity to detect PC 
at its earlier stages [5] and the low incidence of this tumor 
(6.3–7.3 per 100,000 people in Europe) [6], it might seem 
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IntroductIon: Surveillance programs on high-risk individuals (HRIs) can detect pre-malignant lesions or early 
pancreatic cancer (PC). We report the results of the first screening round of the Italian multicenter 
program supported by the Italian Association for the study of the Pancreas (AISP).
Methods: The multicenter surveillance program included asymptomatic HRIs with familial (FPC) or genetic 
frailty (GS: BRCA1/2, p16/CDKN2A, STK11/LKB1or PRSS1, mutated genes) predisposition to PC. 
The surveillance program included at least an annual magnetic resonance cholangio pancreatography 
(MRCP). Endoscopic ultrasound (EUS) was proposed to patients who refused or could not be 
submitted to MRCP.
results: One-hundreds eighty-seven HRIs underwent a first-round screening examination with MRCP (174; 
93.1%) or EUS (13; 6.9%) from September 2015 to March 2018.The mean age was 51 years 
(range 21–80).One-hundreds sixty-five (88.2%) FPC and 22 (11.8%) GF HRIs were included. MRCP 
detected 28 (14.9%) presumed branch-duct intraductal papillary mucinous neoplasms (IPMN), 
1 invasive carcinoma/IPMN and one low-grade mixed-type IPMN, respectively. EUS detected 4 
PC (2.1%): 1 was resected, 1 was found locally advanced intraoperatively, and 2 were metastatic. 
Age > 50 (OR 3.3, 95%CI 1.4–8), smoking habit (OR 2.8, 95%CI 1.1–7.5), and having > 2 relatives 
with PC (OR 2.7, 95%CI 1.1–6.4) were independently associated with detection of pre-malignant 
and malignant lesions. The diagnostic yield for MRCP/EUS was 24% for cystic lesions. The overall 
rate of surgery was 2.6% with nil mortality.
dIscussIon: The rate of malignancies found in this cohort was high (2.6%). According to the International Cancer 
of the Pancreas Screening Consortium the screening goal achievement was high (1%).
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reasonable and advantageous to focus diagnostic efforts to 
identify precursor lesions or early PC on a selected population 
of high-risk individuals (HRIs). Population screening is not 
recommended.
In 2013, the International Cancer of the Pancreas Screening 
(CAPS) Consortium established that PC screening should be rec-
ommended only for HRIs with a lifetime risk of PC greater than 
5% or a fivefold increased relative risk, as this would eventually 
lead to a better prognosis [7].
Guidelines for screening define two groups of HRIs: (a) indi-
viduals with a defined genetic syndrome (GS) (e.g., Hereditary 
breast and ovarian cancer syndrome, familial atypical multiple 
mole melanoma (FAMMM) syndrome, Peutz-Jeghers Syndrome, 
PRSS1-related hereditary pancreatitis, and Lynch syndrome) 
or genetic mutations (PALB2 gene mutations); (b) individuals 
without a diagnosed syndrome but with familiar pancreatic can-
cer (FPC) [8]. According to the CAPS Consortium, the goal of 
a PC surveillance program should be the identification of early 
(pT1N0M0R0) PC, or advanced precursor lesions such as PanIN3 
or high-grade IPMN [7]. However, an internationally standard-
ized protocol for PC surveillance is not available yet, as the cur-
rent evidence is based on single- or multi-centric experiences with 
heterogeneous policies in terms of inclusion criteria, diagnostic 
methods, and frequency of screening being adopted [9, 10]. Three 
recent meta-analyses reported that the probability of reaching the 
screening goal is satisfactory [9–11], thus reinforcing the rationale 
in the pursuit of the early diagnosis of PC.
In 2010, the Italian Association for the Study of the Pancreas 
(AISP) developed a position paper for the surveillance at high-risk 
of PC, including both HRI with familial and genetic predisposition 
[12]. In 2015, an official registry of asymptomatic HRI was created 
following these guidelines. This manuscript reports the results of 
the first-round of screening.
MetHodS
Definition of individuals at high risk and surveillance protocol
In 2015, six Italian high-volume centers started the enrollment of 
HRIs according to the Italian Guidelines [12]. Criteria for entry 
into the registry as an HRI include being defined as FPC if hav-
ing: ≥ 3 relatives affected by PC until the third degree of kinship 
(TDR) or 2 relatives affected if at least one being a first-degree 
relative (FDR); having a known genetic mutation of BRCA1, 
BRCA2, or p16/CDKN2A genes with at least a FDR or a second 
degree relative (SDR) affected by PC; a previous diagnosis of 
PRSS1-related hereditary pancreatitis or Peutz-Jeghers Syndrome 
(PJS). Whenever possible, the diagnosis of pancreatic cancer 
in affected relatives had to be verified through medical records 
evaluation. Demographic, clinical, and anamnestic data were 
prospectively collected by each center involved. HRIs aged > 18 
could enter the surveillance registry after having signed a proper 
informed consent.
Each enrolled subject received an outpatient visit and was offered 
a baseline MRI with 1.5 T to 3.0 T Cholangio-Wirsung-MRI 
(MRCP). MRI with MRCP was chosen as a baseline diagnostic 
method because of no radiation risks, low complication rates, and 
high sensitivity [13–15]. In case of a normal MRCP the subjects 
were planned to receive annual MRI for 5 years. Identified lesions 
were classified as solid or cystic with or without connection to pan-
creatic ducts. Patients who refused or could not be investigated by 
means of MRCP were offered endoscopic ultrasound (EUS) as first 
screening tool. EUS was also proposed to patients with alterations 
at baseline MRI, according to the local practice at each center. Any 
indication for surgery was center-based after a multidisciplinary 
board meeting. Each center received the local ethics committee 
approval and enrolled subjects signed a proper informed consent. 
The registry is currently promoted through word of mouth, social 
networks, YouTube channels, the websites of the individual Insti-
tutions, as well as the website of the AISP (http://www.aisponline.
it). The potential HRIs contact the involved centers spontaneously 
or they are referred by the general practitioner or other medical 
doctors. A genetic testing is not part of the protocol, but can be 
advised at each Centre based on clinical judgment.
Recorded Variables
The surveillance registry data include age, gender, category of 
risk (FPC or defined GS), total number of relatives with PC and 
degree of kinship, age of the youngest relative with PC, smoking 
and alcohol history, personal medical and oncological history, 
presence of diabetes, and time of its diagnosis.
Statistical Analysis
The chi-squared test was performed to test for differences of 
categorical parameters between subgroups, and t-test for con-
tinuous variables. A multivariate logistic regression analysis was 
performed to identify any risk factor associated with MRCP/EUS 
detection of pre-malignant or malignant lesion.
reSultS
Population Characteristics
Between September 2015 and March 2018, 245 eligible subjects 
were offered to enter the registry and accepted, and through 
March 2018, 187 subjects (76.3%) completed the first round of 
screening and represent the study population described in the 
present manuscript. According to the risk categories, FPC and GS 
cases were 165 (88.2%) and 22 (11.8%), respectively. Table 1 shows 
the composition of the risk categories, as well as their demograph-
ics. The population of HRIs included 100 women and 87 men. 
Mean age was 52 ± 12. The mean number of affected relatives 
was 2 (range 1–5). Fifty-two (27.8%) HRIs had ≥ 2 FDR affected 
and the mean age of the youngest affected relative was 61 (range 
28–79). Twenty-five HRIs (13.3%) reported a personal history of 
previous neoplasms, mostly gynecological cancers. MRCP and 
EUS were used as initial screening methods in 174 (93.1%) and 13 
(6.9%) HRIs. Nine HRIs (4.8%) received EUS as supplementary 
investigation after MRCP. Of note, the reliability of reported fam-
ily history of pancreatic cancer was verified in 120 out of 187 HRIs 
(64.1%) through evaluation of charts or other original documents 
of affected family members.
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MRCP Findings and Risk Categories
Figure  1 depicts the flow-chart of screening results. Overall, 44 
(25.3%) HRIs had an abnormal finding at MRCP, with pancreatic 
cystic lesions being the most frequently diagnosed abnormality 
(n = 42). At MRCP the presumed radiological diagnosis of these 
cysts was mostly branch-duct IPMN (BD-IPMN) (n = 28, 64.2% 
of the cysts detected, 14 (51.9%) were multifocal. The mean diam-
eter was 9 mm (range 3–25). Two (1.3%) HRI received a diagnosis 
of a suspected solid pancreatic mass, which was not further con-
firmed at EUS. One subject received a diagnosis of mixed-type 
(M)-IPMN, that was found to be a BD-IPMN at EUS. One sub-
ject with PJS received a diagnosis of malignant main-duct (MD)-
IPMN, which was confirmed by EUS with fine-needle aspiration 
(FNA), and one FPC subject was diagnosed with a M-IPMN, fur-
ther confirmed by EUS. Surgery revealed an invasive carcinoma/
IPMN and a low-grade M-IPMN, respectively, in these two cases. 
No complications related to MRCP were reported. The diagnosis 
rate of MRCP for pre-malignant (IPMNs) or malignant lesions 
was 17.2 and 0.6%, respectively. BD-IPMNs and undefined cysts 
are currently enrolled in institution-specific follow-up programs 
for pancreatic cystic neoplasms. The diagnosis rate of MRCP for 
cystic lesion was 24.1%.
EUS Findings
The flow-chart of Fig.  1 reports EUS findings. Thirteen (6.9%) 
HRIs received EUS as first-line investigation. EUS detected 4 
PC (30.8%) (all confirmed by FNA), 1 (7.7%) undefined cyst, 
2 (15.4%) EUS features of chronic pancreatitis and one solid 
pseudopapillary tumor (7.7%). The examination was normal in 
5 cases (38.5%). Two tumors were deemed amenable to surgery, 
the remaining two being metastatic cases that were treated with 
chemotherapy. In 9 further cases EUS was performed as supple-
mentary diagnostic tool after MRCP, due to suspicious findings. 
In such cases, EUS confirmed 6 MRCP findings and deemed 
insignificant 2 suspected solid lesions and 1 suspected M-IPMN 
found at MRCP, that revealed to be fibrotic areas and a BD-IPMN, 
respectively. No complications related to EUS were reported. The 
2 undefined cysts are currently enrolled in Institution-specific 
follow-up programs for cystic pancreatic neoplasms.
Risk Categories and MRCP/EUS Findings
Table 2 reports the MRCP/EUS findings of the cohort, comparing 
the results obtained in the groups of FPC and GS cases. When 
comparing the FPC and GS HRIs, there was no difference either 
in the rate of abnormalities and malignancies detected (27.9 vs 
27.3% and 2.2 vs 4.5%, Fisher’s exact p = 1 and p = 0.469, respec-
tively). No malignant lesions were diagnosed in the BRCA1/2 
HRIs subgroup.
Surgery and Pathology
After multidisciplinary consultation, surgery was offered to 5 sub-
jects (2.6%). Two total pancreatectomies and 2 distal pancreatec-
tomies with splenectomy were performed. One further PC case 
deemed resectable was found locally advanced intraoperatively 
and a bypass surgery was performed. Pathology revealed an inva-
sive carcinoma/IPMN, 1 PC (T1N0M0R0), a pseudopapillary 
tumor and a low-grade panglandular M-IPMN. No postoperative 
complications were reported. Considering the CAPS guidelines 
[7], the diagnostic yield of the present study for success of surveil-
lance with diagnosis of target lesions was 1%. The 90-day postop-
erative mortality was nil.
Risk Factors Associated with Diagnosis of Pre-malignant or 
Malignant Lesion
A binary logistic regression analysis was performed with the 
diagnosis of pre-malignant or malignant lesion as dependent 
variable (yes/no), to ascertain the effects of age ( ≤ > 50 years), 
gender, alcohol and smoking habit, number of relatives affected 
Table 1 Detail and demographics of HRIs enrolled
Characteristics of asymptomatic HRI who were 
enrolled in the registry
n
FPc 165 (88.2)
hBoc (BRCA1) 5 (2.7)
hBoc (BRCA2) 5 (2.7)
FAMMM (p16/CDKN2A) 3 (2.7)
Peutz-Jegher syndrome (STK11/LKB1) 5 (1.6)
hereditary pancreatitis (PRSS1) 4 (2.1)
Variable All patients 
(n = 187)
FPC 
(n = 165)
GS 
(n = 22)
p Value
Age, mean (sd) 51 ± 12 51 ± 12 47 ± 11 n.s.
Female, gender 100 (53.4) 67 (54.5) 33 (51.5) n.s.
ever smokers/
current smokersa
28 (15) 24 (14.5) 4 (18.1) n.s.
Any regular 
alcohol intake
16 (8.5) 12 (7.2) 4 (18.1) n.s.
AYr with Pc, 
median (IQr)
61 ± 10 60 ± 11 66 ± 8 n.s.
Personal history 
of malignancies, 
n (%)
25 (13.3) 19 (11.5) 6 (24) n.s.
hrI with 1 Fdr 
affected
120 (64.2) 110 (66.7) 11 (50) n.s. < 0.05
hrI with ≥ 2 Fdr 
affected
53 (28.3) 53 (32.1) — n.s
hrI with family 
history of malig-
nancies
118 (63.1) 101 (61.1) 17 (77.3)
number of 
relatives affected, 
median
1 1 1
data are expressed as number (%) or as mean ( ± sd)
HRI high-risk individual, FPC familial pancreatic cancer, HBOC hereditary 
breast–ovarian cancer syndrome, FAMMM familial atypical multiple mole mela-
noma, GS genetic syndrome, AYR age of the youngest relative, FDR first-degree 
relative
aever smoker is a person who has smoked 100 cigarettes or more in his/her 
lifetime.
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( ≤ / > 2), number of FDR affected ( ≤ / > 1), previous history of 
any malignancy (yes/no), medical certification of relatives suffer-
ing from PC (yes/no), and familial or genetic predisposition. At 
the multivariate analysis, age > 50 years (OR 3.3, 95%CI 1.4–8), 
smoking habit (OR 2.8, 95%CI 1.1–7.5), and having > 2 relatives 
with PC (OR 2.7, 95%CI 1.1–6.4) were independent factors asso-
ciated with the diagnosis of pre-malignant and malignant lesions 
at MRCP/EUS (Table 3). Table 4 depicts the detailed individual 
features of HRIs who received a diagnosis of malignancy.
Follow-up
At the time this manuscript was written 2 out of 5 patients that 
received a malignant diagnosis were alive (mean follow-up 6.2 
months, range 2–12). The two patients submitted to surgery 
were alive and free of recurrence after a median follow-up of 6.5 
months. Of the remaining three patients who were diagnosed 
with an advanced disease, two died after a median follow-up of 
7 months from the diagnosis; one patient died due to cardiovas-
cular disease.
dIScuSSIon
This is the first report of the Italian multicenter study on HRIs 
submitted to surveillance. After the first round of screening 28.3% 
(n = 53) of subjects were diagnosed with a MRCP/EUS abnor-
mality. Five malignant lesions were detected (2.6%); an unex-
pectedly high number of PC were identified by EUS (n = 4, 2.1% 
overall), whereas MRCP identified only 1 invasive carcinoma/
IPMN (0.6%). Of note, the category of HRIs that reported the 
245 HRI
enrolled
174 MRCP *9 Supplementary EUS
46 HRI
scheduled to
receive MRCP
or EUS
187 HRI
submitted to
MRCP or EUS
44 Abnormalities
8 Abnormalities
130 Normal
findings
5 Normal
findings
†2 Normal
findings
‡4 Confirmed
BD-IPMNs
¤2 Confirmed with
FNA (1 iCa-IPMN,
1 mixed-type), 1
deemed BD-IPMN
2 Solid
lesions*†
42 Pancreatic
cysts*‡
3 Suspected IPMNs*¤
27 BD-IPMNs
5 Features of CP
7 Undefined cysts
3 PC
1 SPT
2 Features of CP
1 Undefined cyst
13 EUS
Fig. 1 Flow-chart of study results. hrI high-risk individuals, MrcP magnetic-cholangio pancreatography, eus endoultrasonography, IPMn intraductal 
papillary mucinous neoplasm, Bd-IPMn branch-duct intraductal papillary mucinous neoplasm, cP chronic pancreatitis, Pc pancreatic cancer, sPt solid 
pseudopapillary tumor, FnA fine-needle aspiration, icA-IPMn invasive intraductal papillary mucinous carcinoma. * = supplementary eus
Table 2 MRCP/EUS findings per categories (p = n.s.)
Category of risk
Screening results FPC (n = 165) GS (n = 22)
Abnormalities 46 (27.9) 6 (27.3)
 Pc 4 (2.2) 1 (4.5)
  Bd-IPMn 26 (15.7) 1 (4.5)
 undefined cystic lesions 7 (4.2) 1 (4.5)
 suspected solid lesions 2 (1.2) —
 Features of cP 5 (30.3) 2 (18.1)
 M-IPMn 1 (0.6) —
 degenerated IPMn — 1 (4.5)
data are expressed as number
FPC familial pancreatic cancer, GS genetic syndrome, PC Pancreatic ductal ad-
enocarcinoma, BD-IPMN branch-duct intraductal papillary mucinous neoplasm, 
CP chronic pancreatitis, M-IPMN mixed-type intraductal papillary mucinous 
neoplasm
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greatest number of MRCP/EUS abnormalities was the one made 
of FPC subjects, however, the small sample size of the non-FPC 
subcohort does not allow us to make further speculations regard-
ing this difference.
The diagnostic yield for MRCP/EUS was 24% for cystic lesions. 
The great majority of the detected cysts were BD-IPMN (n = 28, 
62.2% of the cysts detected, 14.9% of the whole cohort). This find-
ing is not surprising, as these lesions are frequent incidental find-
ings in the general population, given the wide use of cross-sectional 
imaging, and it is debatable whether they should be considered a 
positive result of the screening process or not. This prevalence is 
in line with data already reported in a metanalysis by Signoretti et 
al. in 2018, where the pooled prevalence of cystic lesions in HRI 
enrolled in surveillance program was around 20% [9].
The rate of malignancies detected (2.6%) in our cohort is one 
of the highest reported so far [9–11, 16]. Notably, all but one 
malignancy was detected by EUS. As only 4.8% of probands was 
submitted to both MRCP and EUS, it is not possible to speculate 
about any possible difference in the detection rate of solid or cystic 
abnormalities with the two techniques. Current literature suggest 
that the two techniques are complementary with MRCP being 
able to detect more easily any cystic lesion, whereas EUS is likely 
more sensitive in the detection of solid ones [9, 17]. Two out of 
the five (40%) cancers diagnosed in the screening asymptomatic 
subjects were at a metastatic stage, and one was locally advanced. 
This rate is higher than in previous reports [9, 10], however this 
finding is consistent with a calculated pooled prevalence of 1% [9], 
and it cannot be considered a failure of a surveillance policy as 
the present results regard first-screening round only. On the other 
hand, in the two PC cases who received radical surgery, pathology 
revealed pT1 disease, thus potentially suggesting that surveillance 
led to early diagnosis with improved survival. Globally, there were 
no unnecessary surgical procedures being performed for benign 
lesions in this series, as the other resections were due to a M-IPMN 
and a solid pseudopapillary tumor, for whom surgery is the treat-
ment of choice.
Personalization of the surveillance strategy is a key issue in 
screening protocols for pancreatic cancer. We therefore investigated 
factors that were associated with an increased risk of diagnosis of 
pancreatic abnormalities. HRIs aged > 50 years, ever smokers, and 
subjects with > 2 relatives with PC had a significantly increased risk 
of having a diagnosed pre-malignant or malignant lesion. Previous 
studies partially explored the association between such factors and 
the detection of a worrisome abnormality [18–20]. However, those 
studies were retrospective and more prone to bias or lack of infor-
mation, and these three factors were not reported as independently 
associated with risk of significant abnormalities at a multivariate 
analysis before. Despite the design of this registry regarding each 
center discretion on the use of MRCP or EUS as a screening tool 
based also on patients’ preference, it likely that in such a subgroup 
of HRIs the combined use of both MRCP and EUS, or their alter-
nate use, possibly at shorter intervals, might be appropriate.
Some limitations, however, should be considered. First, although 
MRI with MRCP was the first-line examination in most cases, 
some subjects were investigated by EUS first, due to personal pref-
erences. However, the results obtained by the two diagnostic tools 
are pooled in the present analysis to reflect the actual rate of sig-
nificant findings in the whole cohort. Secondly, a quote of the diag-
nosed small pancreatic lesions considered BD-IPMN at MRCP 
might be other cystic lesions, despite experienced radiologists 
have been involved. The present protocol, indeed, did not include 
the need to perform EUS in all cases of cystic lesions, but this was 
done in some instances, similarly to what is considered common 
practice in sporadic cystic lesions. Finally, in our logistic regres-
sion analysis we considered as outcome variable the diagnosis of 
any malignant or pre-malignant pancreatic lesion, including BD-
IPMN and not malignant lesions only. This was done due to the 
relatively low rate of malignant lesions which would not permit a 
meaningful analysis. Third, compared to current literature [9, 10], 
our registry differed on the age to initiate the surveillance and this 
might have been responsible for differences in the detection rate 
of pre-malignant or malignant lesions. However, the mean age of 
our cohort is in line with the one other studies [9, 10], giving more 
strength to the finding that HRI > 50 years are at higher risk to be 
diagnosed with a worrisome lesion.
Another limitation of this study regards the lack of a standard-
ized genetic screening for pathogenic mutations associated with 
PC risk in individuals with FPC. Indeed, a significant group of sub-
jects with FPC have been found to carry CDKN2A mutations, both 
in Italy [21] and in the Netherlands [22]. In addition, Vasen et al. 
Table 3 Binary logistic regression analysis for risk factors 
associated with the diagnosis of a pre-malignant or malignant 
lesion at MRCP/EUS
Variable Univariate 
Analysis 
(OR; 95% 
CI)
p Value Multi-
variate 
Analysis 
(OR; 95% 
CI)
p Value
Male sex (1; 
0.4–1.1)
0.946
Age > 50 years (4.1; 
1.7–9.6)
0.001* or 3.3, 
1.4–8
0.008*
ever smoking (4.6; 
1.9–11.1)
0.001* or 2.8, 
1.1–7.5
0.032*
Alcohol drinker (1; 
0.2–3.8)
0.951
number of relatives 
affected > 2
(3.6; 
1.6–8.1)
0.001* or 2.7, 
1.1–6.4
0.026*
number of Fdr af-
fected > 1
(1; 
0.4–2.3)
0.967
Previous history of any 
malignancy
(1; 
0.8–1.2)
0.287
diagnosis of a defined 
Gs
(0.4; 
0.1–1.8)
0.253
Verified certification 
of affected family 
members
(1; 
0.4–2.3)
0.954
FDR first-degree relative, GS genetic syndrome
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found a higher diagnostic yield in GS subjects than in FPC ones 
[23]. Since we have not performed a genetic testing in all HRIs, we 
cannot exclude that some of this subjects may have been carriers of 
genetic mutations and that they have been deemed as belonging to 
the FPC group, due to familial aggregation only. This might have 
been generated an intrinsic bias on our results, when comparing 
the two groups. Recently, the possibility to investigate pancreatic 
cancer susceptibility genes with genetic testing at the time of diag-
nosis of all PC has been proposed [24]. Future studies, especially in 
the setting of HRIs, should therefore include genetic testing.
Some of the limitations reported might have been addressed 
by building a proper surveillance program, based on MRCP and 
EUS imaging, genetic testing, and shared among the Institutions 
involved. The form of the registry, with a high level of center dis-
cretion in the diagnostic pathway to follow, had been chosen since 
no dedicated funds were available and each center draws from per-
sonal resources and facilities.
In conclusion, the first-round screening results in Italy report a 
high rate of pancreatic malignancies (n = 5, 2.6%), mostly being 
advanced at baseline (60%). We identified factors associated with 
an increased risk of diagnosis of malignant or pre-malignant 
pancreatic lesions in HRIs (age > 50, smoking habit and > 2 rela-
tives diagnosed with PC). Whether these data will also reflect an 
increased risk of developing de novo lesions or of progression of 
initial finding needs to be investigated during the following screen-
ing rounds that are planned for a duration of at least five years, 
with a planned end of enrollment in 2020.
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Study Highlights
WHAT IS CURRENT kNOWLEDGE?
✓Pancreatic cancer surveillance programs may detect malig-
nant and pre-malignant lesions in high-risk individuals.
✓two groups of HrIs can be identified, one with a familial 
predisposition and one with a known genetic frailty.
WHAT IS NEW HERE?
✓After the first-round of screening of the Italian registry the 
rate of malignancies was 2.6%.
✓Some risk factors for the detection of pre-malignant or 
malignant lesions were found.
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Background & aims: Pancreatic cystic lesions (PCLs) are frequent incidental findings. As most PCLs
require costly diagnostic evaluation and active surveillance, it is important to clarify their prevalence in
asymptomatic individuals. We therefore aimed at performing a systematic review and meta-analysis to
determine it.
Methods: a systematic search was conducted and studies meeting inclusion criteria were included. The
prevalence of PCLs was pooled across studies. A random effect model was used with assessment of
heterogeneity.
Results: 17 studies, with 48,860 patients, were included. Only 3 were prospective; 5 studies were con-
ducted in the US, 7 in Europe, 4 in Asia and 1 in Brazil. The pooled prevalence of PCLs was 8% (95% CI 4
e14) with considerable heterogeneity (I2¼ 99.5%). This prevalence was higher in studies of higher
quality, examining older subjects, smaller cohorts, and employing MRCP (24.8% vs 2.7% with CT-scan).
The pooled rate of PCLs was four times higher in studies conducted in the US than in Asia (12.6% vs
3.1%). 7 studies reported the prevalence of mucinous lesions, with a pooled rate of 4.3% (95% CI 2e10;
I2¼ 99.2%), but of 0.7% only for worrisome features or high risk stigmata.
Conclusion: The rate of incidentally detected PCLs is of 8%. Mucinous lesions are the most common
incidentally detected PCLs, although they rarely present with potential indication for surgery. The
observed different rates in the US and other geographic Areas suggest that different protocols might be
necessary to help balancing costs and effectiveness of follow-up investigations in asymptomatic subjects.
© 2018 Published by Elsevier B.V. on behalf of IAP and EPC.Introduction
Pancreatic cystic lesions (PCLs) are frequent incidental findings
diagnosed during abdominal ultrasonography or cross-sectional
imaging. The increasingly widespread use and the improved
detection accuracy of imaging tests have led to an epidemic of PCLs
with prevalence rates reported as high as 40%, in a clinical scenario
that might be considered that of a “technology-related disease” [1].
PCLs comprise different entities, each of them with peculiar
biological behavior ranging from benign to premalignant or franklyy and EUS Division, Pancreas
ele Scientific Institute IRCCS,
na n. 60, 20132, Italy.
o).
lf of IAP and EPC.
stematic review and meta-an
ttps://doi.org/10.1016/j.pan.20malignant neoplasms [2]. Mucinous pancreatic cystic lesions are
associated with a potential risk to develop malignancy and deserve
either an active treatment or surveillance [3], while serous cysts are
benign lesions [4]. Intraductal Papillary Mucinous Neoplasms
(IPMNs) represent the most common PCL. According with current
guidelines [5e8] they should be treated surgically in the presence
of major symptoms, morphological changes often defined as high
risk stigmata (HRS), or when malignancy is demonstrated by
cytology. In the presence of an IPMN of the branch ducts (BD-IPMN)
with size exceeding 30mm or thickened and enhanced cystic wall
or non-enhancing mural nodule or moderate main duct dilatation
(5e9mm) or in presence of abrupt change in pancreatic duct
caliber with distal gland atrophy (characteristics usually named
worrisome features eWFe), surgery might be considered and
endoscopic ultrasound (EUS) with or without aspiration/biopsy isalysis: Prevalence of incidentally detected pancreatic cystic lesions in
18.11.014
G. Zerboni et al. / Pancreatology xxx (xxxx) xxx2indicated to better analyze the morphology/cytology of the PCL, in
order to stratify the risk of malignancy.
However, the vast majority of IPMNs are BD-IPMNs without any
of the above mentioned signs and in patients who would be fit for
surgery, these lesions require follow-up by means of Magnetic
Resonance Imaging (MRI) with contrast medium and cholangio-
pancreatography (MRCP) or with EUS with specific time intervals.
In a recent meta-analysis [9] the risk of malignant trans-
formation of these lesions has been calculated to be equal to 7/1000
per year, and despite the need to maintain surveillance in the long-
term is debated [10], recent data suggest that it cannot be stopped
after 5 years [11e13].
The surveillance of PCLs, and particularly of IPMNs, has become
a challenge for health\insurance systems considering their sub-
stantial costs and resource burden. Moreover, the sustainability of a
surveillance policy depends on the actual prevalence of PCLs in the
general population. It is, therefore, important to clarify as accu-
rately as possible the prevalence of PCLs, and particularly of
mucinous cystic lesions, in subjects without a history of pancreatic
disease. However, these data are sparse, heterogeneous, with a
wide range of prevalence rates, but no systematic and compre-
hensive analyses examined this issue. The present systematic re-
view and meta-analysis aimed at evaluating the prevalence of
incidentally diagnosed PCLs, particularly mucinous lesions.
Materials and methods
Search strategy
A computerized literature search of the MEDLINE database did
not identify any publication related to systematic review on the
prevalence of incidentally diagnosed pancreatic cystic lesions in
healthy subjects or in asymptomatic population. A MEDLINE search
was therefore run until January 2018. Specific search terms were:
(pancreatic cyst OR pancreatic cysts OR pancreatic cystic lesions OR
intraductal papillary mucinous neoplasia OR pseudocyst OR pancre-
atic mucinous cyst) AND (radiological technique OR magnetic reso-
nance OR multi-detector OR radiological imaging OR EUS OR
ecoendoscopic ultrasound OR tomography OR MRI OR chol-
angiopancreatography OR abdominal imaging OR US OR MDCT OR CT)
AND (occasional OR incidental OR incidence OR prevalence OR acci-
dentally OR asymptomatic). The methodology was developed from
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [14].
The titles of all identified articles were screened to ascertain
their relevance. Abstracts and/or full texts of selected potentially
relevant papers were evaluated. Possible further articles were
identified by hand-searching reference lists in order to identify
potentially relevant studies, missed at our search. In the case of
duplicate publications, the most recent or the most informative one
in terms of number of cases or available data, was included.
Inclusion/exclusion criteria
Studies were considered if they met the following criteria: 1)
written in English; 2) inclusion of patients without history of
pancreatic disorders or symptoms suggestive for them; 3) all pa-
tients underwent second or third level imaging (CT-scan,
MRI±MRCP or EUS) not to investigate primarily the pancreatic
gland; 4) data about prevalence and characteristics of cystic lesions
were reported.
Studies were excluded if they were available as abstract only
because the abstracts did not allow full data extraction. We also
excluded: 1) case reports or small case series of <20 cases; 2) pa-
pers investigating the prevalence of pancreatic cystic lesions inPlease cite this article as: Zerboni G et al., Systematic review and meta-an
asymptomatic individuals, Pancreatology, https://doi.org/10.1016/j.pan.20specific subset of patient, such as liver/pancreas transplanted pa-
tients or cluster of patients with specific type of neoplastic disease.
Two independent reviewers (G.Z. and M.S.) carried out study
identification and selection and resolved their disagreements by
discussion or by consulting a third reviewer (G.C.). Excluded studies
and the reasons for exclusion were recorded.
Data extraction and quality assessment
Two reviewers (G.Z. and M.S.) independently extracted the data
from each study and resolved their disagreements by discussion or
by consulting a third reviewer (G.C.).
From the studies that met the eligibility criteria, the following
data were collected: 1) study: publication year, study design, study
location; 2) patients: total number of asymptomatic patients eval-
uated, age, sex, risk factors for pancreatic disease; 3) imaging: type
of imaging procedure, imaging review, indication for imaging; 4)
cases: total number of patients incidentally diagnosed with PCLs,
prevalence according with age; 3) cyst features: single cyst, mean/
median cyst size, maximum cyst size, connection to the main duct,
location, calcification, MD dilatation, worrisome features and/or
high risk stigmata; 4) Cyst diagnosis: IPMN, pseudocysts, MCN,
SCN; 5) extra-pancreatic cysts.
We then developed a summary table of the relevant studies
listing the population characteristics and outcomes.
The quality of the studies was evaluated independently by two
reviewers (GZ and MS) using the Newcastle-Ottawa Scale with a
dedicated quality appraisal tool including 7 items. Studies with a
score 7 were considered of high quality [15].
Statistical analysis
A meta-analysis of all eligible studies identified was planned
using the software package Comprehensive Meta-Analysis (Biostat,
Englewood, NJ, USA) using a random-effects model [16]. In addition
to within-study variance, the random-effects model considers
heterogeneity among studies. The corresponding 95% confidence
intervals (CI) were calculated using exact methods and assuming a
Poisson distribution. We present the random-effect model because
we believe that the relevant variation in the risk is most likely a
consequence of inter-study differences. The quantity of heteroge-
neity was assessed by means of the I2 value [17]. The I2 quantity
describes the percentage of total variation across studies that is
caused by heterogeneity and not by chance. We considered an I2
value of 25% or lower as trivial heterogeneity, and an I2 value of 75%
or higher as considerable heterogeneity. Publication bias was
assessed using the Begg and Mazumdar test. A p-value <0.05 was
accepted as statistically significant. Before performing the analysis,
we developed the following a priori hypotheses to examine
whether these had any effect on the prevalence of PCLs in asymp-
tomatic individuals and to explore reasons for any heterogeneity
observed: (a) type of imaging employed to investigate the pancreas
(MRCP vs MDTC or MRI); (b) sample size (<1000 or 1000 in-
dividuals); (c) mean age (55 or <55 years) of the analysed pop-
ulation; (d) area of origin (i.e. United States, European or Asian
countries); (e) quality of the studies (quality score <7 or 7/10).
Results
Search result and study selection
The study selection process is summarized in Fig. 1. A total of
1070 references were identified by the MEDLINE search. After a
primary screening of the titles, 1009 studies were excluded because
they did not fit the area of interest.alysis: Prevalence of incidentally detected pancreatic cystic lesions in
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Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of assessment of studies identified in the systematic review.
G. Zerboni et al. / Pancreatology xxx (xxxx) xxx 3The remaining 61 records were screened in more detail and 24
were considered potentially appropriate for the analysis.
Of these, 7 studies were discarded with reason: 3 studies
[18e20] also enrolled patients with an history or suspect of
pancreatic disorders, 2 studies [21,22] did not provide sufficient
data to calculate the prevalence rate because the denominator was
not expressed, 1 study [23] did not describe the characteristics of
the diagnosed cystic lesions and 1 study [24] analysed a specific
patients’ cluster (renal tumors).
Finally, 17 studies fulfilled all inclusion criteria, and were
considered both for qualitative analysis and quantitative synthesis.
Study characteristics and quality assessment
The 17 included studies were published between 2008 and 2018
[1,25e40]. Five were conducted in the USA, 7 in Europe (4 in Italy
and one respectively in The Netherlands, Germany and Turkey), 4 in
Asian countries (two studies both in Korea and in Japan) and one in
South America (Brazil). All papers were in English language.
Three studies [30,36,39] investigated the prevalence of inci-
dental PCLs in a specific subgroup of patients compared with
controls and we included in our analysis only data concerning the
latter.
Overall, 48,860 asymptomatic patients without history or clin-
ical suspect of pancreatic disorders were included.
The descriptive characteristics of the seventeen included studies
are summarized in Table 1.
All studies were mono-institutional and the study design was
cross-sectional for all of them, being retrospective in 14 andPlease cite this article as: Zerboni G et al., Systematic review and meta-an
asymptomatic individuals, Pancreatology, https://doi.org/10.1016/j.pan.20prospective in 3 [25,34,35], respectively. The number of enrolled
patients ranged from 110 [36] to 21,745 [37], and the percentage of
males ranged from 26% [31] to 65% [28].
The mean age of the enrolled subjects ranged from 47 [31] to 68
years [39], while these data were not available in two studies
[32,33]. The performed diagnostic procedures varied considerably
among the studies. However, all but one study [39] inwhich the 192
enrolled patients underwent different investigations (either CT
scan or MRI±MRCP), employed a single diagnostic tool.
Abdominal MRI with or without intravenous contrast was the
most commonly employed diagnostic procedure (11 studies). MRCP
was also performed in 6 of them [1,29,30,38e40] with a huge
variability: in two studies [1,39] it was employed in a minority of
patients (respectively 19% and 15%) and in another one [29] all
patients underwent MRCP and only a little part of them (20%) was
investigated also with MRI with intravenous contrast.
Five studies considered exclusively MDCT scans± contrast me-
dium [25,26,32,33,37] and only one study [34] employed EUS.
Few studies reported patients’ exposition to well known risk
factors for developing pancreatic disorders (such as cigarettes
smoking, alcohol consumption, increased BMI and diabetes melli-
tus) [1,34,38,40] and first degree family history for pancreatic dis-
eases [1,28,38].
While a “pancreatic indication” for the diagnostic procedure
was an exclusion criterion for study inclusion, the study employing
EUS [34] included 6% of cases with a previous acute pancreatitis
episode. As it was clarified that the episode occurred at least 3
months before the study enrolment, with pain resolution 8 weeks
before the EUS and no evidence of acute fluid collection oralysis: Prevalence of incidentally detected pancreatic cystic lesions in
18.11.014
Table 1
General features of the 17 studies included in the quantitative analysis.
Author
(year)
Country Study
Setting
Study design Patients Male
(%)
Mean
Age
Diagnostic
procedure(s)
Imaging
revision
Indication Patients
with PCLs
(%)
Age of
patients
with PCLs
Patients with
Mucinous
lesions (%)
Kromery
(2018)
[40]
Germany Single
center
Retrospective 1077 521
(48.4)
55.8 WB-MRI
(1.5T) þMRCP
Yes Healthy population 494 (45.9) 60.5
(SD ± 11.6)
NR
Zerboni
(2017)
[39]
Italy Single
center
Retrospective 192 118
(61)
68 MDCT þ c.e.; or MRI
1.5T ± c.e.; or MRCP
Yes Not pancreas related 19 (10) 73 (95% CI
68.1e78.7)
14 (74)
Mizuno
(2017)
[38]
Japan Single
center
Retrospective 5296 3189
(60.2)
55.7 MRI þ MRCP 3T,
(thickness 3e5 mm)
Yes No medical indication 724 (13.7) 62.6
(SD ± 10.7)
393 (54)
Chang
(2016)
[37]
South
Korea
Single
center
Retrospective 21,745 13,046
(60)
51.8 MDCT þ c.e.
(thickness 3 mm)
Yes Not pancreas related 457 (2.1) 58 (SD ± 10) 383 (84)
Kim J.A.
(2016)
[36]
USA Single
center
Retrospective 110 49
(44.5)
47.5 MRI 1.5T (thickness
6e10mm)
Yes Not pancreas related 25 (22.7) NR NR
Ulus
(2016)
[35]
Turkey Single
center
Prospective 118 71 (60) 47.4 WB-MRI 1.5T No Healthy population 1 (0.8) NR 1 (100)
Moris
(2016)
[1]
USA Single
center
Retrospective 500 252
(50)
60 MRI± c.e. (1.5 or
3 T); MRCP 19%
Yes Not pancreas related 208 (41.6) 63.8
(SD ± 11.2)
72 (35)
Sey (2015)
[34]
USA Single
center
Prospective 341 154
(45)
59 EUS± FNA No Not pancreas related 32 (9.4) NR NR
Ippolito
(2015)
[33]
Italy Single
center
Retrospective 6389 NR NR MDCT þ c.e.
(thickness 2e5 mm)
Yes Not pancreas related 192 (3) 63 (SD ± 11) NR
Zanini
(2015)
[32]
San
Marino
(Italy)
Single
center
Retrospective 650 355
(55)
NR 16-MDCT± c.e.
(thickness 2.5mm)
Yes Not pancreas related 35 (5.4) 77 (53e93) NR
de Oliveira
(2015)
[31]
Brazil Single
center
Retrospective 2583 672
(26)
47 MRI (3T) þ c.e. No Not pancreas related 239 (9.3) 61
(SD ± 12.4)
NR
Matsubara
(2012)
[30]
Japan Single
center
Retrospective 1226 686
(56)
62 MRI (1.5 T, thickness
5mm) and MRCP
Yes Not pancreas related 123 (10) 69 (38e88) NR
Girometti
(2011)
[29]
Italy Single
center
Retrospective 152 87 (57) 57 MRCP (1.5 T);
MRI þ c.e. (20%)
Yes Not pancreas related 68 (44.7) NR 48 (71)
de Jong
(2010)
[28]
Holland Single
center
Retrospective 2803 1822
(65)
51 MRI þ c.e. (1.5 T) Yes Without medical
indication
66 (2.4) 60
(SD ± 10.9)
NR
Lee (2010)
[27]
USA Single
center
Retrospective 616 259
(42)
54 MRI (1.5 T, thickness
4mm)
Yes Not pancreas related 83 (13.5) 69 (SD ± 13) NR
Laffan
(2008)
[26]
USA Single
center
Retrospective 2832 1445
(51)
58.2 16-MDCT þ c.e. Yes Not pancreas related 73 (2.6) NR NR
Kim Y.S.
(2008)
[25]
South
Korea
Single
center
Prospective 2230 1338
(60)
57.5 16-MDCT þ c.e. Yes Asymptomatic patients,
CRC screening with CTC
4 (0.2) NR 4 (100)
PCL¼ pancreatic cystic lesion; NR¼ not reported; MDCT¼multidetector computed tomography, MRI¼magnetic resonance imaging, T¼ tesla; MRCP¼magnetic resonance
cholangio-pancreatography, WB-MRI¼whole body magnetic resonance imaging, EUS¼ endoscopic ultrasound, FNA¼ fine needle aspiration; CTC¼ computed tomography
colonoscopy; CRC¼ colorectal cancer; c.e.¼ contrast-enhanced.
G. Zerboni et al. / Pancreatology xxx (xxxx) xxx4pseudocyst at the previous abdominal imaging, this study was not
excluded.
As far as regards the quality of the included studies, the
Newcastle-Ottawa score ranges from 4/10 to 9/10. Only six studies
were scored as “high quality” (>7/10) [1,28,31,34,38,40].
Pooled prevalence rate of pancreatic cystic lesions
The prevalence of incidentally diagnosed pancreatic cystic le-
sions ranges from 0.2% to 45.9%, with a pooled prevalence of 8%
(95% CI 4e14), as detailed in Fig. 2. No publication bias was found
(Begg and Mazudmar Kendall's tau¼0.07, p¼ 0.64). There was
however a considerable heterogeneity between the studies
(I2¼ 99.5%).
In order to explore possible reasons for this substantialPlease cite this article as: Zerboni G et al., Systematic review and meta-an
asymptomatic individuals, Pancreatology, https://doi.org/10.1016/j.pan.20heterogeneity, we repeated the analysis based on our a priori hy-
pothesis considering different covariates (see Fig. 3). Studies with
mean age of the enrolled subjects 55 years old
[1,25,26,29,30,34,38e40] had a pooled prevalence of 11.3%, while
thosewithmean age<55 years [27,28,31,35e37] of only 5.7%. In both
cases, however, the heterogeneity was very high (I2 >99% for both).
When we analysed the results taking into consideration the
performed diagnostic procedure, the pooled prevalence of PCLs
resulted 2.7% (95% CI 2e4) in the studies employing MDCT± c.e.
[25,26,32,33,37,39], without a reduction of heterogeneity
(I2¼ 93.7%). In the four studies using MRCP [29,30,38,40] the
prevalence of PCLs was instead as high as 24.8% (95% CI 10e48),
with similar heterogeneity (I2¼ 99.5%). When the sample size of
the studies (<1000 or 1000) was considered, a higher pooled
prevalence was seen in studies with <1000 enrolled subjectsalysis: Prevalence of incidentally detected pancreatic cystic lesions in
18.11.014
Fig. 2. Pooled prevalence of all pancreatic cystic lesions (PCLs) in the 17 examined studies. The pooled prevalence resulted of 8% (95% CI 4%e14%), with considerable heterogeneity
(I2¼ 99.5%).
Fig. 3. Prevalence of PCLs according to variables considered a priori for sensitivity analysis: A) age (studies with mean/median population age 55 years compared with those with
mean/median age <55 years); B) different diagnostic procedures [studies using CT scan±medium contrast vs Magnetic Resonance Cholangio-Pancreatography (MRCP) with or
without MRI]; C) sample size (<1000 vs 1000 cases); D) geographic area in which the studies were conducted (Asia, Americas and Europe); E) quality of the study (high vs low
quality).
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G. Zerboni et al. / Pancreatology xxx (xxxx) xxx6[1,27,29,32,34e36,39] (13.9%, 95% CI 7e25; I2¼ 97.4%) compared to
those enrolling 1000 people [25,26,28,30,31,33,37,38,40] (4.7%,
95% CI 2e11; I2¼ 99.7%).
When considering the country of origin, the pooled prevalence
of PCLs resulted 3.1% (95% CI 1e10; I2¼ 99.7%) in studies conducted
in Asia [25,30,37,38], 12.6% (95% CI 5e27; I2¼ 99%) for those carried
out in the Americas (either US or South America) [1,26,27,31,34,36],
and 8.6% (95% CI 2e27; I2¼ 99.6%) for those conducted in Europe
[28,29,32,33,35,39,40].
As far as regards the quality of the studies, the six studies of
“high quality” [1,28,31,34,38,40] score had a higher pooled preva-
lence of PCLs of 14.6% (95% CI 6e30), with I2¼ 99.5%, when
compared to the 11 studies with a “lower quality” score
[25e27,29,30,32,33,35e37,39], which showed a pooled estimate
rate was of 5.8% (95% CI 3e12), with I2¼ 98.8%.
Pooled prevalence rate of mucinous cystic lesions and of lesions
harbouring clinically relevant features
Seven of the 17 studies reported data on the specific type of
PCLs. In these studies, the pooled prevalence of all PCLs was 7% (95%
CI 2e19), with substantial heterogeneity (I2¼ 99.6%) and the
pooled prevalence of lesions diagnosed as of likely “mucinous na-
ture” was 4.3% (95% CI 2e10; I2¼ 99.2%) (see Fig. 4). Most of these
PCLs were considered IPMNs.
Of the included 17 studies, 5 did not provide details about the
morphology of the PCLs [25,36e38,40]. Of the remaining studies, 4
did not report cases with morphological aspects suggestive of
“worrisome features” or “high risk stigmata” [1,26,28,29], whereas
in eight studies [27,30e35,39] these characteristics were
mentioned. The rate of lesions with worrisome features (WF) or
high risk stigmata (HRS) such as solid nodules, thickening of the
wall and main duct calibre> 5mm ranged from 0.1% to 3.6%. The
pool prevalence of either WF and/or HRS at diagnosis resulted of
0.7% (95% CI 0e1) with considerable heterogeneity (I2¼ 85.3%) (see
Supplementary Fig. 1).
Most of the included studies did not provide information
regarding the follow-up of the incidentally diagnosed PCLs, and
when available, these data were limited to a small fraction of the
examined cohort.
Discussion
To our knowledge, this is the first meta-analysis investigatingFig. 4. Prevalence of pancreatic Mucinous Cystic Lesions in studies providing sufficient data t
with considerable heterogeneity (I2¼ 99.2%).
Please cite this article as: Zerboni G et al., Systematic review and meta-an
asymptomatic individuals, Pancreatology, https://doi.org/10.1016/j.pan.20the prevalence of incidentally diagnosed PCLs in individuals
asymptomatic for pancreatic disorders. In the present study, data
from seventeen publications were analysed, resulting in a pooled
prevalence rate of 8%, with a wide range (0.2%e45.9%) and
considerable heterogeneity.
Only seven of the included studies provide sufficient data to
define the nature of the PCLs. In these studies, the pooled preva-
lence of PCLs was of 7% and that of mucinous lesions was 4.3%,
representing 60% of all incidentally diagnosed PCLs. However, at the
time of incidental diagnosis, a minority of these lesions (0.7%)
harboured features that might pose the suspicious of malignancy
and an indication for surgery, such as main pancreatic duct dilation,
thickened wall and mural nodules. Unfortunately, the included
studies were not focused on the follow-up of these lesions, so their
clinical relevance in the long-term could not be examined.
The strengths of the present study include an exhaustive liter-
ature search, rigorous statistical methods, and pooling of data to
allow synthesis of all the available evidence examining the possible
yield\burden of testing for pancreatic cysts in asymptomatic in-
dividuals. Nevertheless, the most relevant weaknesses of the study,
as concerns many systematic review and meta-analysis, arise from
the limits of the available evidence.
Most of the studies eligible for the current analysis were
retrospective and for five of them the past medical history was not
available; however, they include patients that were asymptomatic
at the time of examination, without known health co-morbidities.
Moreover, since the included studies evaluated the radiological
results collected during a long time span (up to 10 year), imaging
were obtained with different machines and protocols. The authors
of the studies with a longer time of recruitment considered, how-
ever, the effect of the different distribution of radiological modal-
ities on the PCLs’ rate. Moris et al. [1] tried to objectify this
correlation performing an adjusted multivariate-analysis, that
showed a very strong relationship between PCLs detection and both
the MRI hardware and the software versions. Therefore, they
confirmed the direct relationship between the number of PCLs
detected and the newer MRI version used. On the other hand, Kim
J.A. and colleagues [36] matched cases and controls (respectively
patients affected by autosomal dominant polycystic kidney disease
-ADPKD- and patients who underwent abdominal MRI imaging
without history or suspect of both ADPKD and pancreatic disorders)
not only for demographic characteristics but also for the timing of
abdominal procedures (within 1 year of each other), in order to
reduce the “technology influence” on the results.o define the nature of the PCLs. The pooled prevalence resulted of 4.3% (95% CI 2%e10%)
alysis: Prevalence of incidentally detected pancreatic cystic lesions in
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surprisingly reported by two studies using the same radiological
procedure, such as whole body MRI. Paramagnetic contrast was
not administrated in both, but, probably, the complementary use
of MRCP in one of them [40] could explain the increasing rate of
pancreatic findings, although the difference remains huge.
As mentioned before, a considerable degree of heterogeneity
was present in all the conducted analyses. A number of a priori
hypotheses were made to explain heterogeneity, such as age,
country of origin, number of enrolled subjects, different type of
abdominal cross-sectional imaging and quality of the study. How-
ever, while some of these factors influence the rate of PCLs, they
could not explain heterogeneity.
The pooled estimate rate of occasional PCLs was higher in older
subjects. This result is in line with previous autopsy series [41]
reporting a rate of incidental PCLs of about 25%, which increases
with age. The pooled rate of incidental PCLs also increased in
studies enrolling a lower number of patients, in those with a higher
quality score and in patients undergoing MRCP. As far as concerns
the country of origin, the pooled rate of PCLs was four times higher
in studies conducted in the US than in those conducted in Asia
(12.6% vs 3.1%), with roughly intermediate results in Europe (see
Fig. 3). This pooled data was in contrast with Laffan's et al. results
[26], according to which Asians had an increased odds ratio of 3.57
(CI 95% 1.05e12.13) of having a pancreatic cyst compared with
other racial groups.
A possible explanation for this difference might be that half of
the studies with a better quality score were performed in the US.
Also, risk factors associated with an increased risk of pancreatic
cancer and of PCLs, such as diabetes and obesity [1,38,40,42]
might be more common in the US. The possible role of
geographical/racial differences might deserve further investiga-
tion also in view of “patients’ tailored work-up” during the
management of PCLs.
Despite the limitations listed above, notably the results of the
meta-analysis are similar in terms of incidence of PCLs to those of
the only prospective study performed with EUS (respectively
pooled rates of 8% and 9.4%), strengthening the reliability of the
present data. Indeed, EUS performed after TC or MRI increases the
rate of pancreatic cystic lesions undiagnosed by initial cross-
sectional imaging [43]. A more recent study on this topic and
employing EUS was published after our search [44]. In this study
the rate of PCLs in asymptomatic subjects was as high as 24%, in line
with the data from autopsy series mentioned above [41], con-
firming the high sensitivity of EUS in diagnosing PCLs.
In conclusion, the findings of this meta-analysis highlight the
considerable high prevalence of PCLs in asymptomatic and/or
apparently healthy individuals. Furthermore, taking into account
both the higher prevalence of PCLs in older and asymptomatic
subjects and the presence of comorbidities and the low rate of
potential malignant features, radiological follow-up in this group
of patients is expected not to be always cost-effective [45]. These
data reinforce the need to redefine the surveillance strategy
proposed by international consensus guidelines, according with a
new scale of clinical risk based on individual subjects’
characteristics.Authors’ potential competing interests
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